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introduction
Tumor microenvironment
In 1889 the assistant surgeon Stephen Paget posed his ‘seed and soil’ hypothesis of the 
spreading of cancer cells from the primary site to one or more sites elsewhere in the body 
(metastasis). With this visionary paper he distanced himself from the then prevailing theory 
that cancer cells can home in all tissues and persuade the surrounding cells to grow similarly 1. 
Paget proposed that the distant sites where travelling cancer cells, ‘seeds’, grow out are not 
a matter of chance, but are influenced by the nourishment of the local ‘soil’. His observation 
that breast cancer metastasizes predominantly to the liver led to the hypothesis that some 
organs provide a better ‘soil’ for certain cancer cells than others. Paget’s statement that ‘the 
ploughman’s observation of the properties of the soil may also be useful’ was proven right 
almost 100 years later by Hart and Fidler who showed, that the outcome of metastasis is 
dependent on both tumor cell properties and host factors 2. That local properties of the 
host don’t only play a role in the determination of the distant metastasis site but also in the 
outgrowth of the primary tumor has become clear during the past decade. 
The path that a normal cell takes to become malignant is highly variable and depending on 
several host factors, including environmental factors, polymorphisms and mutations in sus-
ceptibility genes, age and immunity. In addition, tumor development depends on factors in 
the microenvironment; interactions between malignant cells, stromal cells, extracellular-matrix 
components, various inflammatory cells, and a range of soluble mediators contribute to 
tumor development and progression. Before tumors become clinically relevant, tumor cells 
and their products have interacted with, and affected, host cells for a period of time. Tumors 
of patients, especially in advanced-stage disease, consist of an intricate network of cell types, 
like stromal cells and endothelial cells that comprise blood vessels. Also many immunological 
cell types are attracted towards and penetrate into cancer cell areas. These recruited host 
immune cells influence tumor responses in opposing ways and have shown to be a critical 
regulator of tumor biology: this dual role of the immune system in cancer can either suppress 
or promote tumor growth 3. 
Tumors can evade potential immune destruction by the induction of an immunosuppres-
sive microenvironment via secreting factors or creating specific conditions (e.g. hypoxia). 
In addition, it has become clear that the immune system can facilitate tumor progression 
by sculpting the immunogenic phenotype of tumors as they develop 4. The concept that 
the immunogenicity of tumors changes due to the anti-tumor immune response is named 
‘cancer immunoediting’ 5, 6. The immunosurveillance concept is now accepted by the scientific 
community and “avoiding immune destruction” is included as the latest hallmark of cancer 7. 
Outgrowth of a tumor is divided in three phases often referred to as the three E’s of immu-
noediting (Elimination, Equilibrium, Escape). In the first phase, tumor cells are recognized by 
the immune system and eliminated or controlled in their growth. In the equilibrium phase 
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the immune system iteratively selects and/or promotes the generation of tumor cell variants 
with increasing capacities to survive immune attack. In the escape phase the immunologically 
sculpted tumor expands in an excessive manner leading to physical symptoms of cancer by 
the host 8. 
There is accumulating evidence that cancer cells can recruit and subvert normal immune 
cells to serve as active collaborators in their neoplastic program 9. This immunosuppressive 
effect has also been described in thoracic malignancies 10-14. Intriguingly, immunotherapeutic 
approaches have recently shown that modulation of the patients’ immune system is possible 
and can be of benefit for patients with lung cancer and mesothelioma 15-18. Identification 
and targeting of the factors and cell types that play a role in the tumor microenvironment is 
essential to further improve and refine novel (immuno)therapies. In the microenvironment 
of a progressing tumor, regulatory T cells, myeloid-derived suppressor cells (MDSCs) and 
tumor-associated macrophages (TAMs) have an important role in facilitating tumor growth 
and immune escape by suppressing antitumor effector cells 13, 19-22. Regulatory T cells and 
MDSCs are regarded as immune suppressive, as they are capable of inducing T cell apoptosis 
and T cell tolerance 20, 23. TAMs are the major component of immune cell infiltration in the 
tumor microenvironment 21, 24-26. Recently, there is a lot of evidence emerging regarding the 
clinical significance of these tumor-associated macrophages in various cancer types and TAM 
infiltration is correlated with patient outcome in several malignant tumors 27-31. 
Macrophages and their role within tumors 
Macrophages in general 
Elie Metchnikoff was the first to describe in 1882 that there are leukocytes which are able 
to engulf and destroy harmful bodies such as bacteria. His discovery of phagocytosis was 
groundbreaking in a time where leukocytes were thought to take up bacteria in order to 
spread disease and made him the co-winner (together with Paul Ehrlich) of the 1908 Nobel 
Prize in Physiology or Medicine. Metchnikoff promoted the concept of natural, innate host 
defense by cellular mechanisms such as phagocytosis and recruitment of phagocytes during 
acute and chronic inflammation 32, 33. Since their initial description, macrophages are now 
known to exert many essential functions in tissue development and homeostasis beside 
phagocytosis. 
Macrophages are present in all tissues in mammals and these tissue-resident macrophages 
are derived from three sources; yolk sac, fetal liver and hematopoetic stem cells in the 
bone marrow 34-36. The relative contributions of embryonic sources (yolk sac and fetal liver) 
versus hematopoetic sources vary per tissue 37. Tissue-resident macrophages are specialized 
to perform many tissue-specific functions; e.g. osteoclasts (macrophages of the bone) are 
specialized in bone resorption 38, lung alveolar macrophages recycle surfactant molecules 39 
and splenic red pulp macrophages process heme and iron from senescent red blood cells 
40. In concordance, abnormality of tissue-resident macrophages can be linked to various 
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pathologies such as osteopetrosis, alveolar proteinosis and a disturbed iron homeostasis. 
Furthermore, macrophages are known to have a critical role in e.g. atherosclerosis 41, type 
2 diabetes 42, fibrosis 43 and cancer 44. The maintenance of tissue-resident macrophages is 
organ specific. However multiple studies have revealed that tissue macrophage compart-
ments are established prenatally and persist throughout adulthood through local proliferation 
without substantial input from adult hematopoiesis 45-47. Substantial replacement of tissue-res-
ident macrophages by monocyte-derived cells has only been reported for specific organs 
undergoing profound challenges such as the skin and gut which are constantly exposed to 
microorganisms 48. However, these data are currently only based on experiments in mice, 
which have a limited lifespan. 
When tissues are damaged during injury or infection, patrolling inflammatory monocytes 
are recruited from the circulation and differentiate into macrophages once they infiltrate the 
affected tissue 49, 50. Depending on the local signals which the macrophage encounters, it can 
adopt a variety of phenotypes ranging from a proinflammatory cytotoxic phenotype to a 
phenotype capable of tissue remodeling and repair. The diversity and plasticity of phenotype 
and function are characteristic and unique features of macrophages 51-53. The mechanisms 
that regulate the phenotypic switch in macrophages have a major impact on the progression 
or resolution of many chronic diseases, like tumor formation. 
Tumor-associated macrophages (TAMs)
In cancer, monocytes and myeloid progenitors infiltrate tumoral tissues and polarize in a 
broad range of phenotypes depending on the local environment 54. Macrophages in tumors 
are usually referred to as tumor-associated macrophages and their presence can be substan-
tial (up to 60% of the tumor stroma) 55. A hallmark of macrophages is their plasticity, an ability 
to either aid or fight tumors depending on the tumor environment, which has given them the 
reputation of a double-edged sword in tumor biology 56. At the extremes of this spectrum 
are the M1 macrophages (classical activation) and M2 macrophages (alternative activation). 
Although the terms M1 and M2 macrophages are an oversimplification, they can be used to 
explain the opposing effects of different macrophage subsets. In general, M1 macrophages 
act as soldiers of the host and M2 macrophages act as workers of the host, as was illustra-
tively described by Solinas et al 57. M1 macrophages defend the host from viral and microbial 
infections, fight against tumors, produce high amounts of inflammatory cytokines, and activate 
the immune response 57, 58. M1 macrophages originate upon encounter with interferon-γ 
(IFN–γ) and microbial stimuli such as lipopolysaccharide (LPS) and are characterized by IL-12 
and IL-23 production and consequent activation of polarized type I T-cell response, cytotoxic 
activity against phagocytozed microorganisms and neoplastic cells, expression of high levels 
of reactive oxygen species, and good capability as antigen-presenting cells. On the other 
hand, M2 macrophages promote scavenging of debris, angiogenesis, remodeling and repair 
of wounded/damaged tissues. Distinct types of M2 macrophages differentiate when mono-
Introduction
 13
1
cytes are stimulated with e.g. IL-4, IL-10 or glucocorticoids. Hallmarks of M2 macrophages 
are IL-10 production, CCL17, CCL22, and CCL2 secretion, matrix metallo-proteases (MMP) 
production, high expression of mannose receptor (CD206), scavenger receptor (CD163) 
and galactose-type receptor and poor antigen-presenting capability 57, 59. 
In addition, M2 cells control the inflammatory response by downregulating M1-mediated 
functions. The loss of equilibrium between M1 and M2 cell numbers may lead to pathological 
events: an M1 excess could induce chronic inflammation, whereas numbers of M2 could 
promote severe immune suppression 57-59. The equilibrium between M1 and M2 polarization 
can in part be regulated by the bidirectional interaction with lymphocytes, as was reviewed 
by Biswas and Mantovani (Figure 1) 52. 
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Figure 1. The macrophage phenotype can be regulated by interactions with lymphoid cells. Th1: type 1 T 
helper cell, Th2: type 2 T helper cell, NK: Natural Killer cell, NKT: Natural Killer T cell, Treg: regulatory T cell. An 
important hallmark of macrophages is their plasticity. Different lymphoid cell subsets are capable of skewing 
macrophages towards the opposing ends of their phenotypic continuum [35]. M1 polarization can be driven 
by interferon-γ production by Th1 cells and NK cells. M1 macrophages in their turn produce IL-12 which 
stimulates the activation of these cells. M2 polarization can be driven by IL-4 and IL-13 production by Th2 cells 
and IL-10 production by Tregs. The reciprocal production of IL-10 and the chemokines CCL17 and CCL22 by 
M2 macrophages stimulates Tregs and Th2 cells respectively. NKT cells can induce both M1 and M2 polarization, 
depending on their activation status 60. 
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When myeloid cells are attracted to the tumor, they are influenced by several local signals 
able to shape the cells as needed by the tumor. In an early phase of tumor development, the 
TAMs mainly consist of an M1-like phenotype and later in the tumorigenic process, when 
the tumor changes its local environment there is a skewing towards the M2 phenotype 61-63. 
This takes place especially at those regions in the tumor that are hypoxic (Figure 2) 64, 65. A 
subpopulation of TAMs gather in hypoxic sites in the tumor as a result of chemoattractants 
produced by tumor cells 66. Exposure to hypoxia in vitro stimulates TAMs to acquire a pro-an-
giogenic M2 phenotype with high production of pro-angiogenic factors like VEGF and MMP-9 
67. This preferential polarization is also a result of the absence of M1-orienting signals, such 
as IFN-γ or bacterial components in the tumor environment as well as the presence of M2 
polarization factors. In addition to the formation of new blood vessels TAMs also play a role 
in the formation of new lymphatic vessels 68. 
M1 macrophage M2 macrophage
HYPOXIC
    AREA
Immune stimulation
Antimicrobial activity
  ROS and RNS production
      Tumor cell killing
Immune suppression    
Tissue remodeling    
Angiogenesis 
Tumor promotion
Figure 2 Opposing effects of M1 and M2 tumor-associated macrophages (TAMs) in the tumor environment. 
ROS: Reactive Oxygen Species, RNS: Reactive Nitrogen Species. The classically activated M1 macrophages 
and alternatively activated M2 macrophages are at the opposing ends of the polarization continuum and have 
opposing effects in tumor biology. M2-TAMs are abundantly present within the tumor, especially in those areas 
that are oxygen deprived. 
Malignancies induce lymph angiogenesis, which leads to lymphatic and subsequently distant 
metastasis. Many of the pro-angiogenic factors produced by TAMs of the M2 phenotype 
can also contribute to lymh angiogenesis. The association between TAMs and lymph node 
Introduction
 15
1
metastasis has also been confirmed in multiple clinical studies 69-71. In addition to the secretion 
of paracrine mediators, evidence is emerging on the potential of macrophages to transdif-
ferentiate into lymphatic endothelial cell progenitors (M-LECP) that structurally contribute 
to sprouting lymphatic vessels 68. 
TAMs can influence fundamental aspects of tumor biology such as subversion of adaptive 
immunity, promoting tumor angiogenesis and supporting cancer cell survival, proliferation, 
invasion and tumor dissemination 57, 72. In concordance with the pro- and anti-tumor effects 
that TAMs can elicit, clinical studies regarding the prognostic value of TAMs in multiple tumor 
types have also shown contradictory results depending on the prevalent TAM phenotype. 
Pulmonary oncology with emphasis on malignant mesothelioma
Malignant mesothelioma
Asbestos was named by the Ancient Greeks, its name meaning “inextinguishable”. It has 
been said that the Greeks also noted its harmful effects: “sickness of the lungs” in asbestos 
quarry slaves or slaves that wove asbestos into cloth, leading to a recommendation not to 
buy these slaves as they often “died young”. The use of asbestos declined during the Middle 
Ages, but it regained popularity during the Industrial Revolution in the late 1800s. At the 
turn of the twentieth century, researchers began to notice a large number of deaths and 
lung problems in people living in asbestos mining towns and during these first decades of 
that century, a growing number of articles appeared in medical journals 73-75. Some authors 
already suggested a link between inhalation of asbestos fibers and carcinogenesis 76, 77. The 
term mesothelioma entered the medical literature in 1931 when it was identified by Klem-
perer and Rabin 78. However, it was not until 1960 that the link between asbestos fibers and 
mesothelioma became incontrovertible with an article published in Lancet entitled “Primary 
Malignant Mesothelioma of the Pleura” by Eisenstadt and Wilson 79. Over the last decades, 
the association between asbestos exposure and subsequent development of mesothelioma 
has been extensively studied in multiple animal species via inhalation of, or subcutaneous, 
intrapleural, and intraperitoneal inoculation with asbestos fibers 80-83. Inhaled asbestos fibers 
present within the lung cause infiltration of macrophages into the pleural space, which try 
to phagocytose these inhaled foreign bodies 84. In the effort to clear asbestos fibers, reactive 
oxygen species are generated, causing DNA damage to nearby cells. Subsequently, inflam-
matory cytokines and increased recruitment of immune cells to sites of inflammation within 
the pleura are induced 85-88. Given the large size of the asbestos fibers, macrophages fail to 
clear the asbestos fibers, resulting in continued generation of reactive oxygen species and 
secretion of pro-inflammatory cytokines, a process often called ‘‘frustrated phagocytosis” 89. 
In addition to this pro-carcinogenic and pro-inflammatory substance release, asbestos fibers 
can sometimes directly penetrate the cells and injure chromosomes 90. Also, the retained 
asbestos fibers may adsorb other carcinogens on their surface 91. As a result DNA alterations 
occur, such as inactivation of p16INK4a/p14ARF, NF2/Merlin, and LATS2, and the activation 
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of YAP 92, 93.
Treatment options in mesothelioma are scarce and prognosis is poor, with a median sur-
vival of only 9-12 months 94. The classic triad in cancer therapy; surgery, radiotherapy and 
chemotherapy, is also applied in mesothelioma 95. Surgery for mesothelioma is a controversial 
subject. Only a minority of patients is eligible for surgical treatment and the performed clin-
ical studies are too limited and diverse to draw definite conclusions regarding the survival 
benefit of surgery in mesothelioma 96-98. Debates regarding the optimal surgical technique 
and multimodality setting are ongoing 99. Radiotherapy is commonly used following surgery, 
in the palliative setting or as a means to prevent local tumor outgrowth at intervention sites. 
However, there is a distinct lack in randomized trials which support the clinical benefit of 
radiotherapy in mesothelioma. Novel forms and multimodality settings of radiotherapy in 
mesothelioma are currently being investigated and will hopefully lead to evidence-based 
indications of this treatment option in mesothelioma. Currently, chemotherapy is the only 
treatment for mesothelioma that has been proven to improve survival in randomized con-
trolled trials. The landmark study is the publication by Vogelzang and colleagues in 2003 in 
which they compared cisplatin chemotherapy alone with a combination of cisplatin and 
pemetrexed resulting in a survival of 10 months in the control group and 13.3 months in the 
intervention arm 100. This led to the approval of the combination of cisplatin and pemetrexed 
as ‘standard of care’ for the treatment of patients with unresectable mesothelioma. It should 
be noted that similar outcomes were reached with cisplatinum and raltitrexed compared 
to cisplatinum alone, confirming that a combination of cisplatin and an antifolate is superior 
to cisplatin alone in patients with mesothelioma 101. In addition, no head-to-head chemo-
therapeutic comparison has been performed in mesothelioma, for example the comparison 
between the current standard regimen of cisplatinum/pemetrexed to cisplatin/raltitrexed, 
gemcitabine/cisplatinum, mitomycin, vindesine/cisplatin or vinorelbine. However, for every 
separate agent previously studied, the survival improvement was modest.
Several targeted agents have been extensively studied in mesothelioma. Epidermal Growth 
Factor Receptor (EGFR) inhibitors were thought to be a promising target for mesothelioma 
therapy since studies showed that EGFR was highly expressed in malignant mesothelioma 
102, 103. However, most likely due to absence of sensitizing mutations in the EGFR tyrosine 
kinase domain, the results of clinical trials were disappointing 104, 105. Among anti-angiogenic 
agents, thalidomide is the most extensively studied drug. After many trials the phase 3 
NVALT 5/MATES (Maintenance Thalidomide in Mesothelioma Patients) with thalidomide as 
switch-maintenance in non-disease progressive patients after first line pemetrexed chemo-
therapy could unfortunately not prove a survival advantage 106. Phase 2 clinical trials of 
Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitors have shown at best 
modest activity in mesothelioma 107, 108. The addition of bevacizumab, a VEGF monoclonal 
antibody, to standard chemotherapy has been recently shown to induce a modest but 
significant survival benefit in a randomized controlled phase 3 trial in newly diagnosed 
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mesothelioma patients 109. This result warrants routine use of bevacizumab in addition to 
cisplatin and pemetrexed in unresectable mesothelioma 110. An increasing amount of pre-
clinical data highlighting the effectiveness of histone deacetylase inhibition in mesothelioma 
cell lines and mouse xenograft models has led to a number of early phase clinical trials in 
patients with mesothelioma 111. The results of these efforts initiated a multicenter, randomized, 
placebo-controlled phase III study of the histone deacetylase inhibitor vorinostat in patients 
with advanced mesothelioma, which, unfortunately, did not improve survival compared with 
placebo as second-line therapy 112. Furthermore, a recent randomized, placebo-controlled 
phase II trial investigating the Focal Adhesion Kinase inhibitor defactinib in mesothelioma 
patients was discontinued due to lack of efficacy. 
In conclusion, there is no promising chemotherapeutic or targeted agent at the horizon which 
will profoundly improve survival in patients with mesothelioma. Clearly, there is a need for 
a new approach in the treatment of mesothelioma.
Lung cancer
Lung cancer is the most common cause of cancer-related death among males and females 
worldwide and non-small cell lung cancer (NSCLC) accounts for the majority of these 
cases 113. On average, the 5 year survival rate for NSCLC is approximately 17%, with a rate 
around 70% for stage I 114. The treatment of NSCLC is based on the patient’s clinical signs 
and symptoms, tumor stage and subtype, medical and family history, and data from imaging 
and laboratory evaluation. The majority of patients (70%) is diagnosed with advanced (stage 
IV) disease, and until recently, palliative chemotherapy with platinum doublet therapy was the 
optimal treatment for these patients 115-117. However, chemotherapy has a limited impact on 
long-term survival of NSCLC patients and the five-year survival rate is poor 118. 
Recently the concept of driving mutations in NSCLC has dramatically changed the field of 
lung cancer treatment. Identification of these genotypic anomalies including activating muta-
tions and fusion genes has set the stage for personalized medicine for distinct subsets of 
genetically defined NSCLC 119. It involves tailoring treatment according to the genetic profile 
and molecular makeup of each patient, depending on the availability of targeted drugs. To 
date, several prognostic and predictive mutations have been identified in NSCLC; including 
oncogenic activation of epidermal growth factor receptor EGFR (HER1 / ErbB-1); transloca-
tion of EML4-ALK or CD74-ROS; point mutations in BRAF, PIK3CA, and MEK1; amplification 
of MET 120-123. Patients with mutations have benefited from the development of target-specific 
therapy; e.g. gefitinib or erlotinib are effective EGFR tyrosine kinase inhibitors; crizotinib is 
used for ALK activation and sunitinib can be used when PDGFR is amplified 124, 125. Objective 
response rates of 55 to 90 percent are observed when patients were selected based upon 
molecular criteria 121. One of the most disappointing findings is the fact that tumors develop 
resistance to these agents 126. The development of this resistance can either be mutation 
dependent, for instance genetic alteration of the drug target, or mutation independent, for 
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instance via transformation of histology. 
Small cell lung cancer (SCLC) accounts for approximately 15% of the lung cancer cases 127, 
128. In general, SCLC is initially sensitive to chemotherapy and radiotherapy 129. However, 
responses are often short-term and recurrence rates are high 129, 130. Unfortunately, approx-
imately 70% of patients diagnosed with SCLC have extended disease at presentation 131. 
These patients are treated with platinum-doublet chemotherapy and have a median survival 
of 10-12 months 132, 133. The development of targeted therapies for SCLC has proven to be 
challenging, mainly due to the complex and not fully uncovered biology of SCLC 133, 134. 
The limited treatment options and poor prognoses of lung cancer and mesothelioma empha-
size the need for novel treatments. Therefore, immunotherapeutic approaches are being 
investigated in these pulmonary malignancies. 
Immunotherapy in pulmonary oncology
Setting the stage for immunotherapy
Paul Ehrlich stated in 1909 that cancer would be quite common if it wasn’t for the protec-
tive effects of the immune system 135. However, it were Richard Prehn and Joan Main who 
showed in 1957 that tumors induced by chemical carcinogens in mice were recognized by 
the immune system and rejected upon a secondary encounter with the same tumor 136. With 
this observation, the potential of the immune system to eradicate tumors was demonstrated. 
Cancer immunotherapy attempts to activate or enhance the anti-tumor response of the 
immune system of the patient. Developments of therapeutic antibodies, cancer vaccines, and 
cell-based immunotherapeutic approaches reveal both the promise and relative infancy of 
these agents to extend the life of patients with cancer. In 2010, sipuleucel-T (Provenge; Den-
dreon Corporation) received the first FDA approval of a cancer vaccine for the treatment 
of metastatic castration-resistant prostate cancer 137. It employs an adjuvant component to 
enhance the function of antigen presenting cells and immune effectors such as T cells. This 
was followed with the FDA approval in 2011 of the drug ipilimumab (Yelvoy, Bristol-Meyers 
Squibb) for the treatment of metastatic melanoma through potentiating T cell activity 138. 
Both agents, whose activity is discussed in more detail below, demonstrate improved survival 
in randomized phase III trails and reignited enthusiasm for the field of active immunotherapy. 
With the many clinical programs currently underway, new approvals for therapeutic cancer 
vaccines by FDA and other ruling authorities as EMA are expected in the coming years. 
Immunotherapy is now considered as the fourth wave in cancer therapy after conventional 
treatments and targeted agents. 
Types of immunotherapeutic approaches
Immunotherapy attempts to stimulate or restore the body’s natural ability of the immune 
system to fight cancer. There are various strategies to activate the immune system and these 
are classified here into the following categories: biological response modifiers, monoclonal 
antibodies, peptide or tumor cell vaccines, and cellular immunotherapy (Figure 3). There is 
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no consensus regarding which of the four categories is the optimal approach for pulmonary 
malignancies, this will probably be highly dependent on the tumor characteristics of each 
individual patient. 
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Figure 3 Immunotherapeutic approaches. Different immunotherapeutic approaches are currently being 
developed for the treatment of lung cancer and mesothelioma. All approaches aim to elicit an anti-tumor 
immune reponse and they can often work complementary and/or synergistically. Biological response modifiers 
can nonspecifically enhance the immune response, either by directly stimulating the immune system and/or by 
the direct induction of tumor cell apoptosis. Monoclonal antibodies bind specifically to one epitope and can 
be directed against numerous tumor- or immune cell related targets. Tumor vaccines are designed to deliver 
tumor antigens to antigen-presenting cells, which can subsequently induce a tumor specific immune response. 
Cellular immunotherapy includes the adoptive transfer of autologous or allogeneic activated immune cells. 
Biological response modifiers 
Biological response modifiers are compounds, which can aspecifically, enhance the immune 
response, either by directly stimulating the immune system and/or by the direct induction of 
tumor cell apoptosis. These compounds can activate the anti-tumor immune response via 
the direct stimulation of pro-inflammatory immune cells or via the inhibition of detrimental 
suppressive immune cells like regulatory T cells or myeloid-derived suppressor cells. The 
observation that lung cancer patients who developed an empyema after pneumonectomy 
seemed to have a longer survival gave rise to studies involving different biological response 
modifiers in the 1970’s 139. The idea that bacterial infection in the area of the draining 
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lymph nodes of the resected tumor could lead to immune destruction of residual tumor 
cells provoked studies involving the intrapleural injection of bacterial antigens to induce 
immune activation. Bacillus Calmette-Guèrin (BCG) is a vaccine against tuberculosis that is 
prepared from a strain of attenuated live bovine tuberculosis bacillus and its potential for 
cancer immunotherapy has been thoroughly investigated. McKneally et al. were the first to 
study the effect of postoperative injection of BCG into the pleural space of early stage lung 
cancer patients 140. Their observation that intrapleural BCG injection resulted in an improved 
survival lead to numerous studies regarding aspecific immune stimulation with this vaccine. 
Currently, BCG is most often investigated as an adjuvants instead as a single therapeutic agent 
in lung cancer patients 141. In contrast, in patients with superficial bladder cancer, the use of 
intravesical BCG is now well-established 142. In addition to BCG, heat-killed mycobacterium 
vaccae (SRL 172) has been investigated as a nonspecific immunostimulant in lung cancer and 
mesothelioma patients in combination with chemotherapy 143, 144, unfortunately no survival 
benefits were reported. Mycobacterial adjuvant-based agents have been shown to activate 
antigen-presenting cells and induce a Th1-type immune response, partly due to the binding 
of components of the cell wall of Mycobacteria to Toll-like receptors (TLRs) 145. TLRs are 
membrane glycoproteins and belong to a family of pattern recognition receptors (PRRs) that 
recognize specific microbial molecular structures, pathogen associated molecular patterns 
(PAMPs). Recognition of a PAMP belonging to a micro-organism by a TLR leads to activation, 
maturation and induction of proinflammatory cytokines. Immature dendritic cells express 
numerous TLRs and aspecific immune activation via the stimulation of these TLRs has been 
extensively researched. In lung cancer specifically, TLR9 plays an important role and has been 
described to be overexpressed in lung cancer tissue 146. Synthetic TLR9-activating compounds 
(e.g. PF-3512676, CpG-ODN) have been clinically tested in combination with chemotherapy 
in lung cancer patients, unfortunately no clinical benefit was found 147, 148. However, since 
preclinical studies have shown that the use of the TLR9 agonist CpG-ODN as an adjuvants 
in tumor vaccines reduces the number of regulatory T cells and increases the number of 
effector T cells, TLRs remain a potential target in the field of cancer immunotherapy 149. 
In addition to compounds that aspecifically enhance inflammation, the administration of 
cytokines has been amongst the earliest approaches in cancer immunotherapy. Interferons 
have been one of the major cytokine families of interest given their direct antiproliferative 
and immunopotentiating effects. In the 1980s, the first clinical trials were conducted in which 
lung cancer patients were treated with different types of interferons (recombinant alpha and 
beta) 150, 151. Since then, the potential of interferon therapy in lung cancer patients has been 
researched extensively in a number of clinical trials, however no clinical benefits were found 
152-155. Other proinflammatory cytokines of which their potential as a therapeutic target in 
lung cancer patients has been investigated are interleukin-2 (IL-2) and tumor-necrosis factor 
alpha (TNF-α). In general, treatment with the combination of IL-2 and TNF-α induced rela-
tively grave toxicities and no survival benefits156. In mesothelioma patients, the local infusion 
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of granulocyte/macrophage- colony-stimulating-factor (GM-CSF) has been studied with very 
limited success 157. Currently, the direct administration of proinflammatory cytokines in order 
to enhance the anti-tumor immune response has been mostly abandoned in lung cancer and 
mesothelioma patients with the exception of the use of colony-stimulating factors with the 
purpose of the treatment of chemotherapy-induced neutropenia 158, 159. 
Monoclonal antibodies 
Monoclonal antibodies bind specifically to one epitope and their application as potential 
immunotherapeutic agents has received a lot of attention recently. The use of monoclonal 
antibodies directed against tumor growth related antigens on the tumor cell like epidermal 
growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) 
has been well established in lung cancer patients 160, 161. In addition to the direct effect of 
the inhibition of growth factors and/or their receptors, antibodies bound to the tumor cell 
surface can induce antibody-dependent cell-mediated cytotoxicity (ADCC) 162. Mesothelin is 
another tumor-specific antigen which is an attractive target for treatment with monoclonal 
antibodies because of its expression on several epithelial tumors including mesothelioma 
and lung cancer. Clinical studies with monoclonal antibodies against mesothelin are currently 
ongoing in lung cancer and mesothelioma patients 163, 164. 
In addition to monoclonal antibodies directed against antigens specifically expressed by tumor 
cells, antibodies that are directed against tumor products have been clinically implemented. 
In lung cancer and mesothelioma patients, the monoclonal anti-VEGF antibody bevacizumab 
has been extensively investigated in clinical trials. In a meta-analysis, Cui et al showed that 
bevacizumab accompanied by chemotherapy improves clinical outcomes compared to other 
targeted therapies in chemotherapy-naïve lung cancer patients 165. Bevacizumab has been 
developed in order to target blood vessel growth of tumors, however evidence shows that 
bevacizumab also has an immunomodulating effect and enhances circulating CD8 T cells in 
treated cancer patients 166. This two-fold effect makes bevacizumab an interesting compound 
to study in combination with other immunotherapies. 
The blockade of immune checkpoints using monoclonal antibodies can be considered one 
of the major breakthroughs in cancer research of the past years 167. In order to control 
the immune response and to mitigate collateral tissue damage the immune system is har-
nessed with a negative feedback system. T cells have the capacity to upregulate co-inbitory 
receptors in order to inhibit the immune response and mediate immune tolerance. Multiple 
immune-inhibitory pathways (checkpoints) and their accompanying inhibitory co-receptors 
have been identified. In chronic infection and in cancer, expression of these inhibitory co-re-
ceptors is enhanced and associated with an anergic state in T cells 168. Antibodies that bind 
to these co-receptors can block inhibitory signals and therefore augment T cell activation 
and proliferation. 
The development of antibodies which bind to co-inhibitory molecules activated during T 
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cell activation has led to the possibility to prevent T cell inhibitory mechanisms and there-
fore enhance the anti-tumor immune response 169. The first monoclonal antibody against 
a co-inhibitory molecule that showed clinical efficacy in cancer patients was anti-cytotoxic 
T-lymphocyte associated protein 4 (CTLA4, ipilimumab) 138. Currently, ipilimumab is approved 
for the treatment of metastatic melanoma 170. Following the success in melanoma, numer-
ous clinical trials are being conducted investigating checkpoint inhibitors in lung cancer and 
mesothelioma. The programmed death protein 1-protein death ligand 1/2 (PD-1 – PD-L1/2) 
pathway and CTLA4 are currently the most studied immunotherapeutic targets in these 
malignancies. In non-small cell lung cancer (NSCLC), anti-PD-1 antibodies have become part 
of the approved treatment arsenal 171, 172. In mesothelioma the efficacy of checkpoint inhibi-
tion has not yet been proven. The implementation of these immune checkpoint inhibitors is 
hampered by serious immune-related toxicities (e.g. colitis, pneumonitis) and relatively low 
response rates. Therefore, the development of robust, predictive biomarkers is pivotal for the 
clinical implementation of monoclonal antibodies against co-inhibitory receptors. Interestingly, 
in multiple cancers including lung cancer, the mutational landscape (e.g. neoantigen load) has 
been demonstrated to determine the sensitivity to checkpoint blockade 173, 174. 
Tumor vaccines 
The research regarding cancer vaccines has made great progress since the discovery of 
human tumor antigens which can be recognized by T cell receptors 175. Tumor vaccines are 
designed to deliver tumor antigens to antigen-presenting cells, which can subsequently induce 
a tumor specific immune response by the adaptive immune system. These vaccines can con-
sist of various types of antigen sources (e.g. proteins, liposomal complexes and cell-based 
vaccines). An antigen candidate needs to meet certain criteria in order to potentially be able 
to elicit a specific anti-tumor immune response. Tumor specificity, frequency and homogene-
ous expression in tumor cells, role as an oncogene and intrinsic immunogenicity are essential 
features of antigens which determine the success 176. In lung cancer and mesothelioma, a 
broad spectrum of approaches using various antigen sources have been undertaken to 
develop cancer vaccines. Melanoma-associated antigen A3 (MAGE A3) is an antigen which 
is specifically expressed by several human tumors, including NSCLC. Activation of the MAGE 
genes is known to take place in early carcinogenesis of the lung, however the physiological 
function of MAGE gene products is unknown 16, 177. MAGE A3 is detected in approximately 
35-50% of NSCLCs and its expression has been shown to be inversely correlated with 
survival 178, 179. Vaccines composed of recombinant MAGE A3 (and adjuvants) have shown 
promising results in lung cancer patients in phase 2 studies but unfortunately demonstrated 
no survival benefit in a large phase 3 trial 180, 181. In addition to large proteins like MAGE, 
smaller peptides can also be used in tumor vaccines. The WT1 (Wilms’ tumor suppressor 
gene 1) peptide vaccine is composed of four WT1 analogue peptides. WT1 can be expressed 
in both lung cancer and mesothelioma and vaccination with this peptide has been shown 
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to induce T cell mediated immune responses in lung cancer and mesothelioma patients 182. 
Treatment of mesothelioma patients with a WT1 vaccine demonstrated promising effects 
in a phase 2 study183 and a phase 3 trial is currently being conducted. Liposomes are known 
to be potent vaccine delivery systems 184. The best known cancer vaccine which makes use 
of this delivery technique is L-BLP25 or Stimuvax. This liposomal vaccine aims to generate 
an immune response against mucin 1 (MUC1), a cell surface glycosylated phosphoprotein 
that is frequently overexpressed by epithelial tumors including NSCLC 185 186. The L-BLP25 
contains the BLP25 lipopeptide and a liposomal delivery system, which facilitates uptake by 
antigen-presenting cells 186. A phase 2 trial with advanced stage NSCLC patients showed sur-
vival benefits and paved the way for a large phase 3 trial (the START trial) 187. Unfortunately, 
Stimuvax failed to increase overall survival in this trial 188. Viruses can be genetically modified 
in order to express certain antigens and/or co-stimulatory cytokines and are therefore 
useful as ‘viral vaccines’ in cancer immunotherapy. The earlier described MUC1 protein can 
also be targeted by the TG4010 viral vaccine. This vaccine consists of attenuated vaccinia 
virus Ankara which is genetically modified to express MUC1 and IL-2 as adjuvants 189. In a 
phase 2 study it was shown that TG4010 enhances the effect of chemotherapy in advanced 
NSCLC patients, a phase 3 trial is currently being conducted 190, 191. There is a variety of 
cell-based vaccines under development for the treatment of lung cancer and mesothelioma. 
Cell-based vaccines can be autologous or allogeneic and transfected or not with immunos-
timulatory compounds. Autologous tumor cell vaccines are ideal antigen sources because 
they are capable of inducing an immune response to a large variety of antigens expressed 
by the patient’s tumor. However their practical implementation is complex and challenging 
for large scale development 192. An allogeneic tumor cell vaccine that reached phase 3 
clinical trials in NSCLC is belagenpumatucel-L (Lucanix). Lucanix consists of four irradiated 
NSCLC cell lines modified with transforming growth factor β2 (TGF-β2) antisense plasmid. 
TGF-β is known to be associated with the immune escape of tumors and increased levels 
of TGF-β are associated with a worse prognosis in NSCLC patients 193 194. The addition of 
the TGF-β2 antisense plasmid aims to stimulate the vaccine-induced immune response by 
inhibition of the production of TGF-β by the tumor. It is possible to use a combination of 
tumor cell lines as vaccine cocktail because NSCLC tumor cell lines are described to share 
immunogenic epitopes with primary tumors 16. A phase 2 study showed clinical response 
rates of 15% amongst advanced stage NSCLC patients 195. Unfortunately, in a phase 3 study 
belagenpumatucel-L did not meet its predefined endpoint in the entire patient population 196. 
However, in specific subgroups of patients marked improvements in survival were achieved 
resulting in a current continued development of belagenpumatucel-L for specific indications. 
Cellular immunotherapy 
Cellular immunotherapy includes the adoptive transfer of autologous or allogeneic acti-
vated immune cells. Initially, adoptive immunotherapy was used for relapses after allogeneic 
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bone marrow transplantation in leukemia patients 197. Recent advances have facilitated the 
application and clinical success of this method in various solid tumors 198. The most promi-
nent success story regarding cellular immunotherapy is sipuleucel-T, a vaccine for prostate 
cancer that consists of autologous peripheral blood mononuclear cells (PBMCs) including 
antigen-presenting cells that have been activated ex vivo with a recombinant fusion protein 
(PA2024, a prostate antigen that is fused to GM-CSF) 137. After it was demonstrated in a 
phase 3 clinical trial that sipuleucel-T prolonges survival in metastatic castration-resistant 
prostate cancer patients, FDA approval followed in 2010. The general goal of adoptive cel-
lular immunotherapy is to induce a tumor-specific immune response via the infusion of e.g. 
tumor-antigen loaded dendritic cells or specifically activated T cells. Dendritic cells (DCs) are 
the professional antigen-presenting cells of the immune system and they have emerged as the 
most powerful initiators of immune responses. Because of their capacity to engulf tumor anti-
gens and activate T cells in an antigen-specific manner, the use of DCs as immunotherapeutic 
agents is very promising. In DC-based immunotherapeutic approaches, DCs are generated 
ex vivo from monocytes and after arming with tumor-associated antigens, reinjected into the 
patient with the intention to restore proper presentation of tumor-associated antigens and T 
cell activation. This concept has been researched in NSCLC and has shown promising results 
regarding the elicited immune response, safety and tolerability, despite the small sample sizes 
of the trials 199-201. In mesothelioma, treatment with autologous tumor-lysate pulsed DCs 
was shown to be safe and elicited an anti-tumor immune response in two phase 1 clinical 
trials 17, 202. A phase 3 clinical trial with allogeneic tumor-lysate pulsed DCs is currently being 
conducted in mesothelioma patients. 
Based on the principle that tumors can share common antigens, T cell therapy aims to 
develop a ‘universal’  T cell which recognizes tumors in different patients 203. Different sources 
and activation procedures can be used in specifically harnessing the T cells response. Adoptive 
transfer of T cells gene-engineered with antigen-specific T cell receptors (TCRs) has proven 
its feasibility and therapeutic potential in the treatment of various malignancies 204. Clinical 
TCR-engineered T cells currently tested in lung cancer and mesothelioma are directed against 
e.g. MAGE-A3 and WT1. The adoptive transfer of tumor-specific T cells expressing chimeric 
antigen receptors (CAR) is being extensively studied in multiple tumor types. Impressive 
results have been achieved with CAR T cells expressing CD19 in patients with advanced B 
cell malignancies; with up to 95% response rates 205, 206. In mesothelioma and lung cancer, the 
potential of mesothelin-targeted CAR T cells is being studied 207. 
Targeting the tumor microenvironment
Within this research field, there is much attention for activating effector and memory T lym-
phocytes because the release of their cytotoxic granules containing perforin and granzymes 
upon stimulation can lead to death of tumor cells by apoptosis. Indeed, the infiltration of 
NSCLC with effector T cells (CD3+CD8+) and memory T cells (CD45RO+) is associated 
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with longer disease-free survival and/or a better overall survival 62, 208-212. However, many other 
leukocyte types infiltrate the tumor environment: natural killer (T) cells, neutrophils, B- and T 
lymphocyte subsets, myeloid derived suppressor cells, macrophages and dendritic cells. The 
net effect of the interactions between these various cell types and their secreted products 
within the environment of an established tumor participates in determining anti-tumor 
immunity, angiogenesis, metastasis, overall cancer cell survival and proliferation 60. Therefore, 
in addition to the activation of the anti-tumor T cell response, there is increasing inter-
est to modify this immunological balance, e.g. by targeting immune suppressive cell types 
or factors. Different approaches are currently studied to overcome the earlier described 
immunosuppressive environment and to enhance the cytotoxic T cell response. We devel-
oped dendritic-cell based therapy with the intention to potentiate the anti-tumor immune 
response and ultimately improve outcome in mesothelioma patients. It was demonstrated 
that this approach was safe and effective in mesothelioma patients 17, 202, 213. However, in order 
for patients to fully benefit from the potential of immunotherapy, optimal priming of the local 
tumor environment is pivotal. 
TAMs in malignant mesothelioma
After the introduction of asbestos fibers in the lung, macrophages are recruited and activated 
in an attempt to clear the fibers. As the macrophages are unable to eliminate the asbestos 
fibers, a chronic state of inflammation occurs during which the secretion of free radicals 
causes genotoxic damage and the transformation of normal mesothelial cells to malignant 
mesothelioma is facilitated, a process often called ‘frustrated phagocytosis’ as stated earlier 
89. It is known that established mesothelioma tumors contain an abundance of intratumoral 
leucocytes and the phenotype of these cells is topic of recent studies 214. Our group demon-
strated that the inflammatory cell infiltration is rich in macrophages 13. The massive abundance 
of TAMs in the microenvironment of malignant mesotheliomas suggests a pivotal role for 
these cells in the tumor biology of mesothelioma. It is known that normal human mesothelial 
cells and established human mesothelioma cell lines can produce large amounts of cytokines, 
including IL-6, IL-8, granulocyte-colony stimulating factor (G-CSF), and granulocyte-mac-
rophage-colony stimulating factor (GM-CSF) 215, 216. These cytokines recruit monocytes and 
MDSC to the tumor mass, where they can differentiate into macrophages. Unlike in NSCLC, 
not much is known about the phenotype and function of these macrophages in malignant 
mesothelioma. In vitro studies showed that interaction with mesothelioma cells shifts mature 
macrophages toward a M2 phenotype. Izzi et al showed that upon cocultivation with meso-
thelioma cells, macrophages released a significant amount of prostaglandin E2, an arachidonic 
acid metabolite with anti-inflammatory properties 90, 217. The production of this prostaglandin 
stimulates the development of regulatory T cells, promoting an immunosuppressive tumor 
microenvironment 218, 219. Our group investigated the effects of macrophage depletion on 
tumor progression in a murine model of mesothelioma 220. Liposome-encapsulated clodro-
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nate is readily taken up by phagocytic cells, including macrophages, and induces cell-specific 
apoptosis after clodronate is set free into the cytoplasm of cells. Depletion of macrophages 
with clodronate inhibited tumor growth, indicating that macrophages have a significant role 
in the onset and progression of tumor in our murine mesothelioma model. This has been 
confirmed by other studies 221. In addition, we investigated the role of zoledronic acid (ZA), 
a bisphosphonate with antitumor properties, on the myeloid differentiation to TAMs in our 
murine mesothelioma model. ZA inhibits farnesyl diphosphate (FFP) synthase thereby leading 
to a dysfunction of small GTPases which are necessary for normal function of macrophages 
222. Despite the fact that ZA lead to a reduction in TAMs and impairment of polarisation 
towards the M2 phenotype, no improvement of survival was observed 220. This was most 
likely due to the fact that the reduction of TAMs was associated with an increase in the 
number of immature myeloid cells, another immunosuppressive cell type, illustrating the 
complex interactions of immune cells in the tumor microenvironment. 
Burt et al published a study in which they investigated the prognostic significance of circulating 
blood monocytes and tumor-associated macrophages in 667 pleural mesothelioma patients 
who underwent cytoreduction between 1989 and 2009 223. They found that higher numbers 
of circulating monocytes are associated with poor survival in patients with both epithelial and 
nonepithelial mesothelioma. In addition, higher densities of TAMs were associated with poor 
survival in patients with nonepithelial mesothelioma. These TAMs demonstrated an M2-im-
munosuppressive phenotype with high expression of CD163 and CD206 223. Because of the 
high amounts of TAMs present in mesothelioma, manipulation of these cells is a promising 
therapeutic target in this lethal disease. 
TAMs in non-small cell lung cancer
The link between lung carcinogenesis and chronic immune activation is well established. 
Compelling evidence has accumulated that histological assessment of infiltration patterns 
of different host immune response components in NSCLC specimens helps to identify dif-
ferent prognostic patient subgroups 224, 225. TAMs have been implicated in promoting tumor 
growth, progression and metastasis in various solid tumors 27-31. Several studies investigated 
the prognostic value of macrophage infiltration in NSCLC, however the results have been 
contradictory. These discrepancies could reflect differences in the number, grade and stage 
of tumors included in the various studies and the methods used to assess macrophage infil-
tration but most importantly the difficulties to differentiate between M1 and M2 subsets, 
which have varied considerably. Welsh et al were the first to recognize the importance of 
the microanatomical localization of macrophages in the tumor 226. They showed that the 
infiltration of macrophages in tumor islets was related with a good prognosis in contrast to 
infiltration in the tumor stroma, which was related with a bad prognosis in NSCLC. These 
findings indicate that the localization of tumor-associated macrophages is critical in deter-
mining the relationship to prognosis and this has been confirmed by other studies 227. In 
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more recent studies the phenotype of TAMs related to survival has been taken into account. 
Several studies have shown that macrophages in the tumor islets which are associated with 
extended survival are mainly of the cytotoxic M1 phenotype 228, 229. This supports the view 
that immune responses in the tumor islets play a crucial role in preventing NSCLC pro-
gression 228. On the other hand, TAMs of the M2 phenotype which are located in the tumor 
stroma have been related to treatment response to epidermal growth factor receptor-ty-
rosine kinase inhibitors (EGFR-TKIs) and were shown to be independent negative predictors 
of survival in advanced NSCLC treated with an EGFR-TKI 230. In addition, macrophages of 
the M2 immunosuppressive phenotype were correlated with lymph node metastasis and 
poor prognosis in NSCLC 231, 232. More specifically, several studies have shown a possible 
role for the expression of the immunosuppressive cytokine interleukin-10 (IL-10) by TAMs 
in the progression and prognosis of NSCLC 233, 234. IL-10 is produced by a number of cells 
including neoplastic cells and macrophages and Il-10 production is a specific hallmark of TAMs 
with the M2 phenotype. High production of IL-10 has been described to enable tumors to 
evade immunosurveillance and the potential importance of IL-10 in cancer is supported 
by reports of an association between high IL-10 levels in serum or in tumors and worse 
survival in lung cancer patients 235. Zeni et al showed that high IL-10 expression by TAMs and 
not by tumor cells was a predictor of advanced tumor stage and was associated with worse 
overall survival 233. Wang et al showed similar results in their study reporting that high levels 
of IL-10 in TAMs significantly correlated with stage, tumor size, and lymph node metastasis 
234. In another study Wang et al showed that the expression of MMP-9 on TAMs isolated 
from NSCLC samples was higher in patients with late stage disease compared to early stage 
disease, which illustrates the importance of phenotypic analysis of TAMs and their potential 
to create a microenvironment that facilitates tumor progression 236. 
The aforementioned studies show compelling evidence for the prognostic value of TAMs and 
their role in the tumor progression of NSCLC, both beneficial and detrimental. To the best 
of our knowledge there are no clinical studies available on the role of TAMs in small cell lung 
cancer (SCLC). The low incidence (15% of all lung cancer cases) and fast progression resulting 
in little opportunity to obtain histology are possible explanations for this lack in evidence 128. 
TAM-targeted therapy 
Given the emerging evidence regarding the prognostic value of TAMs in both mesothelioma 
and NSCLC, the therapeutic targeting of macrophages represents a valuable strategy to 
complement existing treatments. There is a rationale for re-educating the TAM compartment 
and the (combined) treatment of cancer may benefit from therapies that interfere with the 
attraction or the activation of M2 macrophages or polarize the M2 towards the M1 subtype. 
Influencing the number and functionality of M2 macrophages may improve survival when 
combined with standard or other immunotherapeutic regimens. 
Several strategies are currently investigated that influence TAMs at multiple levels. For exam-
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ple, blockade of factors and cytokines secreted by tumor or immune cells to limit the 
induction of M2 macrophages have been studied. 
These strategies include inhibition of prostaglandin E2 synthesis (cox-2 inhibitor 237), anti-
CCL2 238, anti-TGF-b 239 and anti-IL-6 (Siltuximab 240), however these approaches are at a 
preclinical stage or have met with only limited success so far. Targeting TAM recruitment with 
CSF1R-signaling antagonists improves efficacy of cytotoxic therapies in murine models of 
solid tumors 241, 242. Drastic reduction in TAM density has been achieved using an oral DNA 
vaccine encoding the entire murine Legumain gene (overexpressed by TAMs in murine 
tumor stroma), this vaccine provided effective protection against tumor cell challenge in a 
murine breast tumor model 243, 244. It has been shown that inhibiting IkB kinase (IKK) repro-
grammes the M2 phenotype to the M1 subset 245, 246. Also CD40 therapy seems to skew 
tumor-infiltrating (not the resident) macrophages through CD40-ligation towards the M1 
phenotype 247. In addition, the TLR7 agonist Imiquimod has been associated with a switch 
from M2 tot M1 macrophages in a murine model for gynaecological tumors 248. Furthermore, 
recently depletion of B cells has been demonstrated to be associated with a phenotypic 
switch in macrophages leading to a CD8 recruitment 249. As stated earlier, the effects of bis-
phosphonates (Zoledronic acid) on TAMs were investigated but the impaired polarization 
was associated with increased MDSC levels which diminished the effects on survival 220, 250. 
U’Ren et al have recently shown in a murine tumor model that endogenously produced 
type I interferons suppress the generation of TAMs 251. Therapeutic administration of high 
doses of recombinant IFN-γ has been used to inhibit tumor angiogenesis and growth 252. 
The study of U’Ren et al suggests that in addition to the direct inhibitory effect of IFN-γ on 
endothelial cell migration 252, 253, the inhibition of tumor angiogenesis by recombinant IFN-γ 
may be due in part to inhibition of M2 macrophage generation. An important feature of 
TAMs with the M2 phenotype is their ability to stimulate angiogenesis and thereby aid to the 
evolution, invasion and metastasis of tumors. The abnormal vasculature of tumors impedes 
the delivery of chemo- and immunotherapeutic agents. Moreover, the resulting abnormal 
microenvironment with hyper- and hypoxic regions reduces the efficacy of radiation, chemo-, 
and immunotherapies, selects for more malignant clones, and facilitates disease progression 
254. Thus, restoration of the normal structure and function in blood vessels, referred to as 
vascular normalization, is emerging as a new concept in cancer treatment 255. As stated earlier, 
exposure to hypoxia stimulates TAMs to acquire a pro-angiogenic phenotype and induces 
the production of pro-angiogenic and tissue remodelling factors such as VEGF, placental 
growth factor (PlGF), and MMP-9 256. Rolny et al recently showed compelling evidence 
that histidine-rich glycoprotein (HRG) is capable of polarizing M2 macrophages towards 
a M1 phenotype partly by downregulating macrophage-derived PLGF in multiple murine 
tumor models 257. HRG is a multidomain plasma protein synthesized by hepatocytes and 
has important function in regulation of tumor angiogenesis and immunity 258. After overex-
pression of HRG in cancer cells, tumor vessels became normalized, resulting in decreased 
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hypoxia and improved delivery of chemotherapeutic agents and decreased metastasis 257. 
Critically underlying this effect was the ability of HRG to skew TAM polarization away from 
the pro-angiogenic and immunosuppressive M2-phenotype. Future studies will have to reveal 
whether HRG can live up to its potential as an anticancer drug in humans. 
Hypoxia-inducible factor (HIF) is one of the most important links between low oxygen pres-
sure and macrophage polarization and targeting of its signal transduction pathway could be 
a potential novel therapeutic target 65. The hypoxic cytotoxin Tirapazamine which is activated 
only at very low oxygen levels has been tested in lung cancer but showed no clinical benefits, 
however the treatment success may depend on the selection of patients with high levels of 
tumor hypoxia as we found in a study on hypoxia in NSCLC 259, 260. Instead of the blockade 
or manipulation of hypoxia-induced pathways as an attempt to influence macrophage polar-
ization another possible strategy is to directly decrease the hypoxic conditions in the tumor 
microenvironment. Nitroglycerin, due to its vasoactive effects, tends to redistribute the blood 
supply to the tumor, increasing tumor blood flow, hereby theoretically decreasing hypoxia. 
In a randomized phase 2 trial by Yasuda et al nitroglycerin has been successfully combined 
with chemotherapy in NSCLC, enhancing chemotherapy response, possibly due to better 
delivery of the anti-cancer drugs in the tumor 261, 262. However, a recent randomized phase 
2 study investigating addition of nitroglycerin patches to first-line carboplatin-paclitaxel-bev-
acizumab showed no survival benefit in stage IV NSCLC patients 263. Whether treatment 
with nitroglycerin patches can also influence macrophage polarization will have to be subject 
of future studies. 
Furthermore, an extensive review was published on the influence of aerobic exercise on 
the polarization of macrophages in breast cancer 264. Several animal studies have indirectly 
shown the ability of exercise training to induce an anti-tumor effect of macrophages, how-
ever the exact mechanism and in vivo attribution of potential exercise-induced polarization 
remains to be elucidated. A possible explanation could be the exercise-induced enhanced 
tissue blood flow and inherent decrease of hypoxia, which skews the TAMs towards a more 
M1-like phenotype. 
The emerging understanding of TAM biology and in particular their plasticity has lead to 
the development of numerous potential TAM-targeted therapies. Despite the current lack 
of a strategy that has proven its clinical value, the amount of literature emerging regarding 
TAM-targeted therapy illustrates the great potential of this cell type. Therapeutic targeting 
of macrophages could represent a valuable strategy to complement existing treatments of 
mesothelioma and lung cancer. 
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Aims and outline of the thesis
In the previous chapter, the establishment and importance of the tumor microenvironment 
was described. Tumor-associated macrophages are a pivotal part of this environment and 
have the capacity to greatly influence the natural course of disease and the outcome of 
cancer (immuno)therapy. Especially in mesothelioma, a disease with a profound influx of 
macrophages, their phenotype, function and potential as a therapeutic target could be of 
great value to improve future prognostic and therapeutic strategies. In chapter 2 and chapter 
3 of this thesis, the clinical value of the phenotype of tumor-associated macrophages in mes-
othelioma was investigated. We studied the phenotype of macrophages in tumor biopsies of 
mesothelioma patients and linked this phenotype to the survival of mesothelioma patients 
and their likelihood to develop local tumor outgrowth at an intervention site. The immu-
nosuppressive function of macrophages in a pivotal part of the mesothelioma environment, 
pleural effusion, was investigated in multiple in vitro studies in chapter 4. Furthermore, chapter 
5 illustrates the immunological dynamics in pleural effusion and the relation between the 
immunological composition of pleural effusions and the pleural tumors. After the demon-
stration of the clinical relevance and in vitro suppressive mechanisms of tumor-associated 
macrophages in mesothelioma, their potential as a therapeutic target (monotherapy and in 
combination with dendritic cell-based immunotherapy) was investigated in mesothelioma 
mouse models in chapter 6 and 7. The potential of the novel immunotherapeutic strategy 
using checkpoint blockade in mesothelioma and lung cancer was reviewed and put into per-
spective in chapter 8 and 9. Furthermore, a meta-analysis evaluating the efficacy of different 
immunotherapeutic approaches in NSCLC was included as chapter 10. All presented findings 
are evaluated and put into perspective in the general discussion in chapter 11. 
Together, this work provides a profound translational insight regarding the clinical value, func-
tion and potential as a therapeutic target of tumor-associated macrophages in mesothelioma. 
Furthermore, this thesis thoroughly evaluates the general potential of immunotherapy in 
pulmonary oncology. 
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abstract
Background: The tumor micro-environment and especially the different macrophage 
phenotypes appear to be of great influence on the behavior of multiple tumor types. 
M1 skewed macrophages possess anti-tumoral capacities, while the M2 polarized macro-
phages have pro-tumoral capacities. We analyzed if the macrophage count and the 
M2 to total macrophage ratio is a discriminative marker for outcome after surgery 
in malignant pleural mesothelioma (MPM) and studied the prognostic value of these 
immunological cells. 
Methods: 8 MPM patients who received induction chemotherapy and surgical treatment 
were matched on age, sex, tumor histology, TNM stage and EORTC score with 8 patients 
who received chemotherapy only. CD8 positive T-cells and the total macrophage count, 
using the CD68 pan-macrophage marker, and CD163 positive M2 macrophage count 
were determined in tumor specimens prior to treatment. 
Results: The number of CD68 amd CD163 cells was comparable between the surgery 
and the non-surgery group, and was not related to overall survival (OS) in both the 
surgery and non-surgery group. However, the CD163/CD68 ratio did correlate with 
OS in the total patient group (Pearson r -0.72, p<0.05).  No correlation between the 
number of CD8 cells and prognosis was found. 
Conclusions: The total number of macrophages in tumor tissue did not correlate with 
OS in both groups, however, the CD163/CD68 ratio correlates with OS in the total 
patient group. Our data revealed that the CD163/CD68 ratio is a potential prognostic 
marker in epithelioid mesothelioma patients independent of treatment but cannot be 
used as a predictive marker for outcome after surgery. 
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introduction
Malignant pleural mesothelioma is invariably a lethal tumor with a median survival of 9-12 
months after the first signs of illness. It is one of the diseases caused by exposure to asbes-
tos fibers. The incidence varies from two to 30 cases per 1 000 000 population worldwide. 
Most patients are older than 60 years, a reflection of the latency period of 30–50 years after 
asbestos fiber inhalation.
Chemotherapy is offered to patients as standard of care treatment, as it currently is the only 
treatment that improved survival in randomized controlled trials in mesothelioma patients 1,2. 
The survival benefit of chemotherapeutic treatment is in general modest with 2-3 months 
but long-term survivors do exist.
For decades, clinicians have tried to improve survival by removal of the pleural-based lesions. 
In order to try to completely remove the disease, a pneumonectomy with the complete 
removal of the visceral and parietal pleura is considered necessary, a so-called extra-pleural 
pneumonectomy (EPP). EPP is mostly performed in a multi-modality setting with induc-
tion chemotherapy and adjuvant radiotherapy. Selection of patients appeared crucial in 
the case-series that were published 3. A less invasive procedure, that does not include the 
removal of the affected lung but of the visceral and parietal pleura, if necessary pericardium 
and diaphragm, an extended pleurectomy/decortication (PD), is also performed in patients. 
Whether surgery does lead to increased survival remains a matter of continuous debate, 
but it is evident that long-term survival after surgery occurs 4,5. On the other hand, there 
are also patients in whom survival after surgery is extremely short. This points out the need 
for a biomarker to provide insight in which patients may benefit from surgery and which 
patients do not.
Gordon et al. described a four-gene expression ratio test that can predict good prognosis 
after surgery 6, however this test still has to be validated in a clinical setting. Suzuki et al. found 
in a patient group with predominantly surgical therapy that chronic inflammation in stroma is 
an independent predictor of survival 7, while other groups found a subset of immunological 
cell types to predict for better outcome in patients receiving surgical treatment with a special 
focus on CD8 tumor infiltrating lymphocytes 8,9. The question remains whether these factors 
are prognostic or predictive for the effect of surgery.
The role of immune cells, like CD8 cells, within the tumor microenvironment has become 
a major area of interest in the last decade. It is now established in certain tumor types, that 
these infiltrating immune cells are capable of influencing tumor progression. One of the other 
involved immunological cell types are macrophages, which are known to have a dual role in 
cancer depending on their phenotype. Tumor associated macrophages (TAMs) can be divided 
in classically activated (M1) macrophages and alternatively activated macrophages (M2). 
M1 macrophages, following exposure to interferon-γ (IFN-γ), can secrete chemokines and 
promote T cell proliferation, thus activate type 1 T cell responses and have antitumor activity 
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and tissue-destructive activity. However, M2 TAMs promote the development and metastatic 
capacity of tumors due to the production of multiple cytokines such as interleukin (IL)-1, 
IL-6 and IL-10, vascular endothelial growth factor (VEGF) and transforming growth factor 
beta (TGF-β) 10. In mesothelioma, Burt et al showed that higher densities of tumor-infiltrating 
macrophages are associated with poor survival in patients after surgery, however, this was 
only in patients with non-epithelioid MPM 11.
A large proportion of M1 macrophages in the total macrophage count that can aid in 
tumoricidal activities could provide a better tumor control, since the overall balance in the 
tumor microenvironment shifts to an anti-tumor response. If the TAMs largely consist of 
M2 macrophages, this balance can shift to an overall pro-tumor micro-environment. The 
importance of the percentage of M2 macrophages of the total macrophage count (i.e. the 
CD163/CD68 ratio) and M1/M2 ratio has been found in other tumor types recently, such 
as melanoma, non-small cell lung carcinoma and angioimmunoblastic T-cell lymphoma 12–17. 
In most of these studies, the ratio of M1/M2 macrophages predicts survival and metastatic 
ability of these cancers. Overall, a larger M2 component of the total macrophage count is 
inversely correlated with survival.
With CD8 T-cells and TAMS being the key immune cells in the tumor microenvironment 
18,19, we analyzed if T cells and macrophage subtypes could be useful as a predictive marker 
to select mesothelioma patients for surgical treatment. Furthermore, the prognostic value of 
the different macrophage subtypes and CD8 positive tumor infiltrating lymphocytes (TILs) 
were tested. 
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materials and methods
Patients and specimens
The Erasmus Medical Center ethical commission gave approval for this study. Diagnostic 
paraffin-embedded tumor specimens were used from 8 MPM patients who underwent an 
extended PD during the course of a phase l clinical trial following induction chemotherapy 
in our institute between 2008 and 2010 (a local study which is identified as Erasmus MC 
Cancer Institute MEC number 2008-405). The clinical trial randomized patients to P/D or best 
supportive care. Consent was obtained to use patient material for future research. Unfor-
tunately, from the patients randomized to the best supportive care arm, adequate histology 
was not available in all cases. Therefore, we selected 8 MPM out of the total 89 patients 
that only were treated with chemotherapy during the course of the trial. The selection 
was matched to the surgical cases upon survival, EORTC prognostic score 20 and histology. 
Patient information was anonymized end de-identified prior to analysis. Histopathological 
diagnoses were established by pathologists from our institute and confirmed by the National 
Mesothelioma Pathology Board. Clinicopathological information was collected from patient 
charts. The TNM stage was based on the International Union Against Cancer (UICC) and the 
American Joint Committee on Cancer (AJCC) classification. Overall survival (OS) analysis 
of patients who underwent either chemotherapy or chemotherapy and PD was conducted. 
OS was defined as the time from the completion of chemotherapy to death. Three patients 
are still alive at the time of submitting this manuscript, since these are the 3 patients with 
the longest survival, last contact date was used instead of date of death. 
Immunohistochemistry
The following primary antibodies were used: anti-human CD8 (clone C8/144B, Dako, 
Glostrup, Denmark), anti-human CD68 (clone KP-1, Dako), and anti-human CD163 (clone 
10D6,Leica Biosystems Novocastra, Newcastle, UK). Paraffin-embedded tumor specimens 
were cut into sequential 5 μm thick sections and deparaffinized and stained using a fully 
automated Ventana BenchMark ULTRA Stainer (Ventana, Tucson Arizona, USA) according 
to manufacturers’ instructions at the pathology department. Binding of peroxidase-coupled 
antibodies was detected using 3,3’ - diaminobenzidine (DAB) as a substrate and the slides 
were counterstained with haematoxylin. The specificity of antibodies was checked using 
isotype-matched controls.
Evaluation of CD8, CD68 and CD163 stainings
The number of CD8-positive T-cells, CD68-positive total macrophages and CD163-positive 
M2-type macrophages were independently assessed by two investigators (R.C. and L.L.) who 
were not informed of the patients’ clinicopathological data. To examine TILs and TAMs, the 
number of cells per microscopic field of 0,025cm2 with immunoreactivity to CD8, CD68 
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and CD163 were counted in three independent tumor areas with the most abundant 
immunoreactive cells. For each antibody, the same area was used. Only cells with a visible 
nucleus were counted. We defined the average value of the three times the number of TILs 
and TAMs were counted for each case. 
In vitro measurement of CD80, HLA-DR, IL-10, IL-12, VEGF, PD-L1, CD163, iNOS (NOS2) and 
Arginase-1 in macrophages by quantitative real time PCR
We investigated the influence of mesothelioma-derived factors on the phenotype and func-
tion of macrophages. Monocytes obtained from peripheral blood of an healthy control 
were cultured in the presence of 20 ng/ml recombinant M-CSF (R&D systems, Abingdon 
U.K.) in RPMI medium (Life Technologies, Bleiswijk, the Netherlands) containing 5% normal 
healthy AB serum (NHS) during 6 days at 37 °C /5% CO2. After six days of differentiation, 
macrophages were cultured in the presence of 30 % mesothelioma cell line conditioned 
media (CM) during two days (n=6). CM were obtained from mesothelioma cell lines at 
80% confluency, centrifuged for 10 min at 400 x g to remove cells and debris. These long-
term tumor cell lines were established from the cellular fraction of 6 mesothelioma patient’s 
pleural effusions as described earlier 21. As a control we used standardized M1 (medium 
supplemented with 100 ng/ml LPS [Sigma-Aldrich, Zwijndrecht, the Netherlands] and 20 
ng/ml IFN-gamma [R&D systems) and M2 cultures (medium supplemented with 40 ng/ml 
IL-10 [R&D systems]). Cells were harvested and mRNA was isolated by RNeasy micro kit 
according to manufacturer’s instruction (Qiagen, Hilden, Germany). cDNA was prepared 
from 1 ug RNA sample using First Strand cDNA synthesis kit (Thermo Fisher, Pittsburgh, 
PA, USA). cDNA (5 μL) was amplified by RT-PCR reactions with 1× Maxima SYBR green /
ROX qPCR mastermix (Thermo Fisher) in 96-well plates on an 7300 real time PCR system 
(Applied Biosystems), using the program: 10 min at 95°C, and then 40 cycles of 20 s at 95°C, 
1 min at 58°C and 30 sec at 72°C. The primer sets used for different sets of genes are listed 
in Table 1. Specificity of the produced amplification product was confirmed by examination 
of dissociation curves. Expression levels were normalized to the internal control β-actin.
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Table 1 Primer sequences of genes associated with macrophage phenotype used in RT-PCR
Gene Forward primer Reverse primer
β-actin CTGTGGCATCCACGAAACTA AGTACTTGCGCTCAGGAGGA
CD80 AAACTCGCATCTACTGGCAAA GGTTCTTGTACTCGGGCCATA
HLA-DR AGTCCCTGTGCTAGGATTTTTCA ACATAAACTCGCCTGATTGGTC
IL-10 TCAAACTCACTCATGGCTTTGT GCTGTCATCGATTTCTTCCC
IL-12 GCGGAGCTGCTACACTCTC CCATGACCTCAATGGGCAGAC
VEGF CACACAGGATGGCTTGAAGA AGGGCAGAATCATCACGAAG
PD-L1 TATGGTGGTGCCGACTACAA TGCTTGTCCAGATGACTTCG
CD163 GCGGGAGAGTGGAAGTGAAAG GTTACAAATCACAGAGACCGCT
iNOS ATTCTGCTGCTTGCTGAGGT TTCAAGACCAAATTCCACCAG
Arg1 GTTTCTCAAGCAGACCAGCC GCTCAAGTGCAGCAAAGAGA
Statistical analysis
The numbers of CD8 TILs and CD163 and/or CD68 TAMs were expressed as mean ± 
SD. Statistical differences between the means were analyzed by the Mann–Whitney U test. 
Correlations were made calculating the Pearson r correlation. Statistical calculations were 
performed using IBM SPSS Statistics version 21.0.0.1. Statistical significance was established 
at the p < 0.05 level, and all analyses were two-sided. Overall survival (OS) was calculated 
from the start date of treatment until patient death. 
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results
Patient characteristics
The median age of all participating patients was 62 years (range 36-75 years). There were 12 
men and 4 women. All histologies were of the epithelioid subtype. The patient characteristics 
of the surgery and the non-surgery group are listed in Table 2. Chemotherapeutic treatment 
was given in both groups and consisted of 4 cycles of pemetrexed combined with either 
cisplatin or carboplatin. In case of surgery, P/D was performed 8 to 10 weeks after induction 
chemotherapy in all cases. 
Table 2 Patient characteristics
Surgery Non-surgery
Patients (n) 8 8
Mean age (SD) 60 (11,9) 55 (7)
Male (n) 6 6
EORTC (SD) 1,025 (0,6) 0,88 (0,5)
EORTC high (n) 2 1
EORTC low (n) 6 7
PR after chemotherapy (n) 1 2
TNM
T1-2 (n) 6 5
T3-4 (n) 2 3
N0 (n) 5 5
N1-2 (n) 3 3
M0 (n) 8 7
CD8 Tumor infiltrating lymphocytes in MPM
A representative image of immunohistochemical staining of CD8 TILs are shown in Figure 
1. The mean CD8 numbers were comparable between the surgery and the non-surgery 
group (p=0.51) and no correlation was found between CD8 cell count and OS in the sur-
gery group (p=0.88) and non-surgery group (p=0.96) nor for the whole group (p=0.73).
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Figure 1 Representative image of CD8 staining in the tumor biopsy of one MPM patient.
CD68 and CD163 TAMs in MPM
Representative images of immunohistochemical staining of TAMs are shown in Figure 2a and 
2b. The total count of CD68 was comparable between surgery and the non-surgery group 
(mean 211.3, SD 80.2 vs. mean 213.9, SD 100.4, p=1.0). Also, the total count of CD163 was 
comparable between surgery  and the non-surgery group (mean 168.3, SD 80.2 vs. mean 
164.1, SD 82.5, p=0.8). 
The CD68 count did not correlate with OS (Figure 3a, Pearson r -0.07, p=0.81), the CD163 
count showed an inverse trend with OS (Figure 3b, Pearson r -0.33, p=0.22). 
CD163/CD68 ratio correlating with overall survival
We calculated the CD163/CD68 ratio, i.e. the number of M2 macrophages within the total 
macrophage count. This ratio was significantly negatively correlated with OS in the total 
patient group  (Figure 4, Pearson r -0.72, p<0.05). A correlation analysis for the individual 
groups in regards to the CD163/CD68 and OS showed a significant correlation in the 
non-surgery group (Pearson r -0.91 [p = 0.001]) and a trend for the surgery group (Pearson 
r -0.65 [p = 0.08]).
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Figure 2 Representative images of CD68 (a) and CD163 (b) staining in the tumor biopsy of one MPM patient. 
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Figure 3 Correlation between CD68 (a) count or CD163 (b) count and OS in both surgery and non-surgery 
groups. The CD68 count does not correlate with OS (Pearson r -0.07, p=0.81), the CD163 count shows an 
inverse trend with OS (Pearson r -0.33, p=0.22).
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Figure 4 Correlation between CD163/CD68 ratio in tumor in both surgery and non-surgery patients and OS. 
This ratio is significantly negatively correlated with OS in the total patient group  (Pearson r -0.72, p<0.05)
RT-PCR measurements for macrophage phenotype conditioned in mesothelioma environments
To investigate the influence of tumor-derived factors on macrophage phenotype, we cultured 
monocyte-derived macrophages in the presence of supernatant derived from six mesothe-
lioma cell lines. Tumor cell supernatants (CM) induced macrophages towards a M2 prone 
phenotype with relatively high expression levels of the M2 cytokine IL-10 and low mRNA 
levels of the M1 markers IL-12, CD80 and HLA-DR. The standard M2 marker CD163 and 
the arginase1/iNOS ratio showed differential expressions dependent on the different CM. 
Furthermore, expression levels of the activation marker PD-L1 on macrophages cultured 
in CM were comparable to the M2 condition, in general these levels were lower than 
the M1 condition. Furthermore, results showed that CM have different abilities to influ-
ence macrophage phenotypes (Figure 5). Gene expression of IL-12 was only found when 
macrophages were cultured under M1 conditions and VEGF expression was low/absent 
in all conditions (data not shown). In conclusion, mesothelioma-derived factors influence 
macrophages towards a M2 phenotype to varying degrees.
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Figure 5 Tumor derived factors influence macrophages towards a M2 phenotype to varying degrees. Relative 
mRNA expression levels of IL-10 (a), CD163 (b), CD80 (C), HLA-DR (d), PD-L1 (e), and Arginase-1/iNOS 
(NOS2) ratio (f) in macrophages cultured in six mesothelioma cell line conditioned media (T1 - T6) compared 
to standard M1 and M2 conditions. 
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discussion
Macrophages in tumors are usually referred to as tumor-associated macrophages and their 
presence can be substantial (up to 60% of the tumor mass) 22. A hallmark of macrophages is 
their plasticity, an ability to either aid or fight tumors depending on the tumor environment, 
which has given them the reputation of a double-edged sword in tumor biology 23. At the 
extremes of this spectrum are the M1 and M2 macrophages. In an early phase of tumor 
development, the TAMs mainly consist of an M1-like phenotype and later in the tumorigenic 
process, when the tumor changes its local environment, there is a skewing toward the M2 
phenotype 24–26. Analysis of CD163/CD68 ratio in biopsy material before treatment showed 
a correlation with OS (combined groups: Pearson r -0.72 [p<0.05]; non-surgery group: 
Pearson r -0.91 [p = 0.001]; surgery group: Pearson r -0.65 [p = 0.08]). The total number of 
macrophages did not correlate with OS, indicating that the absolute number of macrophages 
does not influence tumor progression. The percentage of M2 macrophages of the total mac-
rophage count was comparable between the surgery and non-surgery group and therefore, 
the CD163/CD68 ratio does not discriminate in favor of surgery in mesothelioma patients. 
Although the terms M1 and M2 macrophages are an oversimplification of reality, it can be 
used to explain the opposing effects of different macrophage subsets. Our findings indeed 
correspond with the negative prognostic capacities of the M2 macrophages; a large propor-
tion of these CD163 positive macrophages in the total macrophage count correlates with a 
decreased survival. This emphasis that the balance between M1 and M2 macrophages seems 
to play a crucial role in the prognosis of MPM patient. 
As mentioned before, the importance of the CD163/CD68 and M1/M2 ratio is found in 
several other tumor types 12–17. In our study, a similar outcome is found regarding M1/M2 
ratio based on CD163/68 ratio and the prediction of survival in patients with mesothelioma. 
This gives a clinical correlation to the hypothesis of the anti-tumor effect of M1 TAMs and 
the pro-tumor effect of the M2 TAMs. To our knowledge, this is the first publication showing 
the importance of the CD163/CD68 ratio in mesothelioma. Furthermore, this ratio proved 
to be significantly correlated with survival in epithelioid mesothelioma. Previously, it was 
only shown that the absolute number of macrophages was prognostic in non-epithelioid 
mesothelioma after EPP 11. 
In previous studies looking at the number of CD8 TIL’s a high number of CD8 TIL was asso-
ciated with a better outcome in mesothelioma patients after surgery 8(p8),9. We could not 
reproduce these findings in our study. This could be due to the smaller numbers of surgical 
patients that were available for our study. Furthermore, the correlation between TIL count 
and survival was only found in patients that received chemotherapy and EPP, while in our 
study, P/D was performed.
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The six mesothelioma cell lines showed evident heterogeneous effects on the macrophages 
in terms of macrophage polarization. Tumor-derived factors from cell lines induced M1 and 
M2 macrophage phenotypes in varying degrees, in concordance with the broad phenotype 
spectrum found in tumors. However, overall the tumor cell supernatants induced a more 
M2 prone phenotype with relatively high expression levels of IL-10 and low expression 
levels of M1 markers: IL-12, CD80 and HLA-DR. The standard M2 marker CD163 and the 
arginase1/iNOS ratio showed very differential results between the tumor cell lines. Further-
more, PD-L1 expression levels appeared to be relatively low. However, PD-L1 is known to 
be upregulated in a response to high IFN-γ levels as a negative feedback mechanism and 
therefore although PD-L1 is a co-inhibitory receptor, its presence can be indicative of an 
active T-cell response 27–29. This was confirmed by the high PD-L1 level in the M1 condition. 
The in vitro experiments using tumor derived factors to influence macrophage phenotype 
complement the in vivo immunohistochemical findings by demonstrating that tumor-derived 
factors can directly modulate macrophage phenotype multiformity.
In addition to the impact of this finding on prognostic value of the OS of patients, macro-
phages may also reveal as a potential target for therapeutic intervention. Targeting the total 
macrophage population would not be the most optimal approach, since M1 macrophages 
would be decreased as well as the M2 macrophages. In an earlier trial we showed that this 
kind of intervention does not lead to increased survival in a murine model of mesotheli-
oma 30. There are several proposed strategies to counteract the M2 macrophages, including 
inhibiting M2 macrophage recruitment 31, M2 macrophage depletion 32 and blocking M2 
tumor-promoting activity of TAMs 33. However, since M2 macrophages remain the plasticity 
for polarization 34, re-polarization from M2 to M1-type could be the ideal method to tip the 
balance between M1 and M2 to a tumor-hostile situation. Recently, it has become clear that 
there is probably not one single compound that can achieve this goal 22. A proposed strategy 
therefore is a combination of infusion of antibodies against CD40 in order to stimulate the 
secondary lymph node resident macrophages to migrate into the tumor tissue with IFN-γ 
to effectively reprogram tumor-induced M2-like macrophages into activated IL-12 producing 
M1 cells 35. In addition, targeting the nuclear factor κB (NF-κB) signaling pathway, a crucial 
pathway in the activation of M2 TAMs, was shown to switch M2 TAMs to a M1 phenotype 
36. Furthermore, the combined use of Toll-like receptor 9 ligand CpG-ODN and anti-IL-10 
blocking antibodies has been shown to induce the switch from M2 to M1 phenotype 37. 
Also, several other therapeutic strategies are under investigation 38–41. In mesothelioma, Fri-
dlender et al. tested monocyte chemoattractant protein-1 (MCP-1/CCL2) blockade in a 
mouse model for mesothelioma and demonstrated an altered macrophage phenotype and 
improved survival. Currently there are no clinical compounds tested in mesothelioma patients 
which specifically aim at macrophage repolarization 42.
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Our study has several limitations. First, the number of patients included is rather small. This 
is due to the fact that mesothelioma surgery in Europe is advised to be only performed in 
the setting of a clinical trial by the guidelines of the European Respiratory Society and the 
European Society of Thoracic Surgeons for the management of malignant pleural mesothe-
lioma 43. The results of the present trial are based on a trial randomizing patients between 
P/D or observation. This trial was stopped based on slow accrual. Furthermore, only patients 
with the epithelioid subtype of mesothelioma were selected for surgery. The trend seen in 
the surgery group between the CD163/CD68 ratio and OS should be confirmed in a larger 
patient group and we hope that our findings will encourage other researchers who have 
access to patients undergoing surgery to confirm the data presented in this manuscript. 
Second, a definitive M1 macrophage marker would enhance the findings of our manuscript 
for this would give a true insight in the M1/M2 macrophage ratio. NOS2 expression has 
proven be a useful marker for M1 macrophages in several tumor types 44–46. However, for 
mesothelioma, Soini et al. and others 47,48 have demonstrated that NOS2 is highly expressed 
in healthy pleura as well as in cancerous mesothelioma tissues and mesothelioma cell lines. 
These findings complicate the use of NOS2 in pleural diseases as mesothelioma. Whether the 
unique capacity of mesothelial / mesothelioma tumor cells of synthesizing NOS2 is important 
to control a variety of infections in the pleural space in particular is unknown. 
In conclusion, CD163/CD68 ratio was found to be a prognostic marker in a limited number 
of epithelioid mesothelioma patients, but not a predictive marker for outcome after surgery. 
This study emphasizes the importance of the balance between M1 and M2 macrophages 
in tumor behavior. In spite of not being a predictive factor for surgery in mesothelioma, we 
consider that the prognostic value may be of great importance in patients with mesothe-
lioma. Repolarization of macrophages may be a new therapeutic target in mesothelioma 
complementing immunotherapeutic strategies.
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abstract
Objectives: In patients with malignant pleural mesothelioma (MPM), local tumor out-
growth (LTO) after invasive procedures is a well-known complication. Currently, no 
biomarker is available to predict the occurrence of LTO. This study aims to investigate 
whether the tumor macrophage infiltration and phenotype of and/or the infiltration of 
CD8+ T-cells predicts LTO.
Materials and Methods: Ten mesothelioma patients who developed LTO were clinically 
and pathologically matched with 10 non-LTO mesothelioma patients. Immunohisto-
chemistry was performed on diagnostic biopsies to determine the total TAM (CD68), 
the M2 TAM (CD163) and CD8+T-cell count (CD8). 
Results: The mean M2/total TAM ratio differed between the two groups: 0.90±0.09 in 
the LTO group versus 0.63±0.09 in patients without LTO (p<0.001). In addition, the 
mean CD8+ T-cell count was significantly different between the two groups: 30 per 
0.025 cm2 (range 2-60) in the LTO group and 140 per 0.025 cm2 (range 23-314) in the 
patients without LTO (p<0.01). 
Conclusion: This study shows that patients who develop LTO after a local intervention 
have a higher M2/total TAM ratio and lower CD8+ cell count at diagnosis compared to 
patients who didn’t develop this outgrowth. We propose that the M2/total TAM ratio 
and the CD8+ T-cell amount are potential tools to predict which MPM patients are 
prone to develop LTO.
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introduction
In patients with malignant pleural mesothelioma (MPM), local tumor outgrowth (LTO) at the 
intervention site of cytology or biopsy needles, chest tubes, thoracoscopy trocars or surgical 
incisions is a well-known complication of diagnostic and therapeutic procedures, associated 
with substantial morbidity 1–10. Although this phenomenon in general is called tract metastatic 
disease or malignant seeding, this terminology may be misleading. The growth pattern of the 
‘malignant seeding’ appears to be outgrowth of the primary tumor and not related to meta-
static spreading of the tumor along the tract during the procedure. The reported incidence 
of LTO after an intervention is highly variable, with extremes ranging from 0% to 48% 1,2. 
The risk of LTO is ascribed to be related to the invasiveness of the procedure and highest 
following thoracotomy (24%); 9–16% for thoracoscopy; and 0–22% for needle biopsy 3. In 
addition, a recent study describing the occurrence of LTO after indwelling pleural catheter 
placement in 107 patients (60% MPM patients) showed that the duration of interval after 
catheter insertion was a major risk factor for development of LTO 4.
LTO lesions can be very painful and are resistant to analgesics. Surgical resection of LTO is 
rarely feasible and questionable, taking into account the pathophysiology of the disease. In 
spite of the proven, although in mesothelioma limited, effect of chemotherapy on tumor 
load 11, it is mostly ineffective in the treatment of these LTO sites once they have occurred5. 
A recent systematic literature review showed that there is no strong evidence to support 
radiotherapy in treating pain in MPM in general 12. 
Whether chemotherapy prevents LTO in some patients is not known. Prophylactic irradiation 
of intervention track (PIT) was introduced in an attempt to prevent LTO and thus improve 
quality of life for these patients 13. Three randomized controlled trials have addressed this 
subject showed conflicting results, which may be caused by the low incidence of LTO in the 
non-treatment arm 3,6–8. 
The key issue for both patient care and to investigate new agents preventing LTO would 
be to identify patients prone for the development of LTO. We hypothesize that the devel-
opment of LTO is related to immune characteristics within the tumor microenvironment. 
Immune cells are found to be a prognostic factor in MPM. Especially tumor infiltrating CD8+ 
T lymphocytes (TILs) 14,15 were described to inhibit tumor growth whilst tumor associated 
macrophages (TAMs) 16,17 can influence tumor growth. 
Macrophages can develop towards an M1 or M2 subtype 18. Classically activated (M1) macro-
phages have pro-inflammatory, tissue destructive, and anti-tumor activity. On the other hand, 
alternatively activated (M2) macrophages are oriented to tissue repair, tissue remodeling, 
and immunoregulation and therefore can be seen as pro-tumorigenic 19. We hypothesize 
that M2 macrophages could play a role in the development of LTO. In contrast, M1 macro-
phages, together with CD8+ T lymphocytes, could be an indicator of an effective anti-tumor 
microenvironment, preventing LTO. 
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In this study we used the most widely applied T-lymphocyte subset marker and pan-mac-
rophage marker for immunohistochemistry, CD8 and CD68; and CD163, a specific M2 
scavenger receptor that is reliable for demonstrating M2 macrophages by immunohisto-
chemistry 20–23.
The aim of this study is to investigate whether the macrophage number and phenotype 
or the CD8+ TIL number in the tumor microenvironment can predict the development 
of LTO and therefore aid to the selection of patients who could benefit from prophylactic 
interventions. To this end, we quantified TAM and CD8+ TIL numbers in diagnostic tumor 
biopsies of MPM patients who developed LTO and compared them to patients who did not 
develop LTO who were matched for other parameters including clinical outcome.
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materials and methods
Patients and specimens
Retrospectively, paraffin-embedded tumor specimens taken from the diagnostic procedures 
were obtained from 10 patients diagnosed with MPM between 2008 and 2012 who devel-
oped LTO (LTO+ group). LTO was defined as a clear growth of tumor mass in the tract of 
a previous diagnostic or therapeutic procedure while there was no evidence of pleural or 
metastatic disease progression. These 10 cases were matched with 10 cases with compara-
ble age, tumor histology, diagnostic procedures, tumor treatment, and survival that did not 
develop LTO (LTO- group) after diagnostic or therapeutic procedures (Table 1). None of 
the patients did receive PIT. Histopathological diagnoses of mesothelioma were established 
by pathologists from our institute and confirmed by the Dutch Mesothelioma Panel (the 
national mesothelioma pathology board). Clinicopathological information was collected from 
patient charts. The TNM stage was based on CT scan and thoracoscopy report (if available) 
using the International Union Against Cancer (UICC) and the American Joint Committee 
on Cancer (AJCC) classification. Survival and treatment was recorded. Overall survival was 
defined as the time from the date of diagnosis to death. Because of the retrospective nature 
of the study protocol, no ethical institutional review board approval was necessary.
Immunohistochemistry
The following primary antibodies were used: mouse anti-human CD8 (clone C8/144B, Dako, 
Glostrup, Denmark), mouse anti-human CD68 (clone KP-1, Dako), and mouse anti-human 
CD163 (clone 10D6, Leica Biosystems Novocastra, Newcastle, UK). Paraffin-embedded 
tumor specimens were cut into sequential 5μm thick sections, deparaffinized and stained 
using a fully automated Ventana BenchMark ULTRA Stainer (Ventana, Tucson Arizona, 
USA) according to manufacturers’ instructions at the pathology department. Binding of 
peroxidase-coupled anti-mouse antibodies was detected using 3,3’ - diaminobenzidine as a 
substrate and the slides were counterstained with haematoxylin. The specificity of antibodies 
was checked using isotype-matched, non-relevant antibody controls.
Evaluation of slides
Amounts of CD8-positive TIL, CD68-positive TAM, and CD163-positive TAM of the M2 
phenotype were independently assessed by two experienced investigators (R.C. and L.L.) 
and a pathologist (J-L.R) who were blinded to the patients’ clinicopathological data. Three 
representative high-power fields (400x magnification) per slide were manually selected using 
a Leica DM2000 microscope (Leica Microsystems, Wetzlar, Germany). In the thoracoscop-
ically obtained pleural biopsies, the tissue infiltrating tumor front was selected for counting 
of the immune cells 24. In the two patients with only CT-guided needle biopsies, the regions 
with the most tumor cells were chosen for analysis. The number of cells per microscopic field 
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of 0.025 cm2 with immunoreactivity to CD8, CD68 and CD163 were counted manually in 
three independent tumor areas. Cellular staining with a nucleus was counted as a positive 
cell. The same areas were used for analysis for each antibody. For each case, we defined 
the average value of the 3 counts in the slide as the number of TILs and TAMs. To assess 
interobserver reproducibility, the average of the 3 counts of the 3 observers was evaluated 
for comparability. If >10% difference was encountered (2 cases), J-L.R assessed the slides 
for final evaluation.
Statistical analysis
Mean densities of TILs and TAMs were compared between the LTO+ and LTO- group and p 
values were calculated with the Mann–Whitney U test. Correlations were made calculating 
the Spearman’s rank correlation coefficient. Statistical calculations were performed using 
IBM SPSS Statistics 21. Statistical significance was established at the p < 0.05 level, and all 
analyses were two-sided.
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results
Patient characteristics
The median age, sex, disease stage (I–IV), histological diagnosis (epithelioid, biphasic, or 
sarcomatoid), treatment (surgery and chemotherapy), and survival for the LTO+ and LTO- 
group are listed in Table 1. A representative CT scan of a patient who developed LTO is 
shown in Figure 1.
Table 1 Characteristics of the mesothelioma patients that developed LTO and the patients that did not develop 
LTO.
LTO+ LTO-
Patients 10 10
Men 9 8
Average age at diagnosis (range) 61 (38-75) 60 (36-73)
Pathology
Epithelial 9 9
Biphasic 1 1
Stage
Stage I/II 6 6
Stage III/IV 4 4
Diagnostic procedures
Pleuracentesis 4 5
CT guided biopsy 2 1
Thoracoscopy 9 9
Treatment
platinum/pemetrexed 9 10
PR 1 1
SD 7 8
PD 1 1
second line chemotherapy treatment 1 1
experimental drug 2 1
pleurectomy/decortication 1 2
Average survival (range), months 18,9 (11-41) 19,2 (9-38)
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Figure 1 LTO on CT scan. CT scan of a patient with LTO after thoracoscopy on the right side. Outgrowth of 
tumor is seen in the thoracoscopy tract (white arrow).
Tumor-associated macrophages in MPM
Representative images of immunohistochemical staining of TAMs are shown in Figure 2a 
and 2b. The frequencies of CD68 (specific for all macrophages) and CD163 (specific for 
M2 macrophages) TAMs were comparable between the LTO+ and the LTO- group; CD68 
mean 185.1/0.025 cm2 (range 45-408) vs. 219.8/0.025 cm2 (range 92-348) p=0.4, and CD163 
mean 170.5/0.025 cm2 (range 42-422) and 135/0.025 cm2 (range 68-240) p=0.9. A larger 
proportion of CD163+ TAMs amongst the CD68+ TAMs may potentially reflect a more 
detrimental pro-tumor microenvironment. Therefore, we calculated the CD163/CD68 TAM 
(i.e. M2/total TAM) ratio for each patient in the groups with and without LTO development, 
as is shown in Figure 3a. The average M2/total TAM ratio in the LTO+ group was 0.9 (SD 
0.09), compared with 0.63 (SD 0.09) in the LTO- group (p<0.001).
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Figure 2 
Immunohistochemical 
stainings of CD68 
(2a), CD163 (2b), 
and CD8 (2c) in a 
mesothelioma tumor 
specimen. The brown 
color represents 
the CD68 staining 
(2a), the CD163 
staining (2b), and the 
CD8 staining (2c) in 
mesothelioma tumor 
specimens (2a and 
2b are in the same 
microscopic field). 
The blue colored cells 
are CD68, CD163, or 
CD8 negative cells.
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Figure 3 Increased proportions of M2 TAMs and educed numbers of CD8+ cells in diagnostic biopsies from in 
diagnostic biopsies of mesothelioma patients who develop LTO and correlation between M2/total macrophage 
ratio and CD8 lymphocyte count.
a) Ratio of CD163 positive cells (M2) and CD68 cells (all macrophages) of patients who developed local 
tumor outgrowth and those who did not, as determined by immunohistochemistry (N=10 for both groups) 
p<0.001, calculated by MWU test.
b) Quantification of immunohistochemical staining for CD8+ in diagnostic tumor biopsies from patients who 
did (LTO) or did not (non-LTO) develop local tumor outgrowth. N=10; ** p< 0.01.  
c) Correlation between M2/total macrophage ratio and CD8 lymphocyte count. Squares are patients with local 
tumor outgrowth, circles without local tumor outgrowth. A near significant correlation was found between 
the M2/total macrophage ratio and the CD8 TIL count (Spearman’s rho -0.40, p=0.08).
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Tumor infiltrating lymphocytes in MPM
A representative image of an immunohistochemical staining of TILs is shown in Figure 2c. The 
CD8+ TIL counts are shown in Figure 3b. Patients who did not develop LTO had a higher 
number of CD8+ TILs (140/0.025 cm2 (range 23-314)) compared with patients who did 
develop LTO (30/0.025 cm2 (range 2-60))(p<0.01).
CD8 and M2/total TAM ratio
The correlation between the CD8 TIL count and the M2/total TAM ratio is shown in Figure 
3c. Although not statistically significant with a p-value of 0.08 (Spearman’s rho -0.40), all 
patients who developed LTO were clustered in the area representing a high M2/total TAM 
ratio and a low CD8+ TIL count.
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discussion
Within the tumor microenvironment, interactions among tumor cells, immune cells, stromal 
cells, endothelial cells, and the extracellular matrix are vital to tumor progression. MPM 
tumors contain a varying amount of intratumoral leukocytes 25. An improved overall survival 
in patients with MPM tumors that contained a high number of CD8+ TILs was recently 
shown 26. In addition to TILs present in the MPM tumor micro-environment, macrophage 
infiltration in MPM was shown by our group 27, and its prognostic role was also published 16. 
The symbiotic relation between tumor cells and M2 TAMs has been extensively studied in 
the last decade 18,19,28,29. 
In the current study we demonstrated the percentage of M2 TAMs of the total TAM count 
in diagnostic biopsies to be significantly higher in MPM patients who developed LTO after an 
invasive procedure and a significantly lower CD8+ TIL count was also found in patients who 
developed LTO. Although patient numbers were relatively low, this is the first time to our 
knowledge that the composition of the tumor microenvironment is investigated for its poten-
tial use to predict the occurrence of LTO in MPM patients after a diagnostic or therapeutic 
procedure and the first study showing possible markers for the prediction of the occurrence 
of LTO in mesothelioma. The total macrophage or M2 numbers did not differ between the 
two groups, indicating that the phenotype, rather than the total number of macrophages 
is important in LTO. This finding correlates with our earlier finding that the ratio of M2 
macrophages of the total TAM count correlates with survival in epithelial mesothelioma 30.
When macrophages reach the tumor, they can be polarized to a continuum of phenotypes 
with the M1 or M2 phenotype at the ends of the spectrum 18,31. In the presence of M2 polar-
izing cytokines and the absence of signals that give preferential polarization to a M1 TAM they 
polarize towards M2 32. With this increase in M2 of the total macrophage population, several 
M2-derived cytokines involved in the breakdown of extracellular matrix are increasingly 
released (for example VEGF and matrix metalloproteinase 9), which may aid to the process 
of the development of local outgrowth after an invasive procedure 33,34. Vice versa, a more 
M1 TAM oriented microenvironment is more capable to suppress tumor growth by the 
production of e.g. tumor necrosis factor alpha, interleukin 12 and the interaction with other 
anti-tumor immune cells like cytotoxic T-cells. As stated earlier, CD8+ T-cells are capable of 
killing tumor cells directly via e.g. the production of perforin and granzymes. Therefore, in 
concordance with a more M1 TAM oriented microenvironment, in a tumor microenviron-
ment where CD8+ TILs are abundantly present, LTO might be directly suppressed after an 
intervention.   
When combining the M2/total TAM ratio and the CD8+ TIL count, our results suggest an 
interesting potential relationship between these cells. Although only a trend was seen and 
thus speculative; the diagnostic biopsies of patients who developed LTO showed the combi-
nation of a high M2/total TAM ratio and a low CD8+ TIL count compared to the non-LTO 
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group. Comparable results were found earlier in other tumor types 35–37. These results point 
towards a complex interplay within the entire tumor microenvironment. Macrophages and 
T-lymphocytes are known to be able to cross-regulate each other’s function and phenotype 
via multiple pathways 38, e.g. M2 macrophages are able to directly induce regulatory T-cells, 
resulting in suppression of tumor-specific cytotoxic T-cells function and number39. The inter-
actions between macrophages and T-cells in the tumor microenvironment of mesothelioma 
patients will be subject of future studies. 
Our study has several limitations. First, we could only test our hypothesis on a limited number 
of patients. Nevertheless, we show a statistically significant result in the M2/total TAM ratio 
and CD8+ TIL count between the LTO+ and the LTO- group and therefore this should be 
regarded as a preliminary method of predicting LTO.
Secondly, the immune cells that were determined in our study have been correlated to 
survival in previous studies 26,30. While the patients in our study were matched for survival, 
future studies are needed to assess the magnitude of effect of these immune cells on both 
survival and occurrence of LTO. 
Third, in this study we used single staining immunohistochemistry to identify the infiltration 
of TAMs and CD8+ T-cells in mesothelioma biopsies. Ideally, additional markers would be 
useful to identify M2 macrophages in more detail; however, other single immunohistochemical 
markers as CD206 are equivalent to CD163 or still subject of debate. Immunohistochemical 
staining using CD68 and CD163 to characterize TAMs and CD8 for T cell subsets has been 
demonstrated useful in numerous studies 20,21(p163),22–24,40. Furthermore, immunohistochemistry 
is a relatively easy technique that allows characterization of the tumor microenvironment 
that would be feasible in a broad clinical setting. However, further studies will be necessary 
to validate this approach in a larger patient cohort and to establish proper cut-off values. 
conclusions
The macrophage phenotype ratio and CD8+ TIL count in diagnostic biopsies provides an 
opportunity to predict which MPM patients are prone to develop LTO after a local interven-
tion. The M2/total TAM ratio and CD8+ TIL count showed a significant difference between 
the group that developed LTO at a later stage and the group that didn’t. The presence of 
these intra-tumoral immune cells identifies patients who could benefit from prophylactic 
interventions (e.g. in a study of testing PIT). In addition, this study indicates that targeting M2 
TAM function or enhancing CD8+ TILs activity are potential strategies to prevent LTO in 
malignant pleural mesothelioma.
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abstract 
Introduction: Clinical studies have demonstrated beneficial effects of immunotherapy 
in malignant pleural mesothelioma. The pleural cavity seems an attractive compartment 
to administer these types of therapies, however local immunosuppressive mechanisms 
could hamper their efficacy. Macrophages are abundantly present within the meso-
thelioma microenvironment. This study investigates the influence of the macrophage 
phenotype and their capacity to inhibit local immune responses and the decisive role of 
pleural effusion (PE) in this regard.
Methods: We cultured macrophages in the presence of PEs and investigated their phe-
notype. Macrophages and T cells were co-cultured in the presence of PEs and tumor cell 
line supernatants. The levels of 11 cytokines and the prostanoid prostaglandin E2 (PGE2) 
were measured in PEs and supernatants. The presence and phenotype of macrophages 
and T cell subsets was measured in the PE of mesothelioma patients.
Results: PE induced a tumor promoting M2 phenotype in macrophages, which was 
confirmed by the suppressive activity of macrophages on T cell proliferation during 
co-culture. PGE2 was identified as a potential inducer of the suppressive capacity of 
macrophages in PE. Macrophages isolated from PEs displayed an M2 phenotype and 
were negatively correlated with T cells in vivo.
Conclusions: The current study demonstrates that macrophages in PE can play a pivotal 
role in directly hampering the anti-tumor T cell immune response. This emphasizes the 
potential of macrophages as a therapeutic target in mesothelioma and indicates that 
the presence and phenotype of macrophages in PE should be taken into consideration 
in the application of (intrapleural) immunotherapies. 
Key words: mesothelioma, pleural cavity, tumor-associated macrophages, immunosup-
pression, microenvironment
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introduction 
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with currently limited 
treatment options. The immune system is considered to play a major role in the pathogenesis, 
prognosis and, potentially, in the treatment of this devastating disease 1-6.
Despite encouraging results of immunotherapeutic approaches, responses are hampered by 
local and systemic immunosuppressive mechanisms 7, 8. Therefore, attention is focusing on the 
cellular and molecular mechanisms, which play a role in the immunosuppressive tumor envi-
ronment. The pleural cavity is a convenient compartment to administer different treatment 
modalities in close approximation to the tumor and potentially minimizing systemic toxici-
ties. Different intrapleural treatment options are now under investigation 9.Pleural effusion 
(PE) accompanies mesothelioma in approximately 70% of the cases, predominantly in the 
epithelioid subtype 10. PE consists of tumor cells and numerous types of immune cells and 
stromal cells11, 12. Immune cells invade both the tumor and PE of MPM patients 13-15. These 
infiltrating immune cells can exert either beneficial or detrimental effects, depending on 
their phenotype 16. Tumor-associated macrophages (TAMs) are a major component of the 
immune cell infiltration of the tumor microenvironment in mesothelioma patients 17. Under 
the influence of various stimuli within the tumor microenvironment, TAMs can develop into 
a tumor-inhibitory (M1) or tumor-promoting (M2) phenotype 18, 19. Others and we have 
found that the presence and M2 phenotype of TAMs in MPM tumor biopsies was related 
to a worse survival 20, 21. 
Given the close proximity between PE and the pleural tumor, the pleural space is a pivotal 
part of the tumor environment in MPM and characterization of the local immunosuppressive 
mechanisms is essential to improve (local) immunotherapeutic approaches. The aim of the 
present study is to investigate the immunosuppressive properties of PE and its effect on the 
phenotype and function of macrophages. 
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materials and methods 
Collection and processing of pleural effusions
Thoracocentesis was performed using fine-needle aspiration inserted into the pleural cavity 
and the pleural effusion was collected in sterile containers without anticoagulant. Pleural cells 
were pelleted from PE and ficoll density gradient centrifugation was applied to separate the 
red blood cells from the leucocytes as previously described 22. Six PE supernatants were 
selected for the in vitro experiments because accompanying long-term MPM cell lines were 
established from the cellular fractions of these PEs 13. In order to obtain MPM cell lines, the 
original cellular fractions of the PEs were cultured in culture medium (RPMI) supplemented 
with 10% normal human serum. Cell line supernatants (SN) were collected around passage 
number 70 for all cell lines at 80% confluency. Supernatants were collected during passaging 
and centrifuged at 1200G during 10 minutes before use.
Isolation of healthy monocytes and T cells 
Peripheral blood mononuclear cells (PBMC) were isolated from a buffy coat of a healthy 
donor (Sanquin, Amsterdam, The Netherlands) using ficoll density gradient centrifugation 22. 
Monocytes and T cells were isolated with MACS® separation using a Monocyte Isolation 
Kit followed by a Pan T cell Isolation Kit (cat. no. 130-050-201 and 130-096-535, all Miltenyi 
Biotec). Purity of the isolated fractions was confirmed using flow cytometry (>97% pure, 
data not shown). 
Macrophage cultures
For all conditions, normal monocytes from a healthy donor were differentiated to macro-
phages during a 6-day culture in the presence of 10% normal healthy AB serum and M-CSF 
(20ng/ml, R&D systems, cat.no. 216-MC) in RPMI-1640 medium containing GlutaMAX 
(GIBCO, ThermoFisher, cat.no. 61870-010). Subsequent polarization to the M1 or M2 phe-
notype occurred in the presence of lipopolysaccharide (LPS) (100 ng/ml, Sigma-Aldrich, cat.
no. L3012) and IFN-γ (20 ng/ml, R&D systems, cat.no. 285-IF) for M1 or IL-10 (40ng/ml, R&D 
systems, cat.no. 217-IL) for M2 during 2 days. For the PE conditions, the differentiated macro-
phages were subsequently cultured during 2 days in the presence of 10% PE supernatant. 
Gene expression analysis 
Gene expression analysis of selected genes was performed on the macrophages after 8 days 
of culture as described earlier 21. Specificity of the amplification product was confirmed by 
examination of dissociation curves. Expression levels were normalized to the internal control 
β-actin. The primer sequences are depicted in Table 1, Supplemental Data. 
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T cell co-culture and proliferation assay
Monocytes were seeded at 5.104 cells in wells of a 96-well plate and differentiated to macro-
phages during 6 days as described earlier. T cells isolated from the same healthy donor were 
labeled with carboxyfluorescein succinimidyl ester (CFSE, Molecular Probes, ThermoFisher 
cat.no. C34554) as previously described 22.. The CFSE labeled T cells were co-cultured in a 
1:1 ratio with the differentiated macrophages and stimulated using anti-CD3/anti-CD28 
beads (Dynabeads® Invitrogen, ThermoFisher cat.no. 11131D) during 4 days. T cells and 
macrophages were co-cultured during 4 days in 10% normal healthy AB serum, 10% PE 
supernatants (PE, n=6) or 30% MPM cell line supernatants (SN, n=6). Cell division was 
quantified based on serial halving of CFSE intensity, algorithms provided by FlowJo software 
(Treestar) were used. Proliferation percentages were calculated as percentage of T cells 
recruited into cell division, as previously described 23. 
Cytokine measurements 
The levels of 12 cytokines were measured by a magnetic bead-based multiplex assay in 
the six PE supernatants and accompanying MPM cell line supernatants used for the in vitro 
experiments (11-plex and single plex (transforming growth factor beta (TGF-α)) Bio-Plex 
ProTM Magnetic Cytokine Assay, Bio-Rad, specific 11-plex no longer available, TGF-α cat.no. 
171V4001M ). PGE2 levels were measured using a PGE2 Parameter Assay Kit (R&D systems, 
cat.no. KGE004B). MPM cell line supernatants were harvested at 80% confluency in all cell 
lines. The PE supernatants and MPM cell line supernatants were depicted undiluted in the 
cytokines measurements. 
Subjects 
MPM patients were selected from the patient databank which was set up for our immuno-
therapy trials 3. The study was approved by the institutional Ethical Committee of the Erasmus 
MC, Rotterdam, The Netherlands (NL24050.000.08). Thirty patients prior to treatment, 
whose diagnosis was confirmed by the Dutch National Mesothelioma Panel, were included 
in this study based on the availability of stored pleural effusions and accompanying viable 
cellular fractions. Clinical data were retrieved retrospectively. Patient survival was defined as 
the time between diagnosis and death. 
Flow cytometry 
Cryopreserved cellular fractions isolated from pleural effusions were defrosted and stained 
with two marker sets to identify different lymphoid-subsets and myeloid-subsets. The mon-
oclonal antibodies used for flow cytometry are depicted in Table 2, Supplemental Data. All 
samples were stained with a Live/Dead® Fixable Aqua dead cell stain in Amcyan (Invitrogen, 
ThermoFisher cat.no. L34957). The analysis was performed using FlowJo software (Tree Star 
Inc.). 
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Statistical analysis
Data are expressed as mean ± standard deviation. Paired data were compared using the 
paired Wilcoxon rank test. Correlations were made calculating the Spearman’s rank corre-
lation coefficient. Statistical significance was established at the p < 0.05 level, and all analyses 
were two-sided. All statistical analyses were performed using IBM SPSS Statistics 21. 
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Figure 1
Figure 1 Expression of signature macrophage phenotype-related genes after culture under standard M1 or 
M2 condition or in the presence of PE supernatant (n=6). Panel A shows the gene expression of the general 
macrophage marker CD68, panel B and C show the expression of the specific M2 markers scavenger receptor 
CD163 and IL-10. Panel D shows the expression of the activation marker characteristic for the M1 phenotype 
CD80, panel E shows the expression of the activation marker PD-L1 and panel F shows the expression of the 
pro-inflammatory marker HLA-DR. Expression levels are calculated relative to the housekeeping gene β-actin. 
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results 
Pleural effusions polarize monocytes towards a M2 macrophage phenotype
The influence of PE supernatants on the phenotype of monocyte-derived macrophages was 
investigated in vitro. Standard M1 or M2 polarizing culture conditions were used as controls. 
Gene expression of the standard macrophage marker CD68 was used to confirm proper 
macrophage maturation (Figure 1A). Overall, PE supernatants induced gene expression of 
M2 markers with a typical high gene expression of scavenger receptor CD163 (Figure 1B) 
and IL-10 (Figure 1C) and low gene expression of the activation markers CD80 (Figure 1D), 
PD-L1 (Figure 1E) and the typical pro-inflammatory marker HLA-DR (Figure 1F). 
Macrophages suppress T cell proliferation only in the presence of pleural effusions
To investigate the immunosuppressive effect of PE on macrophages we performed mac-
rophage – T cell co-cultures. In addition, we used corresponding MPM cell lines supernatants 
(SN) as a directly tumor cell derived reference. These MPM cell lines were originally estab-
lished from the cellular fractions of the PEs used in this assay 13. We co-cultured PE (10%, 
n=6) and SN (30%, n=6) polarized macrophages with autologous anti-CD3/anti-CD28 
stimulated CFSE-labeled T cells. After 96 hours, T cells and macrophages were harvested 
and T cell proliferation was calculated. The co-culture performed in the presence of 10% 
normal human AB serum was used as a control. Figure 2A demonstrates that macrophages 
significantly reduce the proliferation of T cells in the presence of PE (n=6, p=0.03). This was 
in contrast with macrophages cultured in the presence of MPM cell line SN, in which co-cul-
ture with macrophages enhanced T cell proliferation. The results were comparable for both 
CD4 and CD8 T cells (data not shown). These results indicate that PE induces a functional 
immunosuppressive phenotype in macrophages which cannot be directly attributed to tumor 
cell derived factors. Figure 2B-F demonstrate representative flow cytometry histograms of 
each condition. 
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Figure 2 Macrophages suppress T cell proliferation in the presence of PE. The percentage proliferation of 
only T cells (control, in MPM cell line supernatant (SN) or in PE) was set at 100% and the T cell proliferation 
during co-culture with macrophages was calculated relative to the basic proliferation of only T cells (Panel 
A). Co-culture with macrophages under control conditions (n=3, 10% NHS) did not show a statistically 
significant increase or decrease in T cell proliferation (Panel A). Co-culture with macrophages in the presence 
of SN demonstrated an increase in T cell proliferation (n=6, p<0.05, Panel A). Co-culture with macrophages 
in the presence of PE induced a suppression of T cell proliferation (n=6, p<0.05, paired Wilcoxon test, Panel 
A). Panel B-F demonstrate representative flow cytometry histograms of the following culture conditions: 
unstimulated T cell control (Panel B), stimulated T cells (Panel C), stimulated T cells + macrophages control 
(Panel D), stimulated T cells + macrophages SN (Panel E) and stimulated T cells + macrophages PE (Panel F). 
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PE-cultured macrophages have a robust suppressive phenotype
In order to investigate the robustness of the PE-induced suppressive effect of macrophages 
on T cell proliferation we attempted to rescue the T cell proliferation in vitro (see Figure 
1, Supplemental Data). As macrophages are known for their potential to metabolize piv-
otal nutrients, e.g. tryptophan 24, we added 10% NHS to the 10% PE culture condition to 
investigate whether addition of essential amino acids could enhance the T cell proliferation. 
However, addition of NHS did not result in an increase of T cell proliferation indicating that 
depletion of nutrients doesn’t play a role in the observed suppressive macrophage pheno-
type. In addition, reduction of the PE concentration to 5% did not result in a recovery of T 
cell proliferation. Furthermore, the addition of IFN-γand LPS (M1 culture condition) to PE 
did not result in a recovery of T cell proliferation. These data combined illustrate the vigor 
of the suppressive macrophage phenotype induced by PE. 
PGE2 is a potential mediator of suppressive macrophage function in PE
Given the clear functional difference between macrophages cultured in the presence of PE 
or tumor cell SN we investigated the presence and level of selected cytokines and the pros-
tanoid prostaglandin E2 (PGE2) with known potential to induce a M1 or M2 macrophage 
phenotype 25. We performed a magnetic bead-based multiplex assay and ELISA on the 6 PEs 
and SNs used for the macrophage cultures (Figure 3). In short, these data show a distinct 
similarity in cytokine profile between tumor cell line SNs and the PEs from which these 
tumor cells were originally derived. IL-6 and TGF-α, both associated with a M2 phenotype 
of TAMs 26, were at the highest level amongst the measured cytokines in the PEs and SNs. In 
addition, the pleiotropic cytokine VEGF was measured at relatively high levels. IL-12, TNF-α 
and IFN-γ are associated with a M1 phenotype skewed milieu. IFN-γ was undetectable and 
TNF-α could only be measured at low levels, but a relatively high concentration of IL-12 
was found. The classical type 2 immune response cytokines IL-10, IL-13 and IL-4 could all be 
detected in PE at relatively low levels. Although the MPM cell lines were capable of producing 
IL-17, this cytokine was not detected in the PEs. 
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Figure 3 Concentrations of selected cytokines in PE supernatants and corresponding MPM cell lines 
supernatants (both n=6). Cytokine levels were measured using a magnetic bead-based multiplex assay. The 
prostanoid PGE2 was measured using an ELISA. The depicted concentrations of PE supernatants and MPM 
cell line supernatants are undiluted. 
The measured cytokines in PE are partially or directly tumor cell-derived as the cytokines in 
supernatants of 6 corresponding MPM cell lines show a similar pattern compared to the PEs 
from which the MPM cell lines were developed. Given the marked difference in functional 
suppressive capacity, these cytokines are not likely to play a distinctive role in the suppressive 
effect of PE. In general, the measured cytokines were present at an approximately 3-fold 
increased level in PE compared to the SN. In contrast, PGE2 was present at a 80-fold higher 
level in PE compared to the SN. In addition, PGE2 levels in PE corresponded with the mac-
rophage-induced T cell suppression (see Figure 2, Supplementary Data), which could not 
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be observed for any of the measured cytokines (data not shown). Furthermore, addition of 
synthetic PGE2 to the co-culture in the presence of MPM supernatant (PGE2 concentration 
0.3 ng/ml) at the average concentration that was measured in the PEs (30 ng/ml) resulted 
in a 50.4% reduction of T cell proliferation (see Figure 2, Supplementary Data). These data 
indicate that PGE2 plays a role in the observed induction of an immunosuppressive pheno-
type of macrophages by PE. 
Patient characteristics
In order to investigate the in vivo relevance of the previous in vitro findings, the presence 
and phenotype of TAMs and T cells was investigated in the PE of 30 MPM patients prior to 
treatment or pleurodesis. Patient characteristics are described in Table 1. The mean survival 
of the patients after diagnosis was 13.4 months (±7.5 months). The majority of the patients 
were male and most tumors were of the epithelioid type. All patients presented with con-
siderable amounts of PE. 
Patient characteristics
Age (mean ± SD )
Sex 
Survival (months, mean ± SD)
68.4 ± 8.0
Male
Female
13.4 ± 7.8
30 (100)
29 (96.7)
1 (3.3)
30 (100)
Histology Epithelioid 
Sarcomatoid
Biphasic
26 (86.7)
2 (6.7)
2 (6.7)
Pleural effusion
Volume (ml, mean ± SD) 1353 ± 600 30 (100) 
Macrophages and T cells in PE of MPM patients
Using flow cytometry, the presence and phenotype of T cell and TAM subsets was inves-
tigated in the PE of 30 MPM patients. TAM phenotype was determined according to the 
expression of CD163 (scavenger receptor, M2 marker) and/or CD206 (mannose receptor, 
M2 marker). Figure 3 of the Supplemental Data shows an example of the flow cytometric 
analysis of TAMs. The majority of the TAMs in PE expressed either CD206 or both CD206 
and CD163. Because both markers are frequently used as M2 markers and macrophage 
marker expression is known to be heterogeneous, we classified TAMs that express either 
marker or both as M2. With a mean of 46.8% (±32.2%) of total alive cells, TAMs were the 
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most prevalent of the measured immune cells in PE of MPM patients, however the inter-pa-
tient variation was considerable (Figure 4A). In addition, T cell subsets were detected with 
clear patient-to-patient variability; in general, CD4 T cells were more prevalent than CD8 T 
cells (mean CD3 T cells 26.7±27.9%, CD4 T cells 15.4±18.8%, CD8 T cells 8.5±8.8%). Fur-
thermore, the presence of regulatory T cells (Tregs) in PE of MPM patients was confirmed 
(mean 6.7±7.4% of CD4 T cells) 13, 27. 
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Figure 4 T cell subsets and TAMs in PE of 30 MPM patients.  
Tregs are depicted as percentage of CD4 T cells. All other cell populations are depicted as percentages of total alive 
cells (Panel A). Tregs were classified as CD4+CD25+CD127-FoxP3+ cells. TAMs are CD45+CD14+CD68+, 
M2TAMs are CD206+, CD163+ or CD206+CD163+ TAMs. Panel B shows the correlation between all 
TAMs and T cells in the PE of MPM patients. T cells are all CD3+ cells, TAMs are all CD45+CD14+CD68+ 
cells. Spearman’s rho -0.90, p<0.001. Panel C shows the correlation between all TAMs and Tregs, calculated 
as a percentage of CD3+CD4+ positive cells. Tregs were classified as CD4+CD25+CD127-FoxP3+ cells.
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Based on the in vitro suppressive effect of macrophages on T cells in the presence of PE, 
we investigated the correlation between these cell types in the PE of 30 MPM patients. 
We found a negative correlation between TAMs and all T cells in these PEs (Figure 4B, rho 
-0.90, p<0.001), both CD4 T cells and CD8 T cells contributed to this correlation (rho -0.89, 
p<0.001 and rho -0.85, p<0.001 respectively). Because we confirmed that TAMs in PE are 
mainly of the M2 phenotype, the same correlations could be found when they are calculated 
with M2 TAMs instead of TAMs. Furthermore, Tregs (% of CD4) showed a positive correlation 
with TAMs (Figure 4C, rho 0.58, p<0.01), indicating the co-regulation of immunosuppressive 
cell types. In order to confirm the specificity of the correlation between TAMs and T cells, 
total B cells (CD19+) were also measured in the 30 PEs (mean 7.9±7.8 % of alive cells). 
There was no significant correlation found between B cells and TAMs (rho -0.06, p=0.75). 
Furthermore, PGE2 levels were measured in the 30 PEs but no correlation could be found 
between the PGE2 concentration and the TAMs or T cells present in the PEs (data not 
shown), indicating the multifactorial etiology of cellular trafficking in the pleural space. 
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discussion 
In the present study, we investigated the immunosuppressive properties of PE from MPM 
patients and its influence on macrophage phenotype and interaction with T cells in vitro and 
in vivo. We demonstrated that in PE, cytokines associated with an immunosuppressive envi-
ronment are abundantly present. Macrophages cultured in the presence of PE from MPM 
patients exhibited a M2 phenotype and suppressive function in vitro. PGE2 was identified as 
a potential responsible factor for the induction of the suppressive macrophage phenotype 
in PE. Furthermore, we confirmed that TAMs in PE of MPM patients are predominantly of 
the M2 phenotype and show a negative correlation with T cells in vivo. 
It should be appreciated that the results obtained in this study are restricted to the pleural 
effusion and cannot be regarded as similar to the tumor microenvironment itself. From our 
data, it cannot be concluded that tumor-infiltrating macrophages have similar effects. We 
hypothesize, as can be derived from our data, that the pleural effusion itself may be one of 
the immunosuppressive mechanisms induced by the tumor in a complex way.
We have demonstrated earlier that MPM cell line supernatants are capable of inducing 
macrophages with the M2 phenotype 21. The current study showed that the PEs, which were 
the original source of the MPM cell lines, induce a much stronger functional M2 phenotype to 
suppress T cell proliferation. In addition, both MPM cell line supernatants and PEs contained 
comparable patterns of a selected number of cytokines, suggesting that these cytokines could 
be tumor cell derived. However, the functional properties of the macrophages cultured in the 
presence of MPM cell line supernatants or PEs differed substantially. Macrophages cultured 
in the presence of PE suppressed T cell proliferation whereas MPM cell line conditioned 
media did not exert this effect. The presence of some of the measured cytokines, e.g. IL-6 
and TGF-β, confirms the immunosuppressive character of the intrapleural compartment 
because they are known for their M2-skewing effect and association with a worse clinical 
outcome 25, 28-31. However, our results indicate that these cytokines are not responsible for 
the suppressive function of macrophages in the current study. In contrast, we identified the 
prostanoid PGE2 as a potential inducer of the suppressive effect of PE on macrophages. 
PGE2 is known to be a potent regulator of immune responses and especially suppresses type 
1 immunity, which has made PGE2 a popular target of interest in cancer immunotherapy 32, 
33. We have shown earlier that inhibition of the PGE2 synthesizing enzyme COX-2 resulted 
in an improved effect of dendritic cell immunotherapy in a mesothelioma mouse model 34. 
This beneficial effect was ascribed to the reduction of MDSC levels. In addition, Zelenay et 
al. recently demonstrated that PGE2-dependent suppression of myeloid cell activation is an 
important mechanism of tumor immune escape 35. 
Our current results demonstrate that PGE2 is present at high levels in the pleural effusion 
of MPM patients and could play a role in the immunosuppressive environment of this 
compartment through induction of a suppressive macrophage phenotype. Although PGE2 
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is a known inducer of the immunosuppressive phenotype in macrophages, there are other 
soluble factors present in the pleural space (e.g. M-CSF and CCL2), which can regulate the 
recruitment of monocytes and subsequent differentiation to macrophages. After matura-
tion, we hypothesize that PGE2 produced by MPM cells is an important factor to induce 
the immunosuppressive phenotype which results in an autocrine positive feedback loop as 
macrophages themselves are also capable of PGE2 production. This mechanism provides 
additional rationale for the implementation of COX-2 inhibitors in tumors with known high 
levels of PGE2 and M2 macrophages in their microenvironment. 
By demonstrating a negative correlation between TAMs and T cells in PE of MPM patients 
we have provided an indication that the in vitro suppressive effect of macrophages in the 
presence of PE also plays a role in vivo. The positive correlation between TAMs and Tregs 
further illustrates the immunosuppressive environment of PE in MPM patients. In this paper, 
we classified patient-derived TAMs that expressed either CD163 and/or CD206 as M2 
macrophages. Although expression of these markers does not demonstrate any functional 
properties, CD163 and CD206 are widely used as pivotal human M2 markers 36. 
Recently, Scherpereel et al showed that there is a defect in the recruitment of CD8 T cells 
in malignant PE of various cancer patients 27. Our current data demonstrate a potential role 
for TAMs regarding this T cell inhibition and therefore identify TAMs as a pivotal target to 
improve the immunosuppressive environment in MPM. 
Our study provides important insights regarding the use of the pleural cavity as a compartment 
to administer (immuno)therapies. Inherent to the fact that mostly epitheloid mesothelioma is 
associated with pleural effusions we have restricted our study on this subtype. The advan-
tage of local delivery in close proximity of the tumor may add to an increased efficacy and 
may increase the dosages delivered to the tumor while limiting the toxicity to other organs. 
For instance, it was found that intrapleural dosing of cisplatin was feasible with a very high 
tissue penetration and a low serum concentration 37. The intrapleural administration of 
immunotherapies to treat pleural malignancies has been an approach of interest for many 
years, however this method has remained experimental so far 38. Sterman et al have achieved 
clinical responses in some patients after administration of intrapleural adenoviral-mediated 
interferon gene transfer 39-41. Recently, Adusumilli et al showed promising results regarding 
the intrapleural administration of chimeric antigen receptor (CAR) T cell therapy in a mouse 
model of pleural malignancy 42. This preclinical success will soon be followed by a phase 1 
clinical trial. The immunosuppressive character of the soluble and cellular components in PE 
of MPM patients demonstrated in this study is an important factor to take into account when 
applying intrapleural immunotherapies. We propose that the characterization and targeting 
of the local immunosuppressive mechanisms, e.g. through the use of COX-inhibition, could 
greatly enhance the potential of immunotherapy in mesothelioma. Based on the current study 
the drainage of PE, when high levels of TAMs are present, prior to intrapleural administration 
of immunotherapy seems beneficiary in order to achieve optimal immune stimulation. 
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In conclusion, immunotherapeutic strategies that exploit the anti-tumor potential of the 
immune system are emerging for the treatment of malignant pleural mesothelioma. However, 
the immunosuppressive environment created by the tumor hampers the potential of these 
immunotherapies. The current study demonstrates that pleural effusion is an important 
immunosuppressive compartment in MPM and that TAMs play a pivotal role in hampering 
the anti-tumor immune response.
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supplementary tables
Table 1 Primer sequences
Gene Forward primer Reverse primer
β-actin CTGTGGCATCCACGAAACTA AGTACTTGCGCTCAGGAGGA
CD68 CTTCTCTCATTCCCCTATGGACA GAAGGACACATTGTACTCCACC
CD163 GCGGGAGAGTGGAAGTGAAAG GTTACAAATCACAGAGACCGCT
IL-10 TCAAACTCACTCATGGCTTTGT GCTGTCATCGATTTCTTCCC
CD80 AAACTCGCATCTACTGGCAAA GGTTCTTGTACTCGGGCCATA
PD-L1 TATGGTGGTGCCGACTACAA TGCTTGTCCAGATGACTTCG
HLA-DR AGTCCCTGTGCTAGGATTTTTCA ACATAAACTCGCCTGATTGGTC
Table 2 Flow Cytometry antibodies
Marker Fluorochrome Clone Company
CD3ε APC-Cy7 UCHT1 eBioscience
CD4 FITC RPA-T4 BD Biosciences
CD8a APC-eFluor450 RPA-T8 eBioscience
CD25 PE-Cy7 M-A251 BD Biosciences
CD127 PE M21 BD Biosciences
FoxP3 APC PCH101 eBioscience
CD14 PE Texas Red TuK4 Invitrogen
CD16 Pacific Blue 3G8 BD Biosciences
CD68 Biotin clone Y1/82A Biolegend
Streptavidin
APC-Cy7
Biolegend
CD163 PE GH1/61 eBioscience
CD206 PerCP-Cy5.5 19.2 eBioscience
CD11c APC S-HCL-3 BD Biosciences
HLA-DR PE-Cy7 L243 BD Biosciences
CD45 FITC HI30 eBioscience
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Figure S1 Macrophages cultured in the presence of PE display a robust suppressive phenotype. All depicted 
conditions are co-cultures of macrophages and T cells. One PE with distinct suppressive properties was chosen 
to perform this assay. Proliferation of T cells during co-culture with macrophages in the presence of 10% NHS 
was used as the reference value (set to 100%), all other conditions are calculated relatively to this proliferation. 
Addition of 10% PE to the co-culture resulted in a profound reduction of T cell proliferation, which could not 
be rescued by the addition of NHS, or M1-skewing factors IFN-γ and/or LPS.  
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Figure S2 Prostaglandin E2 (PGE2) could be responsible for the PE-induced suppressive function of macrophages. 
Panel A shows the suppressive effect per tested PE. PE 6 displays a markedly reduced suppressive effect on 
macrophages, compared to the other 5 PEs (panel A). When correlating the relative T cell proliferation during 
co-culture with PGE2 concentrations (panel B), PE 6 also contained the lowest PGE2 concentration. This result 
illustrates the potential role of PGE2 in the suppressive effect of PE on macrophages. Furthermore, addition 
of synthetic PGE2 at 30 ng/ml (average PE concentration) to one of the tumor cell line supernatants with an 
average PGE2 concentration (0.3 ng/ml, MQ control condition) resulted in reduction of T cell proliferation of 
50.4% during co-culture with macrophages (MQ PGE2 condition, panel C). 
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Figure S3 Flow cytometric analysis of TAMs in PE. TAMs were characterized as CD45+CD14+CD68+ cells. 
These TAMs were further classified depending on their CD206 and CD163 expression. All TAMs which 
expressed either CD206, CD163 or both, were classified as M2 TAMs.  
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abstract
Objectives: Clinical studies have proven the potential of immunotherapy in malignancies. 
To increase efficacy, a prerequisite is that treatment is tailored, so precision immune-on-
cology is the logical next step. In order to tailor treatment, characterization of the 
patient’s tumor environment is key. Pleural effusion (PE) often accompanies malignant 
pleural mesothelioma (MPM) and is an important part of the MPM environment. Fur-
thermore, the composition of PE is used as surrogate for the tumor. In this study, we 
provide an insight in the dynamics of the MPM environment through characterization 
of PE composition over time and show that the immunological characteristics of PE do 
not necessarily mirror those of the tumor. 
Materials and Methods: From 5 MPM patients, PE and tumor biopsies were acquired 
at the same time point. From one of these patients multiple PEs were obtained. PEs 
were acquired performing thoracocenteses and total cell amounts were determined. 
Immunohistochemistry was performed to quantify immune cell composition (T cells, 
macrophages) and tumor cells in PE derived cytospins and tumor biopsies. 
Results: The PE amount and (immune) cellular composition varied considerably over 
time between multiple (n=10) thoracocenteses. These dynamics could in part be attrib-
uted to the treatment regimen consisting of standard chemotherapy and dendritic cell 
(DC)-based immunotherapy. In addition, the presence of T cells and macrophages in PE 
did not necessarily mirror the infiltration of these immune cells within tumor biopsies 
in 4 out of 5 patients. 
Conclusions: In this proof-of-concept study with limited sample size, we demonstrate 
that the composition of PE is dynamic and influenced by treatment. Furthermore, the 
immune cell composition of PE does not automatically reflect the properties of tumor 
tissue. This has major consequences when applying precision immunotherapy based on 
PE findings in patients. Furthermore, it implies a regulated trafficking of immune regulating 
cells within the tumor environment. 
Keywords: malignant mesothelioma, pleural effusion, immunotherapy, tumor environ-
ment
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introduction
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor mainly caused by the 
inhalation of asbestos fibers. MPM can develop from both the visceral pleura and the parietal 
pleura. The occurrence of pleural effusion is associated with approximately 70% of the MPM 
patients, especially in MPM of the epithelioid subtype 1. Pleural effusion accumulates in the 
pleural space when influx of effusion outweighs efflux. Increased production occurs due to 
excessive plasma leakage through hyperpermeable intratumoral vessels. In addition, blockade 
of the pleuropulmonary lymphatics by tumor cells results in reduced absorption 2. Build-up 
of pleural effusion can result in profound shortness of breath and deterioration of quality 
of life. Although effusion cytology for diagnostic purposes in MPM is controversial and not 
recommended in the ESMO Clinical Practice Guidelines for malignant pleural mesothelioma, 
drainage is commonly performed to relief symptoms 3. Pleural effusion of mesothelioma 
patients can comprise different cell types and soluble factors, which can be derived directly 
from the tumor, its environment and/or from the vasculature. Immune cells like T cell subsets 
(e.g. CD8 T cells and regulatory T cells) and tumor-associated macrophage subsets (anti-tu-
mor M1 or pro-tumor M2 TAMs) are present in most malignant pleural effusions 4-7.
As immunotherapy is gaining ground in many different tumor types, various immunother-
apeutic approaches are also being investigated in clinical studies in mesothelioma patients 
8-12. In order to optimize the efficacy of immunotherapy in mesothelioma, a tailor-made 
approach is warranted. 
Given the close proximity of pleural effusion to the pleural tumor, it is an important part of 
the mesothelioma environment and often used as a surrogate marker for the tumor tissue. 
Furthermore, the pleural cavity can be an attractive site to locally administer (immuno)
therapies. In this study, we investigate the robustness of the pleural effusion composition and 
whether it reflects the pleural tumor in mesothelioma. 
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materials and methods
Patient material
Five MPM patients were selected from whom tumor biopsies and pleural effusion cytospins 
were derived at the same time point. The biopsies and effusions were acquired during VATS 
surgical biopsy procedures, prior to any treatment. All patients were diagnosed with MPM of 
the epithelioid subtype by the Dutch National Mesothelioma Panel. Pleural effusion was col-
lected in sterile tubes or bags without anticoagulant. Pleural cells were pelleted from pleural 
effusions using centrifugation at 400G for 10 minutes. Ficoll density gradient centrifugation 
was applied to pleural effusions with evident blood contamination to separate the red blood 
cells from the leucocytes. Tumor biopsies were embedded in Tissue-Tek II OCT-compound 
(Miles, Naperville, IL, USA), snap frozen in liquid nitrogen and stored at -80ºC. Tissue sections 
(6 μm) were cut using a HM-560 cryostat (Microm, Heidelberg, Germany). Cytospin prepa-
rations were made of an optimally diluted PE cell suspension (Shandon Cytospin 4, Thermo 
Electron Corporation, Massachusetts, United States). This study is a retrospective analysis of 
data, all patient materials were acquired between 2010 and 2013. 
Immunohistochemistry
Cytospins and tumor biopsies were stained with CD8 (Dako, Glostrup, Denmark) and 
the commonly used M2 macrophage marker CD163 (eBioscience, San Diego, USA). The 
cytospin series of the patient followed in time were stained for calretinin, CD68 and CD3 
(Dako). Antibodies were incubated for 1 hour and detected using the RAM - APAAP method 
(Dako). Naphtol-AS-MX-phosphate (0.30 mg/ml, Sigma-Aldrich Chemie B.V., Zwijndrecht, 
the Netherlands) and new fuchsine (160 mg/ml in 2M HCl; Chroma-Gesellschaft, Köngen, 
Germany) were used as substrate. An isotype-matched antibody was used as control. The 
percentage of CD8- or CD163- positive cells in representative areas of the tumor biopsies 
was determined as described earlier 13, 14. In the cytospins, in three representative areas the 
amount of positively stained cells among a total of 100 cells was counted and we defined 
the average value of three counts as the percentage of positive cells in the cytospin. Tumor 
slides and cytospins were independently evaluated by L.L. and K.B. 
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results
Longitudinal pleural effusion follow-up 
One patient underwent 10 thoracocenteses to relieve dyspnea symptoms in the course 
of one year. The maximum pleural effusion amount was drained until the flow through the 
drain stopped. During this year the patient was treated with four courses of cisplatin and 
pemetrexed and as a maintenance treatment with three courses of dendritic cell-based 
immunotherapy and pleurodesis attempts with talc 15. Treatment responses were evaluated 
according to the Modified RECIST criteria 16, 17. Since no measurable lesion was present 
when the diagnosis was made, initiation of chemotherapeutic treatment was delayed until 
a measurable lesion had developed. Chemotherapy induced a partial response (PR) and 
immunotherapy was followed by a stable disease state (SD), which lasted one year. The 
thoracocenteses were performed prior to a pleurodesis procedure with talc slurry (fig. 1 
– week 50 time point) which did not result in pleurodesis and ultimately the placement of 
an indwelling PleurX® catheter. In order to gain insight in the dynamics of pleural effusion 
formation and composition we evaluated the cellular amount and the proportion of tumor 
cells and T cells in time. In figure 1A the amounts of pleural effusion in time are depicted. This 
amount varied between 400ml and 1600ml. In addition to the amount of pleural effusion, the 
total cellular amount varied considerably (fig. 1B). The total cellular amount decreased mark-
edly after chemotherapy and immunotherapy. In concordance with the total cellular amount, 
the percentage of cells positive for the frequently used mesothelioma tumor cell marker 
calretinin (fig. 1C) decreased after chemotherapy. Tumor cell amounts in pleural effusion also 
depicted clinical response; progression of disease was associated with an increase and partial 
response with a decrease in tumor cells. After immunotherapy the percentage of calretinin 
positive cells was not affected. In addition to tumor cells, the dynamics of CD3 positive T 
cells were studied (fig. 1D). Over time the cellular compartment consisted of 3% to 20% of T 
cells. The relative amount of T cells in the pleural effusion of this patient was diminished both 
after chemotherapy and immunotherapy (fig. 1D). There was no evident correlation between 
the amount of T cells and disease state. In addition to T cells, CD68 positive macrophages 
were measured, this subset was not influenced by treatment regimen or disease state and 
their presence in the pleural effusion of this patient was constitutively high (data not shown). 
Over the course of one year the pleural effusion amount and (immune) cellular composition 
varied considerably in this patient. These dynamics can partly be explained by the treatment 
regimen; however apparent fluctuations beyond the treatment timeframes are visible. Since 
the final pleural effusion sample (fig. 1 – week 54 time point) was acquired after a pleurodesis 
procedure with talc slurry (performed at week 50 time point), the presence of talc in the 
intrapleural space could have influenced the immune infiltrate, however we found no changes 
in T cell or macrophage amounts. 
Chapter 5
116
Figure 1 Dynamics in pleural effusion amount and cellular composition in an MPM patient over one year 
from diagnosis onwards. Abbreviations: PE=pleural effusion, PD=progression of disease, PR=partial response, 
SD=stable disease. CT-scan evaluated disease states are depicted above the graphs. The grey bars depict the 
period during which the patient received 4 courses of chemotherapy (cisplatin/pemetrexed, light grey bar) 
and 3 courses of DC immunotherapy (dark grey bar). Ten subsequent thoracocenteses were performed in 
order to relieve dyspnea. Panel A shows the variation in pleural effusion amount. Panel B shows the variation 
in total cellular amount. Panel C shows the percentage of calretinin positive tumor cells. Panel D shows the 
variation in relative amount of CD3 positive T cells over time.
Pleural effusion vs. tumor
In order to further clarify the interactions between pleural effusion cells and the pleural 
tumor a study was performed to investigate the infiltration of CD8 T cells and M2 TAMs in 
tumor biopsies and accompanying pleural effusions which were acquired at the same time 
point, before the start of any treatment. None of the investigated pleural effusions were 
contaminated with blood and no further purification was necessary. An example of the 
immunohistochemical staining of patient number 5 is shown in Figure 2. 
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Figure 2 Immunohistochemical staining of MPM biopsy and pleural effusion cytospin of patient number 5. 
Arrows indicate cells positive for either CD163 (Panel A and B), or CD8 (Panel C and D). Panel A and B 
show staining of M2 macrophage marker CD163 in the tumor biopsy (panel A) and pleural effusion cytospin 
(panel B). Panel C and D show staining of CD8 in the tumor biopsy and pleural effusion cytospin respectively.
This study among five patients showed that there can be a discrepancy between the distri-
bution of CD8 T cells and M2 TAMs in pleural effusion and the presence of these immune 
cells in the tumor tissue (fig. 3). In patient 3 and 5 no M2 TAMs were detected in the PE 
while the accompanying tumor biopsies contained a substantial amount of M2 TAMs (fig. 
3A). Patient 1, 2, and 5 had high levels of CD8 T cells in their pleural effusion but CD8 T cells 
were virtually absent in the corresponding tumor biopsies (fig. 3B). Furthermore, M2 TAMs 
were predominantly present in the tumor biopsies while CD8 T cells were mostly present 
in the pleural effusions. 
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Figure 3 M2 TAM amounts and CD8 T cell amounts in pleural effusions do not mirror the content of 
the tumor. Of five MPM patients tumor biopsies were available which were acquired at the same time 
points as the accompanying pleural effusions. M2 TAMs (CD163) and CD8 T cells (CD8) were identified via 
immunohistochemical staining of cytospins derived from pleural effusions and tumor biopsy slides. Panel A 
shows the differences in presence of M2 TAMs between pleural effusions and tumor biopsies, Panel B shows 
these differences for CD8 T cells. Results are depicted as percentages of positively stained cells within the 
total tumor slide or cytospin.    
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discussion
The current study shows for the first time that the cellular composition of pleural effusion 
in MPM patients is dynamic and influenced by treatment response. In addition, the immune 
cell composition of pleural effusion does not necessarily reflect the properties of the tumor. 
Pleural effusion is often studied as an easy-access reflection of the properties of the pleural 
tumor. As therapies are becoming more individualized and precise, a thorough characteri-
zation of the local milieu is warranted. Because of the limited patient number, the current 
study should be regarded a proof-of-concept for future studies. 
We presented a patient who underwent 10 thoracocenteses in the course of one year to 
relieve dyspnea symptoms, on the patients’ request a pleurodesis procedure with talc slurry 
was postponed until the treatment regimen was completed. In this patient we showed that 
the cellular composition is influenced by response to therapy. The amount of tumor cells 
found in PE correlated with the response to treatment. The composition of immune cells is 
more complex and cannot be explained from this single patient experiment. The main conclu-
sion to be drawn is that timing, disease status, and treatment may all have an influence on the 
cellular content of pleural effusion. Furthermore, we showed that the immune composition 
of pleural effusion can differ greatly from the intratumoral composition. We constitutively 
found higher levels of CD8 T cells in the pleural effusions compared to the tumor biopsies, 
which could indicate that the tumor has a protective mechanism against the influx of these 
immune cells with anti-tumor effects. McCoy et al. showed that higher proportions of prolif-
erating CD8 T cells in peripheral blood were associated with poor survival in patients with 
advanced thoracic malignancies 18. This finding supports our hypothesis that high levels of 
pro-inflammatory immune cells in the periphery (e.g. pleural effusion, blood), could be a sign 
of potent defense against an anti-tumor immune response in the tumor itself. In contrast to 
CD8 T cells, anti-inflammatory M2 TAMs showed the opposite trend with higher levels in the 
tumor biopsies compared to pleural effusions. M2 TAMs are well known for their potential 
to counter act the anti-tumor immune reponse 19-22. The found discrepancy between the 
presence of CD8 T cells and M2 TAMs in pleural effusion and tumor biopsies demonstrates 
the potential controlled trafficking of immune cells within the mesothelioma environment. 
Unfortunately, in the current study there were no matched blood samples available from 
the included patients. It would be of great interest to simultaneously measure immune pop-
ulations in tumor, pleural effusion and peripheral blood in larger patient cohorts to further 
investigate the trafficking and interactions of immune cells between different compartments. 
In this study we have chosen to focus on T cells and TAMs because these immune cells are 
prevalent and clinically relevant in MPM. Furthermore we have shown earlier that the influx 
of CD8 T cells and phenotype of TAMs in MPM biopsies can predict survival and local tumor 
outgrowth 13, 14. 
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Conclusions
Based on our current study and earlier findings we propose the following model. Depending 
on the tumor stage and treatment regimen, both the MPM tumor and the accompanying 
pleural effusion can be infiltrated by different pro- and anti-tumor immune cells (Figure 4). We 
found that the immune infiltrate in the tumor may not be mimicked in the pleural effusion, 
and propose that pleural effusion provides a dynamic insight in the tumor-host interactions. 
Therefore, in order to further develop precision immunotherapy in MPM, pleural effusion 
should be considered as a separate immunological compartment from the pleural tumor. 
This finding should be taken into account in order to properly tailor immunotherapy to the 
individual MPM patient. Our proposed model has to be confirmed in larger MPM patient 
cohorts, however the current findings indicate that precise and longitudinal characterization 
of the pleural effusion microenvironment in MPM patients reveals local tumor-host interac-
tions essential to further optimize immunotherapy in MPM. 
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Figure 4 Proposed model for dynamics of  the mesothelioma and accompanying pleural effusion milieu. An 
expanding mesothelioma tumor will consist of relatively high amounts of M2 macrophages which can locally 
induce an immunosuppressive environment. In addition, low amounts of tumor-infiltrating CD8 T cells are 
present. In the pleural effusion of the expanding tumor higher amounts of CD8 T cells are present. The relative 
amount of macrophages is higher in the tumor compared to the pleural effusion, both in the expanding and in 
the regressing tumor. Furthermore, the regressing tumor contains relatively high amounts of infiltrating CD8 
T cells, and less CD8 T cells and tumor cells in the pleural effusion.
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abstract
Background: The potential of immunotherapy in mesothelioma has recently been 
demonstrated in multiple (pre)clinical studies. The success of immunotherapy relies 
on the induction of an anti-tumor immune response which has to overcome the local 
immunosuppressive environment in established tumors. Tumor-associated macrophages 
(TAMs) are an important part of the suppressive environment in mesothelioma and 
reprogramming these TAMs towards a more pro-inflammatory phenotype using a CD40 
agonistic antibody has shown promising results in multiple solid tumors. Dendritic cell 
(DC) immunotherapy has been shown to elicit anti-tumor T cell responses and is cur-
rently being studied in mesothelioma patients at our institution. We hypothesize that the 
combination treatment with a CD40-agonist and DC therapy has synergistic effects and 
the aim of the current study is to investigate the efficacy of this combinatorial approach. 
Methods: Wildtype Balb/c mice were injected intraperitoneally (i.p.) with the AB1 
murine mesothelioma cell line. Different treatment regimens were compared as follows: 
untreated control group (n=6), monotherapy with CD40-agonist (FGK4.5 monoclonal 
antibody, n=5), monotherapy with DC immunotherapy (n=5) and combination therapy 
of DC immunotherapy followed by treatment with the CD40-agonist (n=5). Three days 
after completion of the treatment regimens, blood was drawn and analyzed using flow 
cytometry to investigate peripheral immune activation. All mice were monitored and 
sacrificed when showing signs of severe illness. 
Results: Blood analysis revealed that peripheral monocytes of the CD40-agonist group 
and the combination therapy group showed an increase in expression of MHC-II and 
PD-L1 compared to the mice in the control group and the DC immunotherapy group. 
In addition, the combination therapy induced a profound increase in effector CD8 T-cells 
and proliferating CD8 T-cells compared to the monotherapies. The survival analysis at 
day 90 post tumor cell injection demonstrates a 17% survival of the control group, 60% 
survival of the DC therapy group, 80% survival of the CD40 group and 100% survival 
of the combination therapy. 
Conclusion: Combination therapy of DC immunotherapy and a CD40-agonistic antibody 
induces additive immune activation in the peripheral blood of mesothelioma-bearing 
mice compared to the monotherapies. The presented data demonstrate the potential 
of the combination of cellular immunotherapy and targeting of the local tumor microen-
vironment in mesothelioma. 
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introduction
CD40 is a member of the TNF receptor superfamily and is broadly expressed by e.g. anti-
gen-presenting cells (APCs; dendritic cells, B cells, monocytes, macrophages), platelets and 
endothelium1. Furthermore, CD40 is expressed by most B cell lymphomas and a substantial 
number of epithelial malignancies. CD40-CD40L interactions are central to the generation 
of T cell dependent, humoral and cytotoxic T cell responses 2. 
The expression of CD40 on a broad range of malignancies and its central immunostimulatory 
role has made CD40 a popular immunotherapeutic target 3. The discovery of the potential 
of agonistic CD40 antibodies to mimic the signal of CD40L initiated the first preclinical 
studies investigating the potential of these antibodies to induce effective anti-tumor immune 
responses 4-7.  
Although historically most attention has been focused on the role of the CD40-CD40L 
interaction on lymphocytes, recently the importance of CD40 activation on macrophages 
in the tumor environment has been discovered. It has been shown that CD40 stimulation 
enhances the capacity of APCs to activate tumor-specific T cells and T cell–independent 
immunity by activating tumoricidal tumor-associated macrophages 8. The group of Beatty et 
al showed that in a mouse model of pancreatic ductal carcinoma, the regression of tumors 
required the presence of macrophages, and not T cells.  This specific role for TAMs in the 
therapeutic effect of CD40 agonists has led to our hypothesis that CD40 activation could 
also be beneficial in the mesothelioma environment, which is known to be dominated by 
macrophages 9. Furthermore, because we propose that the combination of re-education 
of the local environment with cellular immunotherapy is an effective strategy to induce 
an anti-tumor immune response, we conducted a pilot study to investigate the safety and 
efficacy of combining a CD40 agonistic antibody with dendritic cell (DC-) immunotherapy 
in a murine mesothelioma model. 
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materials and methods
AB1 tumor cell culture and tumor lysate
The AB1 cell line was derived from tumors induced by crocidolite asbestos injected intra-
peritoneally into a BALB/c mouse 10. AB1 tumor cells were cultured in AB1 TCM (RPMI 1640, 
5% FBS, and gentamicin (Gibco/Invitrogen Breda, the Netherlands) in T20, T75 or T175 tissue 
culture flasks (Thermo Scientific) in in a humidified atmosphere at 37°C and 5% CO2, in air. 
When cells grew until a density between 60-80% confluence was reached and cells were 
treated with trypsin (0.05% trypsin, 0.53 mM EDTA in phosphate buffered saline (PBS, all 
GIBCO/Invitrogen) and replated in a concentration depending on previous cell density. For 
tumor lysate, cells were harvested, counted and dissolved in PBS to be further processed 
for lysate. The cell suspension was frozen in liquid nitrogen and disrupted by four cycles of 
freeze-thawing followed by sonication for 4 × 10 seconds with an amplitude of 10 microns, 
using a Soniprep 150 ultrasonic disintegrator equipped with a microtip (Sanyo Gallenkamp 
BV, Breda, The Netherlands) on ice. Cell lysate was aliquoted and stored at −80°C.
Dendritic cell cultures
Dendritic cells were cultured in Petri dishes from bone marrow cells of healthy 8-week old 
female BALB/c mice for 10 days in the presence of DC TCM (RPMI 1640 + Glutamax  5% 
FBS, 0,75% gentamicin (Gibco/invitrogen Breda, the Netherlands), 50μM β-Mercaptoeth-
anol) and 20ng/ml GM-CSF (recombinant)  in a humidified atmosphere at 37°C and 5% 
CO2, in air. DC-TCM + GM-CSF was refreshed every 3 days. On day 9 one plate of DCs 
was harvested and cells were counted to determine the amount of cells per plate. Next, 
AB1 tumor cell lysate was added to the plates in a concentration of 2-3 tumor cells/DC. 8 
Hours later, CpG (1668 phos, Invitrogen, Breda, the Netherlands) was added to the plates in 
a concentration of 1μM/plate. On day 10, DCs were harvested and purified by lympholyte 
mammal density gradient centrifugation (lympholyte-M, Cedarlane, Hornby, ON, Canada) 
to lose excess lysate. DCs were counted and analyzed with flow cytometry to check for 
maturation status of the DCs. 
Injection of mice, administration of CD40 antibody and monitoring 
Experiments were approved by the local Ethical Committee for Animal Welfare and complied 
with the Guidelines for the Welfare of Animals in Experimental Neoplasia by the United 
Kingdom Coordinating Committee on Cancer Research (UKCCCR) and by the Code of 
Practice of the Dutch Veterinarian Inspection. 8-Week old female WT BALB/c mice were 
injected intraperitoneally (i.p.) with 0.5x10^6 AB1 tumor cells (harvested at a cell density 
of 50-80% confluence) dissolved in 250 μl PBS. A 25G needle was used to inject the tumor 
cells in the left lower abdominal quadrant while mice were fixated. 
100 μg (5 mg/kg) of the mouse monoclonal CD40-agonistic antibody (FGK 4.5. BioXCell) or 
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the IgG2a isotype control (kindly provided by L. Boon, Bioceros, Utrecht, The Netherlands) 
was dissolved in PBS in a final volume of 250μl and injected similar to the DCs. Both anti-
bodies were endotoxin-free. Mice were monitored every 1-2 days until 90 days when the 
experiment ended. When mice reached a humane endpoint (severe symptoms of distress 
e.g. hunched back, ruffled fur, no grooming, cachexia, anemia or jaundice, tumor breakthrough 
through the abdominal wall) they were euthanized by CO2 asphyxiation. Hereafter, mice 
were exsanguinated by heart puncture and blood was collected in an EDTA tube. Next, the 
abdominal wall was incised and the tumor nodules were located and extracted. The spleen 
was also excised for further experiments. All solid tissues were weighed on a microbalance 
and further processed for flow cytometry, immunohistochemistry and storage to used later. 
Flow Cytometry 
Cells were put in a 96-well plate and washed with FACS buffer (0.05% NaN3, 2% BSA in PBS) 
and Cells were stained with 50μl antibody mix containing 1:300 2.4G2 antibody (Fcγ II/III 
receptor blocking antibody; kindly provided by L. Boon, Bioceros, Utrecht, The Netherlands) 
for extracellular markers, 30 minutes at 4°C in the dark in FACS buffer (in Brilliant Violet 
buffer (BD) when a mix contained >1 BV marker), and for 15 minutes in 50μl PBS with 
Amcyan (Invitrogen) for live/dead staining. For intracellular staining, cells were fixated for 
30 minutes using fix/perm buffer (eBioscience) followed by 60 minutes permeabilization in 
permeabilization buffer (eBioscience). Subsequently, cells were stained in 50μl antibody mix 
containing intracellular antibodies. Cells were washed in permeabilization buffer and in FACS 
buffer before being measured. 
Anti-mouse antibodies directed against the following extracellular markers were used for 
flow-cytometry: F4/80, MHCII, CD40, CD115, CD11b, CD335, CD3e, CD8a and CD19 
(eBioscience), LyC6, CD11c, CD80, PD-L1, Ly6G, PD-1 and CD25 (BD biosciences), CD206 
(AbD Serotec), CD45 (Abcam) and KLRG1 (Biolegend). For intracellular staining anti-mouse 
antibodies were used directed against Foxp3 and Ki-67 (eBioscience). Data acquisition was 
performed by flow cytometry (LSR II; BD Biosciences) and data analysis was performed with 
FlowJo software (Tree Star, Inc.)
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results
First, the effect of the CD40-agonistic antibody FGK4.5 in a mesothelioma mouse model was 
assessed. Because major side-effects have been reported (mainly auto-immunity) with the use 
of CD40-agonistic antibodies in mice, we performed a dose-escalation study to determine 
the safest applicable dose. 8 week old female BALB/c mice were injected intraperitoneally 
(i.p.) with increasing concentrations of FGK4.5. Although the mice injected with the highest 
concentration of the antibody (5 μg/kg) experienced symptoms of discomfort in the days 
following injection, alterations in peritoneal macrophage phenotype and T-cell proliferation 
were most pronounced at this concentration (fig.1A, B). Peritoneal macrophages displayed 
a more pro-inflammatory phenotype characterized by higher MHC-II and lower CD206 
expression compared to PBS treated mice. The 5 μg/kg antibody treated group showed 
more Ki-67 positive proliferating CD4 and CD8 T-cells in blood compared to the lower 
dosages treatment groups.  Spleen size and weight increased dose-dependently following 
3 injections of the CD40-agonistic antibody once every 48 hours (fig. 1C, D) but did not 
cause apparent symptoms in the mice.
To test whether CD40-ligation with FGK4.5 was beneficial as monotherapy or additive or 
synergistic when combined with DC-therapy, we injected wildtype BALB/c mice with AB1 
tumor cells i.p. on day 1 followed by DC-therapy or PBS on day 10 (fig. 2A). DCs were cul-
tured in 10 days from WT BALB/c bone marrow cells in TCM supplemented with GM-CSF 
as previously described by Hegmans et al. Cells were loaded with AB1-tumor cell lysate on 
day 9 and matured with CpG to be harvested and injected i.p. on day 10. DCs were mature 
as demonstrated by the increased expression of MHCII, CD80, PDL1 and CD40 on the cell 
surface (data not shown). We previously established that treating mice with DC-therapy 10 
days following tumor injection is suboptimal, and results in the majority of mice dying from 
the tumor. Treating mice with this treatment schedule allows the assessment of a possible 
treatment benefit of combination therapy over monotherapy. Following injection, DCs were 
allowed to migrate to the lymph nodes and 48 hours later, the CD40-agonistic antibody 
(FGK4.5) was administered i.p. (5 mg/kg) or an isotype antibody for the control group. Mice 
were inspected every 1-2 days during therapy for any possible symptoms of the treatments 
or the tumor load. Mice were euthanized when they showed signs of severe illness or at the 
end of the experiment 90 days after tumor cell injection. A blood sample was taken from all 
mice 48 hours after the last injection of the CD40 antibody (day 16, fig. 2A). The combination 
of DC-therapy with an anti-CD40 agonistic antibody resulted in the complete survival of all 
mice for the entire 90 day duration of the experiment, in contrast to the untreated group 
where all but one animal died from end-stage mesothelioma (fig. 2B). Monotherapy of the 
CD40-agonist or mere DC-therapy also increased survival in mesothelioma bearing mice 
compared to giving no treatment. Although this experiment was not designed to investigate
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the mechanisms underlying the treatment benefit of CD40-agonist/DC-therapy treated mice, 
we analyzed the blood of mice following treatment on day 16 of the experiment to look for 
signs of enhanced immune responses. 
CD40-activation ‘matured’ myeloid cells in the blood as evidenced by the higher expression 
of MHCII, PDL1 and CD80 (not shown) on monocytes, suggesting a M1-like differentiation 
pattern (fig. 3). B-cell proliferation was also significantly enhanced by CD40 ligation in vivo 
(data not shown). Nonetheless, B-cell numbers in blood were reduced compared to con-
trol conditions, possibly due to the CD40-induced splenic accumulation of these cells and 
concomitant splenomegaly observed earlier (fig. 1C). 
Although T cell populations varied only marginally between different conditions, the T cell 
phenotype was evidently altered (fig. 3). Both CD8+ cytotoxic T cells and CD4+ helper T 
cells (not shown) were highly proliferating as demonstrated by the increased proportion 
of cells positive for Ki-67. An increased fraction of cells CD8+ T cells became positive for 
KLRG1, a marker for (short-lived) effector T cells or terminally differentiated cells, indicating 
altered dynamics in CD8+ T-cell memory formation following CD40-agonistic treatment 
and DC-therapy. The combination of both DC-therapy and the CD40 agonistic antibody 
resulted in an additive increase of the above-mentioned parameters both in monocytes and 
in T lymphocytes.
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A
Tumor	cell injection
t=0
Group	A:	Control
Group	B:	CD40-agonist
Group	C:	DC	therapy
Group	D:	CD40-agonist	+	DC	therapy
Blood	analysis
†
†
†
†
t=16t=10 t=12 t=14
Figure 2 A Treatment schedule: 8 week-old female WT BALB/c mice were injected i.p. with 0.5x10^6 AB1 
tumor cells on t=0 followed by i.p. injection of 2.5x10^6 tumor-lysate loaded DCs for treatment groups C 
(n=5) and D (n=5) or with PBS for group A (n=6) and B (n=5). 8 Hours later, mice from groups B and D 
received 5mg/kg CD40-agonist (FGK4.5) whereas mice from groups A and C were injected with an IgG2a 
isotype control. Antibody treatment was repeated twice in the following days and mice were monitored for a 
total of 90 days to assess survival. Panel B demonstrates the Kaplan Meier curve showing the survival of the 
different treatment groups for the duration of the experiment (90 days). 
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Figure 3 Leukocyte populations in blood during therapy in mesothelioma bearing mice untreated (control) 
or treated with a CD40-agonist (FGK4.5), DC-therapy or the combination.  Cells were gated after exclusion 
of doublets, dead cells (Amcyan +) and CD45- cells. Monocytes were gated from CD45+ lineage (CD3+ 
CD19+) negative, CD11b+ LyC6high Ly6-. CD8+ T cells were gated from CD45+ CD3+ lymphocytes. The 
proportions of CD8+ T cells positive for Ki67 and KLRG1 were assessed, as were the frequencies of MHCII+ 
and PDL1+ monocytes. All data presented as mean ± SEM.
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discussion
This pilot study demonstrates that the combination of a CD40 agonistic antibody and 
DC-immunotherapy is feasible in a mesothelioma mouse model. Furthermore, the combina-
tion therapy induced additive systemic immune activation compared to the monotherapies. 
Although the survival difference was not statistically significant compared to the monother-
apies, the combination therapy did result in 100% survival, which is promising. Although this 
pilot study was undertaken based on the hypothesis that a CD40 agonistic antibody could 
induce a more pro-inflammatory macrophage phenotype in the tumor environment, the cur-
rent study was designed to investigate the feasibility and effect on survival of the combination 
of a CD40 agonistic antibody and DC immunotherapy. Therefore, the effect of the antibody 
on local macrophage phenotype will have to be the subject of future studies. However, the 
current pilot study did demonstrate that combining a CD40 agonistic antibody with cellular 
immunotherapy is safe and feasible in mesothelioma mouse models. Furthermore, treatment 
with a CD40-agonistic antibody in mesothelioma bearing mice enhances survival and alters 
both myeloid and lymphoid cell populations in the blood following therapy. CD40 is widely 
expressed on many different cells both in secondary lymphoid organs, in the blood and in 
the TME 3. Our tumor cells did not express CD40 in vitro or in vivo (data not shown) which 
has been the case for other tumor types 11. Although we hypothesized that CD40-ligation on 
TAMs would skew their phenotype and result in better T-cell responses locally in the tumor, 
the effects of systemic CD40-ligation are most likely diverse in nature. The importance of 
CD4+ helper T cells for CD8+ T cell function in cancer has long been appreciated and found 
to be relevant for immunotherapy as T cell therapy greatly benefited from infusion of both 
CD4+ and CD8+ T cells 4, 12. Dendritic cells express CD40 which enables them to become 
‘licensed’ by CD4+ T cells during CD8+ T cell priming and hence induce stronger effector 
CD8+ T cell responses. DC-licensing has been found to be primarily important in settings of 
limited inflammation (e.g. cancer) when additional signals are mandatory for effective T cell 
priming to occur 13. Furthermore, different CD8+ T cells are generated when primed in a 
setting of abundant inflammatory signals such as CD40-signalling 14-16. When priming occurs 
during inflammatory settings, short lived effector cells (KLRG1+ CD127-) are formed at the 
expense of CD8+ memory T cells. The fact that KLRG1+ CD8+ T cells were increased in 
the blood of mice effectively treated with combination immunotherapy, suggests a potential 
role of these cells in mediating tumor regressions and prolonging survival. Whether the 
observed T cells are tumor specific could not be assessed in this model. The survival data 
and phenotypic analysis of blood suggests an additive effect between treatment with a CD40 
agonistic antibody and DC immunotherapy. Which specific alterations in cell function and 
phenotype underlie this beneficial effect remains to be investigated. 
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abstract
New immunotherapeutic strategies are needed to (re-)sensitize tumors to the destruc-
tive power of the host immune system in all patients. Malignant mesothelioma is a cancer 
characterized by a poor prognosis, resistance to conventional therapies and a prominent 
tumor associated macrophage (TAM) infiltrate linked to immune suppression, angio-
genesis and tumor aggressiveness. TAM depletion using the M-CSFR-inhibitor PLX3397 
could potentially reactivate anti-tumor immunity. 
We show, that M-CSFR-inhibition effectively reduced TAMs, circulating non-classical 
monocytes, neo-angiogenesis and ascites in mesothelioma mouse models, but without 
improving survival. Combined with DC-therapy, however, survival was synergistically 
enhanced with a concomitant decrease in TAMs and enhanced CD8+ T-cell frequency 
and functionality. Finally, combination therapy treated mice were protected from tumor 
rechallenge and displayed superior T-cell memory responses.
These data indicate that decreasing local immune suppression in the tumor without 
providing proper immune activation does not result in improved survival but in combi-
nation, generates robust and durable antitumor immunity. 
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introduction 
With the implementation of checkpoint inhibition therapy for several malignancies, immu-
notherapy has evolved to become an effective strategy in the treatment of advanced cancer 
1. However, it has become apparent that although a subgroup of advanced disease stage 
patients benefits and shows prolonged overall survival to these therapies, the majority of 
patient tumors does not respond or eventually relapses. Efforts have been made to charac-
terize the mechanisms behind immunotherapy efficacy, leading to the distinction between 
inflamed, immune sensitive tumors, and non-inflamed tumors where there is immunological 
exclusion or ignorance 2-4. PD-1 blocking antibodies appear to be most effective in patients 
with a pre-existing immune cell infiltrate in the tumor, which can be functionally enhanced 
by this form of immunotherapy 5. The next breakthrough in cancer immunotherapy will be 
finding ways to sensitize non-inflamed and resistant inflamed tumors to therapy, thereby 
increasing response rates and survival in advanced stage cancer patients 2,3. 
Malignant mesothelioma (MM) is a cancer with a dismal prognosis that has not improved sig-
nificantly in the last decades with the broad implementation of conventional cancer treatment 
modalities 6. MM is often characterized by a prominent stromal component, dominated by the 
presence of macrophages 7,8. These tumor associated macrophages (TAMs) often display an 
‘alternatively activated’ (‘M2’) immune inhibitory phenotype characterized by the production 
of interleukin 10 (IL-10) and surface expression of CD206 and inhibitory molecules such 
as PD-L1 9. Furthermore, TAMs have been shown to be critical regulators of angiogenesis 
and they are closely linked to local tumor outgrowth and pleural fluid mediated immune 
suppression in MM patients 10-12. 
TAMs are known to be highly dependent on macrophage-colony stimulating factor (M-CSF) 
for their survival, proliferation, and recruitment towards tumors 9,13. In addition, M-CSF pro-
motes an M2 phenotype 14,15 and its levels in the tumor and circulation are correlated 
with poor survival in several solid tumor types 16. For these reasons different approaches 
to inhibit the M-CSF/M-CSFR pathway have been designed in order to deplete TAMs 17-19. 
Broadly, these molecules can be subdivided into antibodies targeting M-CSF (sparing IL-34-
M-CSFR signaling), the M-CSFR, and small molecule tyrosine kinase (TK) inhibitors with 
targeting downstream receptor signaling with different specificities for M-CSFR, c-kit and 
FLT3 16. The advantage of TK-inhibitors over antibody targeted therapies is their capability of 
targeting both murine and human M-CSFR-signaling improving translatability across species, 
inhibition of autocrine M-CSF/M-CSFR-signaling, and the lack of rebound monocytopoeiesis 
after cessation of therapy due to intact receptor-mediated internalization of M-CSF which 
is TK-independent 13. PLX3397 is a clinically tested M-CSF-receptor (M-CSFR) and c-kit 
tyrosine kinase inhibitor shown to be relatively safe and effective in reducing TAMs in several 
solid tumor types 19,20. Whether PLX3397 is effective in depleting TAMs in mesothelioma, 
and possibly capable of restoring anti-tumor immunity in these tumors in currently unknown. 
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Cell-based immunotherapies such as dendritic cell (DC)- and T-cell based therapies cir-
cumvent aberrant antigen presentation and the formation of ineffective immune responses 
in cancer, possibly explaining their efficacy over conventional tumor vaccines 21. We have 
previously demonstrated that DC-therapy is a safe and effective way to generate functional 
anti-tumor immunity and clinical responses in MM patients 22,23. We hypothesize that TAM 
mediated immune suppression could limit DC-therapy efficacy and that depletion of TAMs 
would improve response rates and response durability in MM models. 
We show that PLX3397 is effective in depleting TAMs from mesothelioma but that mon-
otherapy does not improve survival. Combining M-CSFR-inhibition with DC-therapy to 
induce effective anti-tumor immune responses improved survival in our mouse models 
with mice being protected from disease following tumor rechallenge. This therapeutic syn-
ergy may prove to be an alternative strategy to improve response rates and survival with 
immunotherapy. 
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methods 
Mesothelioma Mouse Models 
Female 8-12 week old BALB/c (H-2d) mice (Envigo, Zeist, The Netherlands) and CBA/J 
mice (Janvier, Hannover, Germany) were housed under specific pathogen-free conditions at 
the animal care facility of the Erasmus MC, Rotterdam. Experiments were approved by the 
local Ethical Committee for Animal Welfare. The AB1 cell and AC29 mesothelioma cell lines 
were kindly provided by Professor Bruce W.S. Robinson of the Queen Elizabeth II Medical 
Centre, Nedlands, Australia. The cell line was derived from tumors induced by crocidolite 
asbestos injected intraperitoneally into CBA/J and BALB/c mice 26. Tumor cells were cultured 
in RPMI 1640 medium containing 25 mM HEPES, Glutamax, 50 g/ml gentamicin, and 5% (v/v) 
fetal bovine serum (FBS) (all obtained from Gibco) in a humidified atmosphere and at 5% 
CO2, in air. For culture, either T25, T75 or CellSTACKs (Corning Life Sciences) were used to 
reach appropriate tumor cell frequencies for injection. AB1 and AC29 cells were passaged 
once or twice a week to a new flask by treatment with 0.05% trypsin, 0.53 mM EDTA in 
phosphate buffered saline (PBS, all Gibco). The cell line was regularly tested and remained 
negative for mycoplasma contamination. At the start of the experiment, CBA/J or BALB/c 
mice were intraperitoneally injected with either 20x10^6 AC29 cells or 0.5x10^6 AB1 cells 
respectively, dissolved in PBS, or with PBS as control in a volume of 200μl using 25G needle 
syringes. Mice were inspected daily for signs of disease and a Body Condition Score (BCS) 
was assessed. When mice reached their predefined humane endpoint (in all cases due to high 
tumor burden) they were euthanized by CO2-mediated asphyxiation, and relevant tissues 
including blood, spleen, tumor and ascites were collected. 
Tumor Lysate Production 
AB1 cell line-derived tumor lysate was prepared from cells suspended per ml PBS. The cell 
suspension was frozen in liquid nitrogen and disrupted by four cycles of freeze-thawing 
followed by sonication for 3x 10 seconds with an amplitude of 10 microns, using a Soniprep 
150 ultrasonic disintegrator equipped with a microtip (Sanyo Gallenkamp BV, Breda, The 
Netherlands) on ice. Cell lysate was aliquoted and stored at -80˚C. 
Culture Conditions of Bone Marrow-Derived DC Used for Vaccination
DCs were generated following an adapted protocol (Lutz et al. 1999) as previously described 
24. Both femurs, tibiae and fibulae were collected from healthy control mice (8-10 weeks 
old) and were crushed in a pastel and mortar. After filtration over a 100 μm nylon mesh cell 
strainer (BD Biosciences), bone-marrow derived cells were lysed and seeded in 100-mm 
Petri dishes (day 0) and cultured in 10 ml DC Culture Medium [DC-CM]: RPMI 1640 
containing glutamax-I (Gibco) supplemented with 5% (v/v) FBS, 50 M -mercaptoethanol 
(Sigma-Aldrich), 50 g/ml gentamicin (Invitrogen), and 20 ng/ml recombinant murine gran-
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ulocyte macrophage-colony-stimulating factor [GM-CSF, kindly provided by Professor B. 
Lambrecht, VIB Ghent, Belgium]. Cells were cultured at in a humidified atmosphere at 5% 
CO2, in air. At day 3, 10 ml of fresh DC-CM was added. On day 6, 10 ml of each plate was 
replaced with 10 ml of fresh DC-CM. After 9 days of culture, AB1 cell lysate was added to the 
DC cultures, to the equivalent of three AB1 cell-equivalents per DC. After 8 hours, 10 g/ml 
CpG (ISS-ODN 1668, Invitrogen) was added to the culture to allow complete maturation 
while incubated overnight. The next day, DCs were harvested by gentle pipetting and purified 
by Lympholyte-Mammal (Cedarlane) density gradient centrifugation, the interphase washed 
three times in PBS and resuspended at a concentration of viable cells. The quality of the DC 
preparation was determined by cell-counting, morphologic analysis and cell surface marker 
expression by flow cytometry, as previously described 24. 
DC-culture with PLX3397
Mature, lysate pulsed-DCs were generated as demonstrated above and cultured for 48 
hours in GM-CSF DC-TCM and varying concentrations of PLX3397 (provided by Plexxikon 
inc. as part of a material transfer agreement) or the vehicle (Dimethyl sulfoxide, DMSO, 
Sigma-Aldrich) in 6-well plates. PLX3397 was reconstituted in DMSO to reach a stock 
concentration of 20mM, which was then diluted to a concentration range of 0.1 to 10μM 
in DC-TCM. After 48 hours, cells were gently pipetted from the 6-well plate and analyzed 
for viability and surface expression of immune markers using multi-color flow-cytometry. 
Treatment with Tumor Lysate-Pulsed DCs and/or PLX3397 
On day 0, BALB/c or CBA/J mice (4 groups each consisting of 6-8 mice) were inoculated 
intraperitoneally with AB1 or AC29 tumor cells, respectively. On day 10, mice were treated 
with either 2-3x10^6 DCs dissolved in 200μl PBS, or PBS alone. Also, depending on the 
treatment arm, mice were fed ad libitum PLX3397-containing chow or control chow of equal 
nutritional value and consistency until the end of the experiment or prior to rechallenge. On 
day 15 post-tumor cell injection and prior + after rechallenge, blood was extracted via the 
tail vein while mice were fixated. During the remainder of the follow-up period, mice were 
examined daily for evidence of illness caused by overt tumor growth. Mice were killed if 
profoundly ill, according to UKCCCR regulations and body condition score, and were scored 
as a death in survival analysis. No mice had to be censored for survival analysis. 
Immunohistochemistry (IHC) on Tumor Material
Tumor biopsies were embedded in Tissue-Tek II optimum cutting temperature medium 
(Miles, Naperville, IL, USA), snap-frozen, and stored at at -80˚C . Tissue sections (6 m) were 
cut on a cryostat (Cryostar NX70, Thermo-Fisher Scientific). Frozen sections were warmed 
to RT, fixed with acetone for 10 minutes and rinsed in PBS. Sections were incubated in 
peroxidase blocking solution (0.1% H2O2 and 0.1% sodium azide in PBS) for 30 minutes 
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and rinsed with PBS. Slides were placed in a semi-automatic stainer (Sequenza) and incu-
bated in 1:10 diluted normal Goat serum (CLB, Amsterdam, Netherlands) for 10 min and 
subsequently for 60 min with the diluted primary Abs, followed by rinsing in PBS for 5 min 
and incubation for 30 min with diluted secondary Abs. Double-immunostaining was carried 
out using PE-conjugated rat anti-mouse CD8 (1:20, clone MEC13.3, BD Biosciences), with 
FITC-conjugated CD206 (1:80, clone mr5d3, Bio-Rad) and FITC-conjugated F4/80 (1:10, 
clone BM8, eBioscience) with CD31 antibodies (1:10, clone MEC13.3, BD Biosciences). Bind-
ing of antibody was detected using alkaline phosphatase- (AP-) or peroxidase- conjugated 
goat anti-rat (Sigma-Aldrich) and Naphtol-AS-MX-phosphate (0.30 mg·mL−1; Sigma-Aldrich) 
+ new fuchsine (160 mg·mL−1 in 2 M HCl; Chroma-Gesellschaft, Köngen, Germany) or AEC 
(0.1M NaAc + 1% AEC stock [100mg AEC in 10ml DMF], Vectorlabs), respectively, were used 
as substrate. The specificity was checked using a protein concentration-matched non-relevant 
rat antibody and PBS. Finally, the sections were rinsed in distilled water and mounted in vecta 
mount (Vector). Slides were scanned using a Nanozoomer 2.0 HT (Hamamatsu).
Quantification of IHC Images
Scanned IHC-slides were viewed using NDP-viewing software (Hamamatsu) at 20x and 
40x magnification and regions of interest were captured and imported into ImageJ software 
(NIH). Colors were separated, thresholds were installed to select for positive cells and these 
were depicted as percentage of total area. For each sample, 5 random areas (including tumor 
rim and center) at 20x magnification were selected, analyzed and averaged. CD8-positive 
cells were well demarcated and counted (average of 5 random tumor areas per sample) to 
be expressed as cells/mm2. 
Preparation of Single Cell Suspensions from Tissues
Single cell suspensions were generated from the spleens, blood and tumors of mice from 
each group. All tissues were either weighed in a microbalance (Shimadzu) in case of tumors 
and spleens, or volume determined for blood. Briefly, spleens were aseptically removed and 
mechanically dispersed over 100 μm nylon mesh cell strainer (BD Biosciences) followed by 
erythrocyte lysis using osmotic lysis buffer (8.3% NH4Cl, 1% KHCO3, and 0.04% Na2EDTA 
in Milli-Q). Blood was collected in EDTA tubes (Microvette CB300, Sarstedt) and subse-
quently lysed. Tumors were collected, and dissociated using a validated tumor dissociation 
system (Miltenyi Biotec). Cells suspensions were filtered through a 100 μm nylon mesh cell 
strainer (BD Biosciences) and counted in trypane blue with a hemocytometer using the 
Burker-Turk method. 
Flow Cytometry
For measurements of cytokine production in lymphoid cells by flow cytometry, cells were 
re-stimulated for 4 h at 37°C using PMA and ionomycin supplemented with GolgiStop (BD 
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Biosciences). For assessing cytokine production by myeloid cells, cells were only subjected to 
4 hours incubation with Golgistop. For cell surface marker staining, cells were washed with 
FACS-wash (0.05% NaN3, 2% BSA in PBS) and Fc II/III receptor blocking was performed 
using anti-mouse 2.4G2 antibody (1 : 300; kindly provided by L. Boon, Bioceros, Utrecht, The 
Netherlands). After the blocking procedure, properly diluted antibodies (supplementary table 
1) for cell surface staining were added into each sample and placed on ice for 30 minutes 
protected from light. Cells were washed in FACS-wash followed by a PBS wash, and then 
stained for viability using fixable LIVE/DEAD aqua cell stain (Thermo-Fisher Scientific, 1:200). 
After two additional washes with FACS-wash, cells either measured (in case of only surface 
staining) or in case of intracellular staining; fixated, permeabilized and stained using Fix/Perm 
buffer (in case of nuclear protein staining including Foxp3 and Ki-67, eBiosience) or 4% PFA 
and 0.5% saponin (in case of cytokine stainings, Sigma-Aldrich). Antibodies were stained for 
30 minutes in case of the PFA/Saponin protocol and 60 minutes for the intranuclear staining 
protocol, on ice in the dark. A fixed number of counting beads (Polysciences Inc.) was added 
prior to data acquisition to determine the absolute amount of cells. Data were acquired using 
an LSR II flow cytometer (BD) equipped with three lasers and FACSDiva software (BD) and 
analyzed by FlowJo (Tree Star Inc., USA) software V10.1. 
Statistical Analysis
Data are expressed as medians with interquartile range. Comparisons between groups were 
made using the Mann-Whitney U-test for independent samples, or the Wilcoxon signed 
rank test in case of paired samples. When correlations were depicted, Spearman’s rank cor-
relation test was performed to test for statistical significance. A two-tailed value of p<0.05 
was considered statistically significant. Survival data were plotted as Kaplan-Meier survival 
curves, using the log-rank test to determine statistical significance. Data was analyzed using 
Graphpad Prism software (Graphpad, V5.01) 
Macrophage depletion and DC immunotherapy in mesothelioma
 147
7
results
DC-therapy synergizes with M-CSFR-inhibition in orthotopic mesothelioma mouse models 
In the past we have shown that applying DC-therapy in syngeneic and orthotopic meso-
thelioma mouse models is an effective and translational system for assessing anti-tumor 
T-cell responses and evaluating treatment efficacy 24,25. In both the BALB/c model (using 
the AB1 mesothelioma cell line) and the CBA/J model (AC29 cell line) tumor cells are 
injected intraperitoneally (i.p.). Compared to the BALB/c model, the CBA/J has a more 
pronounced TAM-dependent phenotype (including higher expression of M-CSF, data not 
shown) and mice develop ascites, reflecting disease heterogeneity 26-28. The M-CSFR-inhibitor 
PLX3397 was used to target TAMs in our models. To ensure that there was no direct effect 
of PLX3397 on the murine mesothelioma cell lines, expression of both receptors was deter-
mined using flow cytometry and tissue microarray analysis, which showed negligible levels 
of both molecules (data not shown). Also, to exclude any direct effects of PLX3397 on the 
DCs administered, maturated tumor-lysate pulsed DCs were cultured in vitro with increasing 
levels of PLX3397 or vehicle alone and cell viability and membrane expression of several 
relevant surface markers was assessed using multicolor flow cytometry (Fig. S1). As previously 
reported by others, GM-CSF-cultured cells are comprised of a heterogeneous population 
of dendritic cells and macrophages, which we could also identify in our system (Fig. S1A) 
29. There was no major effect of PLX3397 on DC viability (Fig. S1A) or surface expression 
of MHC-II, CD86, PD-L1, M-CSFR, and c-kit (data not shown). There was a minor decrease 
in viability beyond therapeutic concentrations (>3μM), which occurred in the macrophage 
fraction of the heterogeneous cell population (data not shown). This lack of DC-sensitivity 
towards PLX3397 could be explained by the rapid down-regulation of M-CSFR surface 
expression following maturation using unmethylated CpG (Fig. S1B-C). 
Mice were treated at day 10 when solid tumors had established i.p. and at the site of injection 
24,30 and the M-CSFR-inhibitor PLX3397 was administered in chow at the day of DC-injec-
tion and continued for duration of the experiment unless indicated otherwise (Fig. 1A-B). 
PLX3397 monotherapy did not improve survival in both mesothelioma tumor models (Fig. 
1C-D). DC-therapy prolonged survival only in the AC29 tumor model. Combination therapy, 
however, significantly enhanced survival in both tumor models (Fig. 1C-D). 
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Figure 1 Efficacy of DC-therapy is synergistically enhanced by combination therapy with TAM-depletion in 
mesothelioma mouse models.
(A-B) Wildtype, female BALB/c (n=6/arm) and CBA/J (n=8/arm) mice were intraperitoneally injected with 
either 0.5x10^6 AB1 or 20x10^6 AC29 syngeneic tumor cells, respectively. Mice were then treated once on 
day 10 with either intraperitoneal administration of PBS or mature, autologous tumor lysate loaded dendritic 
cells. Concurrently, mice were started on control or PLX3397-containing chow until the end of the experiment 
or until rechallenge. Blood was extracted on t=15 and before and after rechallenge in case of CBA/J mice. 
Animals were monitored daily for the duration of 160 days and euthanized in case of severe illness. 
(C-D) Kaplan-Meier curves of the survival experiments in CBA/J (AC29) and BALB/c (AB1) mesothelioma 
tumor models. Statistical significance was determined using the Log-rank test with p<0.05 being statistically 
significant. *=p<0.05, **=p<0.01, ***=p<0.001, ns=not significant
M-CSFR-inhibition causes a decrease in CD206+ F4/80+ TAMs, blood vessel density and ascites. 
No gross macroscopic changes in tumor volume between untreated and M-CSFR-inhibitor 
treated mice was found, reflecting the lack of a difference in survival between these two 
groups (data not shown). To assess whether M-CSFR-inhibition was effective in depleting 
TAMs, we compared tumors of the more TAM-dependent CBA/J mice treated with or 
without PLX3397 using immunohistochemistry (IHC). Microscopically, there was an evident 
decrease in F4/80+ TAMs, CD31+ endothelial cells and CD206+ (M2) cells in treated mice 
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compared to control mice (Fig. 2A-G). It has been recently shown that TAMs are crucial for 
tumor angiogenesis and concomitant ascites production in metastatic ovarian carcinoma31. 
In line with these findings we found a strong correlation between CD31+ endothelial and 
TAM areas in these tumors and a decrease in ascites volume in the M-CSFR-inhibitor treated 
mice (Fig. 2D-E). Tumors of untreated mice already contained a CD8+ T-cell infiltrate which 
was not further enhanced following TAM-depletion (Fig. 2H). 
DC-therapy induces CD8+ T-cell responses and decreases Tregs whereas M-CSFR-inhibition 
specifically depletes non-classical monocytes in blood during therapy
We next sought to investigate the potential mechanisms that lead to enhanced survival 
in DC-therapy only and combination immunotherapy arms. To observe the presence of 
functional anti-tumor immune responses underpinning prolonged survival in these mice, 
we extracted blood 5 days after start of treatment and analyzed the circulating immune 
compartment using multicolor flow cytometry (Fig. S2) DC-therapy produced a significant 
increase in CD8+ T cells with CD4+ T-helper cells remaining at a constant level, whereas pro-
liferation was increased in both T-cell subsets (Fig. 3A-D, S3A). T-regulatory cells (Tregs) were 
decreased following DC-therapy and this was further amplified by the addition of PLX3397 
mediated M-CSFR-inhibition, resulting in an improved CD8+ T-cell/Treg-ratio (Fig. 3C, Fig. 
S3B). Besides proliferation, CD8+ T cells from DC-therapy treated mice were predominantly 
of an effector phenotype, illustrated by the expression of Killer-cell lectin like receptor G1 
(KLRG1) and CD4-CD8 double positivity (Fig. 3D-F) 32,33. These CD4-CD8 double positive 
cells were also highest in proliferation in all treatment arms as demonstrated by a higher 
fraction of cells being Ki-67-positive (Fig. S3C-D).
Whereas DC-therapy primarily influenced lymphocyte dynamics and phenotype, PLX3397 
therapy predominantly affected myeloid subsets (Fig. 4). Granulocytes and total monocytes 
were increased by DC-therapy but only granulocytes were expanded by PLX3397 as mono- 
and combination therapy (Fig. 4A-B). Monocytes can be subdivided into classical Ly6Chi- and 
non-classical Ly6Clow monocytes with each subset having different functions and migration 
patterns in blood 34,35. Dissecting monocyte subsets in our model revealed near complete 
depletion of non-classical (Ly6Clow) monocytes in the PLX3397 treated arms, whereas 
classical (ly6Chi) monocytes increased (Fig. 4C-D). Interestingly, non-classical monocytes were 
highest in PD-L1 expression compared to their Ly6Chi classical counterparts, which was 
also significantly decreased by M-CSFR-inhibition (Fig.4E). Classical monocytes reached equal 
numbers and levels of PD-L1 expression in blood of DC-therapy and combination therapy 
treated mice (Fig. 4D,F). Overall, the observed synergy between therapies was illustrated 
by an improved CD8+ T-cell phenotype which was primarily DC-therapy mediated, and 
a decrease in predominantly PD-L1+ non-classical monocytes due to M-CSFR-inhibition. 
Similar patterns in blood immune cell dynamics could be discerned in the AB1 tumor model, 
however, numbers of mice were limited at day 5 after start of treatment (Fig. S4).
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Figure 2:  TAM depletion causes a decrease in ascites production in CBA/j mice accompanied 
by a decrease in CD206+ F4/80+ macrophages and blood vessel density  
Figure 2 TAM depletion causes a decrease in ascites production in CBA/j mice accompanied by a decrease 
in CD206+ F4/80+ macrophages and blood vessel density.
(A) Tumors of untreated and PLX3397 only treated mice were extracted and tissue sections were double 
stained for tumor associated macrophages (TAM), (F4/80, red) and endothelial cells (CD31, blue) using 
immunohistochemistry (IHC). Tissues are displayed at a 20X magnification (error bar length is 400μm) with 
a further close-up at 40X magnification (error bar length is 200μm). 
(B-C) F4/80+ TAMs and CD31+ endothelial cells were quantified in both groups using ImageJ software on 
5 independent tumor sections (including tumor center and rim) at 20X magnification and averaged to be 
expressed as percentage of total area. 
(D) When mice were sacrificed at end stage disease, ascites was aspirated and the volume was measured 
and expressed as milliliters. 
(E) TAM- and endothelial cell density was correlated in untreated (circles) and PLX3397-treated (squares) mice. 
(F) Tissue sections were double stained for CD206-positivity (M2-TAM marker, red) and CD8 (cytotoxic T 
cells, blue) using IHC. 
(G) CD206+ positive cells were quantified similar to (B-C) and expressed as percentage of total area. 
(H) CD8+ T cells were counted (5 individual areas per tumor and averaged) and expressed as cells per cubic 
millimeter of tumor area (mm2).
All data are displayed as dot plots including the median and error bars indicating interquartile range. Statistical 
significance was determined using the Mann-Whitney U test with p<0.05 being statistically significant. The 
Spearman’s Rank Correlation coefficient (rho) was determined in case of Fig. 2E. *=p<0.05, **=p<0.01, 
***=p<0.001, ns=not significant, DC-Tx= DC-therapy, TAM= tumor associated macrophage. 
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Figure 3 CD8+ T-cell proliferation and effector phenotype are further enhanced when combining TAM-
depletion with DC-therapy whereas Tregs decrease in blood during therapy. 
(A-C) Blood was extracted 5 days after start of treatment (day 15 after tumor cell injection) from all CBA/J 
mice (n=8/group) and was analyzed by multicolor flow cytometry. Counting beads were used to quantify 
populations as cells per μl blood. Immune cell-subsets were characterized as displayed in supplementary 
figure S2A. 
(D-F) CD8+ T cells were further analyzed for percentage of proliferating (Ki67+ in D), and effector (KLRG1+, 
in E or CD4+, in F) cells.
These data are representative of two independent experiments. All data is displayed as dot plots with including 
the median and error bars indicating interquartile range. Statistical significance was determined using the 
Mann-Whitney U test with p<0.05 being statistically significant. Healthy controls were measured to depict 
cell frequencies and phenotypes in the non-tumor bearing host, but were not included in further statistical 
testing. *=p<0.05, **=p<0.01, ***=p<0.001, ns=not significant, DC-Tx= DC-therapy, Th cells= T-helper cells, 
Tregs= T regulatory cells. 
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Figure 4: Non-classical monocytes are specically depleted following M-CSFR-inhibition and 
these cells are highest in PD-L1 expression in blood of mice during therapy 
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Figure 4 Non-classical monocytes are specifically depleted following M-CSFR-inhibition and these cells are 
highest in PD-L1 expression in blood of mice during therapy. (A-B) Total monocytes (A) and granulocytes (B) 
in treated tumor bearing CBA/J mice were measured in parallel with the lymphoid cell subsets depicted in Fig. 3. 
(C-D) Monocytes were further classified into classical (Ly6Chigh) and non-classical (Ly6Clow/-) monocytes 
and expressed as number of cells per μl blood.
(E-F) PD-L1 positivity was determined on both monocyte subsets and expressed as percentage of PD-L1-
positive cells in each subset. 
These data are indicative of two independent experiments. All data is displayed as dot plots with including 
the median and error bars indicating interquartile range. Statistical significance was determined using the 
Mann-Whitney U test with p<0.05 being statistically significant. Healthy controls were measured to depict 
cell frequencies and phenotypes in the non-tumor bearing host, but were not included in further statistical 
testing. *=p<0.05, **=p<0.01, ***=p<0.001, ns=not significant, DC-Tx= DC-therapy, PD-L1= programmed 
death- ligand 1.
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Tumors of combination therapy treated mice exhibit a favorable tumor microenvironment char-
acterized by low IL-10+ TAMs and increased functional CD8+ T cells during therapy 
Circulating immune cell subsets could be manipulated early after DC-therapy and M-CS-
FR-inhibition but whether the tumor microenvironment (TME) was equally affected during 
treatment was unclear. Therefore, we sacrificed mice at day 15 to examine the TME for the 
effects of treatment and to relate possible changes in immune cell composition to those 
observed in spleen and blood. Five days after commencing therapy there was already a 
considerable tumor burden which was at that point still comparable between the different 
treatment groups (Fig. 5A). TME immune composition at day 15, however, markedly differed 
between treatment groups in line with interim analysis in blood and end stage disease tumors 
of diseased mice (Fig. S5A). M-CSFR-inhibition diminished both IL-10+ (M2) and IL-10- (M1) 
TAMs as monotherapy and in combination with DC-therapy (Fig. 5B). Confirming earlier 
results, the number of CD8+ TILs was not altered following PLX3397 monotherapy, and 
these TILs displayed an exhausted phenotype 36, defined as PD-1 positive, lymphocyte-activa-
tion gene 3 (LAG-3) positive, and interferon-gamma (IFN-γ) negative (Fig. 5C). DC-therapy 
in contrast, enhanced the number of non-exhausted CD8+ T-cells in the tumor (Fig. 5C).
As circulating non-classical monocytes and TAMs were preferentially depleted by PLX3397, 
we assessed whether these cell types were correlated to each other. Non-classical monocytes 
correlated with gross TAMs whereas classical monocytes did not (Fig. 5D). This correlation 
became more significant when non-classical monocytes were related to IL-10+ TAMs in 
contrast to the classical monocytes (Fig. 5E). We also further characterized non-classical 
monocytes as being higher in IL-10 and PD-L1 expression, whereas these cells were lower in 
surface MHC-II, further establishing the immune suppressive phenotype of these cells (Fig. 5F). 
In contrast to tumor burden at day 15, tumor induced splenomegaly was abolished in 
PLX3397 treated mice, which was strongly linked to the depletion of splenic macrophages 
(Fig. S5B-F). Similar findings regarding macrophage- and monocyte depletion were made in 
the spleens of mice during treatment, but in contrast to the TAMs, splenic macrophages were 
strongly correlated to classical monocytes (Fig. S5G-H). 
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Figure 5 M-CSFR-inhibition decreases tumor-associated macrophages in mesothelioma whereas DC-therapy alters CD8+ TIL 
phenotype in mice during treatment. Identical to previous experiments, CBA/J mice were intraperitoneally inoculated with tumor 
cells and treated on day 10 with either DC-therapy or control PBS, and/or continuous PLX3397- or control treatment. Only now, 
mice were sacrificed on t=15 days to examine the tumor microenvironment, blood and spleen in the different treatment groups.
(A) Tumors were extracted from the peritoneal cavity and weighed. 
(B) Tumors were dissociated using a commercially available kit generating single cell suspensions that were stained and analyzed 
by flow cytometry. To assess IL-10 production by TAMs, cells were pre-treated for 4 hours with Golgistop, followed by membrane 
and intracellular staining and sample acquisition. TAMs were divided into IL-10 positive and negative and denoted as percentage 
of non-lymphoid cells, to correct for changes in lymphoid cells due to treatment. 
(C) Similar to (B), CD8+ tumor infiltrating lymphocytes (TILs) were identified after 4 hours of in vitro stimulation but now, cells 
were also stimulated using phorbol myristate acetate (PMA) and ionomycin with Golgistop followed by antibody staining and 
analysis. The distinction was made between ‘exhausted’ (Program Death 1+ [PD-1], Lymphocyte-activating-gene 3+, [LAG3+] 
& Interferon-gamma-[IFN-γ]) and ‘non-exhausted’ (PD-1-, LAG3-, IFN-γ+) CD8+ TILs. Cells were depicted as percentage of 
total lymphoid cells, to correct for changes in the myeloid compartment due to treatment
(D-E) Blood classical- and non-classical monocytes (as percentage of non-lymphoid cells) were correlated to total TAMs (D) 
or IL-10+ TAMs (E). 
(F) Circulating classical- and non-classical monocytes were further characterized by assessing surface expression of PD-L1, MHC-II 
and IL-10 by flow cytometry. All data is displayed as dot plots or bar graphs including the median and error bars indicating 
interquartile range. Statistical significance was determined using the Mann-Whitney U test or in case of correlations using the 
Spearman’s Rank Correlation test with p<0.05 being statistically significant. Healthy controls were measured to depict cell 
frequencies and phenotypes in the non-tumor bearing host, but were not included in further statistical testing. 
*=p<0.05, **=p<0.01, ***=p<0.001, ns=not significant, DC-Tx= DC-therapy, TAM= tumor associated macrophage, MHC-II= 
major histocompatibility complex-II, IL-10= interleukin 10. 
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Figure 6: Mice treated with DC-therapy and/or M-CSFR-inhibition were protected from tumor-rechallenge with
 combination therapy treated mice displaying superior recall responses
#c
el
ls
/μ
l
#c
el
ls
/μ
l
Non-Classical 
Monocyte
Classical 
Monocyte
%
of
 F
ox
p3
- C
D
4+
%
of
 C
D
8+
%
of
 C
D
3+
%
of
 c
el
ls
Prechallenge PD-L1+ Monocytes #Prechallenge Monocytes 
ns *
**
*
*
*
*
*
ns
ns
ns
ns
ns
ns
ns
**
p=0.05
**
**
***
***
**
*
*
p=0.07
Post-challengePre-challengePost-challengePre-challenge
Post-challengePre-challengePost-challengePre-challenge
Control DC-Tx 
treated
DC-Tx +
PLX3397 treated
Control DC-Tx 
treated
DC-Tx +
PLX3397 treated
#CD8+ T-cells
0
100
200
300
400
Ki67+ CD8+ T cells 
0
20
40
60
80
CD4+ CD8+ cells
0
1
2
3
Ki67+ CD4+ Th cells
0
5
10
15
20
25
Tumor naive mice
DC-therapy treated
DC-PLX337-combination treated
0
5
10
20
40
60
80
100
0
5
10
15
20
25
30
 
 
B C
G H
E F
D
Rechallenge
A
0 20 40 60 80 100 120 140 160
0
20
40
60
80
100
days
Pe
rc
en
t s
ur
vi
va
l
100 20 110 160
Blood 
extraction
PLX3397 
(CSF1Ri)
DC-therapy
AC29
i.p. injection
100
AC29 i.p. injection survivors/
naive age-matched controls
Pre-challenge 
Blood extraction
Post-challenge 
Blood extraction
Cessation of PLX3397
120
Figure 6 Mice treated with DC-therapy and/or M-CSFR-inhibition were protected from tumor-rechallenge 
with combination therapy treated mice displaying superior recall responses. (A) Surviving mice from Figure 
1 and age-matched tumor naïve mice were rechallenged with 20x10^6 tumor cells intraperitoneally and 
were subsequently monitored for signs of illness. Three days prior to rechallenge, PLX3397-treatment in 
the combination therapy treated mice was terminated and mice were put on control chow for the further 
duration of the experiment. Also, blood was extracted at that time point, and again eight days after rechallenge. 
(B-C) Monocyte subsets and related PD-L1 expression was assessed by flow cytometry in blood prior to 
rechallenge.
(D) Kaplan-Meier curve of survival following rechallenge. For DC-only (red) and combination therapy treated 
mice (blue), curves were identical to the KM-curve in figure 1 but on day t=110, mice were rechallenged to 
observe whether treated mice were protected from cancer recurrence. Tumor naïve littermates (grey) were 
injected with tumor cells in parallel to ensure tumor pathogenicity and correct for age-dependent issues.
(E-H) Several T-cell features were analyzed in DC-only, DC+PLX3397 combination and untreated mice before 
and after rechallenge. 
All data is displayed as bar graph or line graphs including the median and error bars indicating interquartile 
range. Statistical significance was determined using the Mann-Whitney U test with p<0.05 being statistically 
significant. *=p<0.05, **=p<0.01, ***=p<0.001, ns=not significant, DC-Tx= DC-therapy, PD-L1= programmed 
death-ligand 1. 
Mice treated with DC-therapy and/or M-CSFR-inhibition were protected from tumor-rechal-
lenge with combination therapy treated mice displaying superior recall responses
To test whether surviving mice were free of tumor and protected against a second tumor 
encounter, they were re-challenged with the same dose of mesothelioma cells in parallel 
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with age-matched tumor naïve mice (Fig. 6A). Prior to rechallenge, PLX3397 treatment 
was stopped and blood was extracted before and after tumor cell injection. Before rechal-
lenge, combination therapy-treated mice exhibited increased levels of classical monocytes 
compared to DC-monotherapy treated mice, whereas non-classical monocyte levels were 
comparable (Fig. 6B). While PD-L1 expression was negligible on classical monocytes, mono-
cyte frequency was significantly lower in mice treated with both therapies (Fig. 6C). After 
rechallenge, all tumor naïve mice reached their humane endpoint due to high tumor burden 
whereas DC-therapy treated and combination therapy treated mice remained disease free 
(Fig. 6D). Following cessation of treatment and tumor rechallenge, monocytes and related 
PD-L1 levels in combination therapy treated mice reached those of DC only treated mice 
(data not shown). CD8+ T-cell levels were higher in protected mice before and after chal-
lenge compared to control mice, and CD8/CD4 double positive cells were similarly elevated 
after rechallenge (Fig. 6E-F). The same increase in Ki-67-positivity during the primary immune 
response was also evident in CD8+ T cells and CD4+ T-helper cells of combination therapy 
treated mice during the recall-response, indicating superior CD8+ T-cell memory in these 
mice (Fig. 6G-H).
Taken together, these findings demonstrate that targeting the TME and simultaneously direct-
ing the immune system to combat cancer can lead to durable responses in mesothelioma 
bearing mice.
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discussion
We have shown that combination therapy using two safe anti-cancer treatment strategies 
being DC-therapy and M-CSFR-inhibition (PLX3397) results in improved overall survival 
and superior immune reactivity towards the tumor. Whereas TAM-depletion in its self was 
insufficient to increase and improve anti-tumor T-cell responses, DC-monotherapy improved 
survival in mice but still most mice progressed after treatment, similar to a fraction of patients 
that develop resistance immunotherapy 22,23,37. When we analyzed these tumors to look for 
mechanisms of therapeutic resistance, there were dense CD206+ F4/80+ TAM infiltrates 
similar to untreated mice (unpublished observations). TAMs are a major leukocyte subset in the 
stroma of mesothelioma and other cancers and capable of potently suppressing endogenous 
or treatment-induced anti-tumor T-cell responses 9,12. Depletion of this immune suppressive 
cell type may thus render previously immune resistant or escaped tumors sensitive to 
checkpoint inhibition 38, chemo- and radiotherapy 39-41, and cellular therapies such as adoptive 
T-cell transfer 42,43 and now also DC-therapy. Therapies such as chemo(radio)therapy and 
PD-1 checkpoint inhibitors, however, come with significant side effects and appear to be 
most effective in boosting a pre-existing anti-tumor T cell response 3,4. DC-therapy effectively 
induces novel anti-tumor immune responses, which can be further sustained and improved 
by targeting the generally immune suppressive TME 24,44. 
M-CSFR-inhibition has been shown to effectively deplete TAMs in multiple tumor models but 
its effects on survival as monotherapy or combined with other therapies differ considerably 
between systems. For example, when M-CSFR-inhibition was combined with a tumor vaccine 
or with certain chemotherapeutic drugs, efficacy of these therapies was abrogated, question-
ing the role of TAMs in tumor behavior and response to these therapies 18,45,46. In our models, 
M-CSFR-inhibitor monotherapy was insufficient to prolong survival on its own despite gross 
changes in stromal composition. These differences in drug efficacy may be explained by 
TAM-dependency of certain therapies, mechanism of M-CSFR-inhibition, timing of therapy 
and tumor stage and type 46. Using the M-CSFR-inhibitor BLZ945 as monotherapy, Pyonteck 
et al. showed significant improvement of survival in glioblastoma bearing mice 18. Although 
resistance to monotherapy ensued in the majority of mice, tumors regressed due to skewing 
rather than depletion of M2 TAMs. They then showed that this skewing was dependent of 
glioblastoma cell-derived factors including granulocyte-macrophage colony stimulating factor 
(GM-CSF) 18,47. GM-CSF is often used to culture pro-inflammatory M1 macrophages and DCs 
whereas M-CSF cultured macrophages display a pronounced M2 phenotype 14,29,48. In other 
tumor types such as mesothelioma, both patient and mice produce considerable amounts 
of M-CSF, but only sparsely produce GM-CSF 49 (unpublished observations) being a possible 
explanation for the depletion, rather than skewing of TAMs in our models. 
Although there were CD8+ TILs present in mesothelioma tumors of untreated mice, these 
cells did not increase in frequency or functionality following TAM-depletion and displayed an 
Chapter 7
158
exhausted, dysfunctional phenotype. By inducing an immune response using DC-therapy in 
late stage disease, survival was unaltered in BALB/c mice, or prolonged in the CBA/J model 
with most mice showing disease progression/recurrence during follow-up. These responses 
were only durable in the majority of mice when DC-therapy was applied in a TAM-deficient 
tumor environment. We could detect this synergy between therapies in blood T cells of 
mice during therapy and following rechallenge, but not explicitly in the tumor on day 15. This 
may be a time-dependent process (e.g. T-cell persistence in the tumor) or a still unknown 
mechanism responsible for treatment combination efficacy. However, as (IL-10+) TAMs were 
effectively depleted and tumor vasculature was normalized following M-CSFR-treatment, 
T-cell functionality and persistence likely benefited 50. 
Despite the fact that we could not fully exclude an indirect effect of TAMs on CD8+ T cells 
via DCs, as was shown for breast cancer by Ruffell and colleagues 51, we did not observe 
intratumoral DCs in our murine mesothelioma models (data not shown). Supportive of these 
observations is the decrease or lack of circulating DCs and loss of DC immune stimulatory 
capacity in mesothelioma patients, which correlated with a worse survival 52. This highlights 
the limited functionality of endogenous anti-tumor immune induction and acquisition of a 
functional TIL pool in these tumors, and advocates the use of immunotherapeutic strategies 
that broaden and improve novel anti-tumor immune reactions such as DC-therapy 53,54. 
Uncertainty remains about the ontogeny of TAMs in solid tumors. While it is appreciated that 
classical (Ly6Chi) monocytes are known to be the main precursors of inflammatory DCs and 
macrophages including TAMs, incongruences exist regarding the sequence of events that pre-
cludes M2-TAM development 55-57. Seminal studies by Geissmann and Yona et al. have shown 
that classical monocytes are obligatory precursors of non-classical monocytes, and that 
the functions and migration patterns of both cell types differ, with non-classical monocytes 
being crucial for endothelial and tissue integrity 34,35,58. Others have also previously described 
non-classical monocytes to be particularly dependent on M-CSF for their survival 13,59. The 
fact that non-classical monocytes and TAMs share a similar immune suppressive phenotype 
and are most sensitive to M-CSFR-inhibition suggests a likely relationship between these 
cell types. Future research will have to further delineate the contribution of non-classical 
monocytes to TAMs in cancer. 
The spleen has been reported to be a major contributor of macrophage and neutrophil 
precursors to tumors 60. Coincidentally, we observed a dramatic decrease in spleen weight 
in M-CSFR-inhibitor treated mice (which was closely linked to the depletion of splenic 
macrophages) but not in total spleen cell numbers (data not shown). Although we cannot 
exclude the possibility that depletion of TAM precursors in the spleen by M-CSFR-inhibition 
negatively impacted the number of macrophages in the tumor, there was no clear correlation 
between the two cell populations (data not shown) which is in line with more recent data 
confirming the spleen to be a minor contributor of myeloid cells in tumors 61. 
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In conclusion, we have demonstrated that therapeutic efficacy of M-CSFR inhibition as 
monotherapy is limited in mesothelioma, and that this efficacy likely depends on the tumor 
type and remaining tumor-derived molecules produced. TAM-depletion combined with an 
effective DC-mediated anti-tumor T-cell response is capable of producing durable tumor 
responses and functional anti-tumor immunity. 
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Figure S1 GM-CSF cultured dendritic cells are minimally affected by PLX3397. Mature, lysate loaded DCs were cultured for 48 
hours with varying concentrations (no adds, 0.1μM, 0.33 μM, 1.0 μM, 3.33 μM, 10.0 μM) of PLX3397 or the vehicle DMSO to 
assess effects of the inhibitor on DC-survival and phenotype. 
(A) DC-viability was assessed using a live/dead marker and measured by flow cytometry. For all conditions, 1x10^6 cells were 
added to each well and viability was expressed as percentage from baseline (being DC with no adds after 48 hours). In the 
upper middle panel, the populations derived from the GM-CSF-based culture are depicted based on differential expression of 
CD11c and F4/80, with DCs being CD11c high-F4/80 low-intermediate (blue), macrophages being CD11c intermediate – F4/80 
high (red), and precursor cells (orange) being double negative for both markers. In the upper right panel: differential expression of 
CD86, PD-L1 and MHC-II on the different cell populations after 48 hours of culture without adds. 
(B) expression of CD115 (M-CSF-receptor) and CD117 (c-kit) on the cell populations in (A) after 48 hours of culture without 
adds. 
(C) Dynamics in CD115 and CD117 expression in (unstimulated) DCs (blue) or macrophages (red) either unstimulated and 
immature (clear) or after six hours of stimulation with unmethylated CpG motifs (filled). 
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Figure S2 Gating of immune cell subsets in the blood of mice during therapy. (A) Immune cell subsets were 
defined based on markers derived from literature and measured by multicolor flow cytometry
(B) Cells were derived from lysed blood, tumor and spleen derived single cell suspensions. Counting beads, 
doublets and dead cells were gated out leaving viable single cells for subsequent immunophenotyping. For 
the analysis of myeloid cells, gating was preceded by removal of lymphocytes and NK-cells using a lineage mix 
(CD3+, CD19+ CD49b+). 
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Figure S3:  CD4/CD8 Double positive T cells are most abundant after DC- TAM-depletion combi-
nation therapy and highest in proliferation marker Ki-67 compared to single positive CD8+ T cells 
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Figure S3 CD4/CD8 Double positive T-cells are most abundant after DC-TAM-depletion combination therapy and highest in 
proliferation marker Ki-67 compared to single positive CD8+ T cells. (A) Similar to Figure 3D, proliferation was assessed in 
circulating CD4+ T helper cells on day 5 following treatment using the intracellular marker Ki-67. Proliferating cells are depicted 
as percentage of total CD4+ cells. 
(B) The ratio of absolute CD8+ T cells and T regulatory cells in blood on day 5 following start of treatment was calculated and 
depicted on a log axis.
(C-D) CD4+ CD8+ double positive cells were assessed in all treatment groups but were especially evident in the combination 
therapy treated group. In the right panel, Ki-67-positivity in the parent population is depicted in CD4+ CD8+ double positive 
(grey) and CD8+ single positive cells (white). 
Data is displayed as dot plot or bar graph including the median and error bars indicating interquartile range. Statistical significance 
was determined using the Mann-Whitney U test with p<0.05 being statistically significant. *=p<0.05, **=p<0.01, ***=p<0.001, 
ns=not significant, DC-Tx= DC-therapy, Treg = T-regulatory cell
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Figure S5: The TME spleen immune contexture in response to treatment on day 15 post tumor injection
Figure S5 The TME spleen immune contexture in response to treatment on day 15 post tumor injection. 
Tumor bearing CBA/J mice were sacrificed on t=15 days to examine the tumor microenvironment, blood and 
spleen in the different treatment groups. (A) The TME of all mice in the 4 treatment groups was dissected by 
multicolor flow cytometry into lymphoid cells and myeloid cells, with further subset characterization per cell 
type. Cells are depicted as percentage of alive leukocytes (CD45+), followed by subset characterization that 
was depicted as percentage of lymphoid (CD3+/CD19+/CD335+) or myeloid (CD11b+) cells. (B) After 
sacrifice of mice on t=15, spleens were extracted and weighed. (C, E) Splenic macrophages and non-classical 
(NC) monocytes were determined using flow cytometry and depicted as percentage of non-lymphoid 
leukocytes. (D, F) Correlations were made between splenic non-classical monocytes or macrophages and 
spleen weight. (G-H) Correlations were made between classical monocytes or non-classical monocytes in 
blood versus splenic macrophages. All data is displayed as dot plots or bar graphs including the median and 
error bars indicating interquartile range. Statistical significance was determined using the Mann-Whitney U test 
or in case of correlations using the Spearman’s Rank Correlation test with p<0.05 being statistically significant. 
Healthy controls were measured to depict cell frequencies and phenotypes in the non-tumor bearing host, 
but were not included in further statistical testing. *=p<0.05, **=p<0.01, ***=p<0.001, ns=not significant, 
DC-Tx= DC-therapy, TAM= tumor associated macrophage, NK-cell = Natural Killer cell, Th cell= T helper 
cell, Treg= T regulatory cell. 
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letter to the editor 
Biomarkers for immune checkpoint inhibitors 
We read with interest Luana Calabrò and colleagues’ phase 2 study 1 , which investigated 
the efficacy, safety, and immunological activity of tremelimumab, an anti-CTLA4 monoclonal 
antibody, in patients with advanced malignant mesothelioma 1 2. They noted disease control 
in nine (31%) of the 29 enrolled patients and proposed CD4-positive, ICOS-positive T cells 
as a predictive marker of treatment outcome. Although these results are promising we 
believe that studies concerning biomarkers for immune checkpoint inhibitors should take 
another direction.
Different checkpoint targeting agents have been developed and investigated to overcome the 
inhibitory signaling pathways that switch off T cells. Besides treatments that act on CTLA4, 
drugs targeting the programmed death (PD) protein 1 or its ligands PD-L1 and PD-L2, LAG3, 
HAVCR2, IDO1, CD276, and VTCN1 have now been tested for a wide variety of different 
cancers 3. However, in view of the low response rates and potential serious side effects, the 
development of robust predictive biomarkers is needed. 
The authors made a clear effort to identify lymphocytic subsets as biomarkers of response. 
Intriguingly, the increase in peripheral CD4-positive, ICOS-positive T cells 30 days after treat-
ment was shown to be a potential predictive marker of tremelimumab treatment outcomes 
in patients with mesothelioma. An increase in peripheral CD4-positive, ICOS-positive T cells 
after treatment with tremelimumab provides information regarding the T cell activation 
induced by CTLA4 blockade. Differences in these T cell counts after treatment imply differ-
ences in the proportion of immunosuppression attributable to CTLA4 expression. However 
in the present approach the underlying cause of differences in peripheral T cell activation 
after treatment with tremelimumab remains unclear and this result can only be obtained 
after the start of therapy. The investigators did investigate several lymphocytic subgroups 
at baseline, however the selected populations are non-specific and are not related to the 
treatment approach. It would have been very informative if the investigators had reported 
data regarding CTLA4 expression in the tumour or peripheral blood before treatment to 
gain insights into the mechanisms of treatment response. 
Without a doubt, biomarkers that can predict response to these checkpoint inhibitors before 
use are desirable. The part played by different immunosuppressive mechanisms can change 
during treatment and disease progression dependent on cellular interactions and local signals, 
clearly affecting the efficacy of any immunotherapy 4. Proper biomarkers for the different 
immune checkpoint inhibitors enable the selection of the appropriate inhibitors for an opti-
mized, patient-tailored treatment 5. The search for these biomarkers is now warranted by the 
encouraging clinical activity of tremelimumab in patients even with chemotherapy-resistant 
advanced malignant mesothelioma. 
The authors have no conflicts of interest to declare. 
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abstract
In the past decade, immunotherapy has emerged as a new treatment modality in cancer. 
The most success has been achieved with the class of checkpoint inhibitors; antibodies 
which unleash the anti-tumor immune response. Following the success in melanoma, 
numerous clinical trials are being conducted investigating checkpoint inhibitors in lung 
cancer and mesothelioma. The programmed death protein 1-protein death ligand 1/2 
(PD-1 – PD-L1/2) pathway and cytotoxic T-lymphocyte associated protein 4 (CTLA4) 
are currently the most studied immunotherapeutic targets in these malignancies. In non-
small cell lung cancer (NSCLC), anti-programmed death receptor -1 (PD-1) antibodies 
have become part of the approved treatment arsenal. In small cell lung cancer (SCLC) 
and mesothelioma the efficacy of checkpoint inhibition has not yet been proven. In this 
concise clinical review, an overview of the landmark clinical trials investigating checkpoint 
blockade in lung cancer and mesothelioma is provided. Since response rates are around 
20% in the majority of clinical trials, there is much room for improvement. Predictive bio-
markers are therefore essential to fully develop the potential of checkpoint inhibitors. To 
increase efficacy, multiple clinical trials investigating the combination of CTLA4 inhibitors 
and PD-1/PD-L1 blockade in lung cancer and mesothelioma are being conducted or 
underway. Given the potential benefit of immunotherapy in these devastating diseases, 
implementation of current and new knowledge in trial designs and interpretation of 
results is essential to move forward. 
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introduction 
Lung cancer and mesothelioma are malignancies with uniformly poor outcome as the 
majority of patients are diagnosed with advanced, non-curable disease. These patients have 
traditionally been treated with cytotoxic chemotherapy with modest increases in survival 1-3. 
In advanced non-small cell lung cancer (NSCLC), platinum-based combination chemotherapy 
followed by maintenance treatment with single-agent chemotherapy and/or an anti-angio-
genic agent remains the cornerstone of therapy in the majority of patients, increasing both 
progression-free survival (PFS) and overall survival (OS) by several months 4-6. In second-line, 
NSCLC patients have historically been treated with docetaxel with or without anti-angiogenic 
agents, again offering modest survival benefits 7. The discovery of targetable genetic altera-
tions, which are present in a minority of patients with NSCLC, has improved outcomes, but 
these patients also eventually relapse 8, 9.
Similarly, in extensive stage disease small cell lung cancer (ED-SCLC), platinum-based com-
bination chemotherapy remains the treatment of choice. Despite high objective response 
rates with chemotherapy, most patients with SCLC relapse within the first year after initial 
treatment 10, 11. Standard second-line therapy in SCLC consists of salvage chemotherapy with 
limited efficacy 12, 13. 
In malignant pleural mesothelioma (MPM), platinum/multi-targeted anti-folate combination, 
offering a 3 month overall benefit, is the only FDA approved treatment 14. No second line 
treatments for MPM have been approved for standard-of-care treatment.
Immunotherapy has, however, emerged as a potential new treatment modality in lung 
cancer and mesothelioma, with the aim to induce anti-tumor immunity with durable clinical 
responses. Recent progress has been made with the class of checkpoint inhibitors: antibodies 
directed against inhibitory receptors and ligands which can be co-opted by tumor cells or 
stromal cells 15-17. Encouraged by the FDA-approval of the CTLA4 blocking antibody ipili-
mumab in metastatic melanoma, clinical trials have been conducted in NSCLC and to a lesser 
extent in SCLC and mesothelioma 18-21. This concise clinical review provides an overview of 
the landmark clinical studies investigating checkpoint blockade in lung cancer and mesotheli-
oma, and focuses on the hurdles necessary to overcome in order to successfully implement 
this class of drugs in these notoriously treatment-resistant malignancies. 
PD-1 and PD-L1 blockade in lung cancer and mesothelioma
PD-1 blocking antibodies
The programmed death protein 1-protein death ligand 1/2 (PD-1 – PD-L1/2) pathway is 
currently the most studied immunotherapeutic target in lung cancer. Table 1 summarizes 
results of the landmark clinical trials investigating monotherapy with checkpoint blocking 
antibodies. Antigen-experienced effector T cells express PD-1 upon activation and are con-
secutively downregulated after PD-1 binds to one of its ligands, PD-L1 or PD-L2, expressed 
Chapter 9
178
on various antigen-presenting cells (APCs), stromal cells, and/or tumor cells. Since tumor 
cells are capable of upregulating PD-L1, the PD-1 checkpoint is active in the tumor microen-
vironment 15. The PD-1 blocking antibody nivolumab was the first checkpoint inhibitor to 
receive FDA-approval for the treatment of advanced NSCLC, demonstrating an increase 
in OS in patients who had disease progression after platinum-based chemotherapy in two 
phase 3 randomized clinical trials, comparing nivolumab and docetaxel in squamous and 
non-squamous NSCLC respectively 22, 23. The incidence of grade 3-4 adverse events (AEs) 
was lower in the nivolumab arm compared to docetaxel in both trials. 
The most common reported immune-related toxicities were hypothyroidism, colitis, pneu-
monitis, nephritis and rash. Although presence of PD-L1 expression in the tumor was not 
an inclusion criterion, responses to nivolumab did improve with increasing levels of PD-L1 
expression. 
After the approval as a second-line treatment for advanced NSCLC patients, the potential 
of nivolumab as first-line treatment is now being studied. CheckMate 026 is a phase 3 rand-
omized clinical trial investigating the treatment of advanced, treatment-naive squamous and 
non-squamous NSCLC patients. Only patients with PD-L1 positive tumors (>1% positivity 
on tumor cells) were included, the primary outcome PFS was assessed in patients with ≥5% 
PD-L1 expression. Initial results were recently presented at the ESMO 2016 meeting, and 
although not all outcome measures are currently available, there was no improvement in 
PFS in advanced NSCLC patients treated in first-line with nivolumab monotherapy versus 
platinum-based chemotherapy 24. This may be ascribed to the chosen inclusion criteria, mainly 
the cut-off level of >5% PD-L1 positivity, which may not enrich the population sufficiently to 
outperform chemotherapy in the first line setting. In addition, nivolumab is currently being 
tested in the neoadjuvant setting in early-stage, resectable NSCLC patients, and promising 
preliminary results were presented at the ESMO 2016 meeting, with 40% of patients (6 of 
16) achieving major pathologic responses (<10% residual viable tumor, NCT02259621) 25. 
Nivolumab is currently also being investigated as a first-line treatment for advanced NSCLC 
patients in combination with the CTLA4-blocking antibody ipilimumab in the CheckMate 
227 trial (NCT02477826). 
Pembrolizumab is another PD-1 blocking antibody that has been FDA approved as sec-
ond-line therapy for advanced NSCLC patients and as first-line therapy of patients with 
NSCLC whose tumors have ≥50% expression of PD-L1. The KEYNOTE-001 phase 1 trial 
demonstrated the safety of pembrolizumab, and showed a positive correlation between 
outcomes and PD-L1 expression 26. The randomized phase 2b study, KEYNOTE-010, showed 
an OS benefit in patients with advanced NSCLC who were treated in second-line with 
pembrolizumab (2 dose levels) compared to docetaxel 27. Grade 3-5 AEs were observed in 
13% of the patients on the pembrolizumab 2mg/kg arm, 16% of those in the pembrolizumab 
10mg/kg arm, and in 35% of subjects in the docetaxel arm. One of the inclusion criteria of 
KEYNOTE-010 was ≥1% expression of PD-L1 on tumor biopsies, and consequently, unlike 
Checkpoint blockade in lung cancer and mesothelioma
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nivolumab, pembrolizumab was registered in combination with a companion diagnostic 
PD-L1 immunohistochemical test documenting a ≥1% PD-L1 positivity in tumor biopsies 26. 
The use of archival tissue samples appeared justified since the demonstrable clinical benefit 
was irrespective of whether archival or new tumor samples were used.
The phase 3 study KEYNOTE-024 was positive for its primary endpoint PFS in previously 
untreated advanced NSCLC patients with ≥50% PD-L1 expression on tumor cells and 
without an EGFR mutation or ALK translocation. Patients were randomized to treatment 
with either pembrolizumab or the investigator’s choice of platinum-based chemotherapy 28. 
Grade 3-5 AEs occurred in 26.6% of the pembrolizumab arm compared to 53.3% of the 
chemotherapy arm. On the basis of the second interim analysis, the trial was stopped and 
patients in the chemotherapy group were offered pembrolizumab. Pembrolizumab is now 
the first immunotherapy that is FDA-approved for first-line use in advanced NSCLC. The 
use is restricted to patients with ≥50% PD-L1 expression on tumor cells. 
In addition, the KEYNOTE-042 phase 3 trial in which first-line pembrolizumab is compared 
to standard chemotherapy in advanced NSCLC patients with a lower PD-L1 expression 
threshold of ≥1% is currently ongoing, with a planned subgroup analysis in different PD-L1 
levels (NCT02220894). Pembrolizumab in combination with, carboplatin/pemetrexed (CP) 
chemotherapy demonstrated increased PFS compared to CP alone in cohort G of the 
KEYNOTE-021 study 29. 
In SCLC, there are no randomized data available regarding the efficacy of PD-1/PDL-1 check-
point inhibitors. The phase 1/2 study CheckMate 032, in which patients with advanced SCLC 
were treated with nivolumab or nivolumab plus ipilimumab, showed promising preliminary 
results, however these have to be confirmed in a randomized trial 30. The KEYNOTE-028 
study, a phase 1b study of pembrolizumab in advanced PD-L1 positive solid tumors, included 
an advanced SCLC cohort. Of the 135 screened SCLC patients, 37 (27%) had PD-L1 positive 
tumors and 17 patients were treated with pembrolizumab 31. The ORR was 35% in this small 
patient group and final clinical outcomes are pending at this time point. 
In progressive mesothelioma patients, nivolumab monotherapy is currently being investigated 
in the phase 2 single-arm NivoMes study (NCT02497508) without a PD-L1 expression 
selection criterion.  At the World Conference of Lung Cancer (WCLC) 2016, the results 
after 24 weeks of treatment were presented demonstrating disease control (partial response 
and stable disease) in 33% of 34 treated patients 32. In the mesothelioma cohort of the 
phase 1b KEYNOTE-028 study, 84 patients were screened, 38 (45%) had PD-L1 positive 
(≥1%) tumors and 25 patients were treated with pembrolizumab 33. As presented at the 
WCLC 2016, the ORR was 20% 34. Furthermore the interim analysis of a phase 2 trial of 
pembrolizumab in 34 progressive mesothelioma patients presented at the WCLC 2016 
demonstrated a response rate of 21% (12% in PD-L1 negative patients and 27% in patients 
with ≥1% PD-L1 positive tumors) 35. 
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PD-L1 blocking antibodies
In addition to PD-1 blocking antibodies, PD-L1 blocking antibodies are currently under devel-
opment. The PD-L1 blocking antibody atezolizumab is being developed with a companion 
diagnostic scoring PD-L1 expression on tumor cells (TC) and/or tumor-infiltrating immune 
cells (IC) 36. In the single-arm phase 2 BIRCH trial, treatment-naïve or pretreated advanced 
NSCLC patients with ≥5% PD-L1 expression received atezolizumab infusions, with the 
primary endpoint ORR of 17% in the pretreated patients - an updated analysis is awaited. 
Recent results of the patients treated in first-line demonstrated an ORR of 32% (TC group) 
and 24% (IC group) 37. The phase 2 POPLAR study compared atezolizumab to docetaxel 
in platinum-pretreated patients with advanced NSCLC without PD-L1 preselection 38. The 
study was positive for the primary endpoint, OS; an association was found between an 
increasing OS and higher PD-L1 expression level. Interestingly, both PD-L1 expression on 
tumor cells and tumor-infiltrating immune cells independently predicted an improved OS 
with atezolizumab. Grade 3-4 AEs were reported in 11% of patients in the atezolizumab 
arm compared to 39% of patients in the docetaxel arm. 
Recently, the results of the phase 3 randomized OAK trial involving 1225 pre-treated 
advanced NSCLC patients unselected for PD-L1 expression were presented at the ESMO 
2016 meeting 39. In this study, the primary endpoint OS was significantly improved in the 
atezolizumab arm compared with the docetaxel arm, regardless of PD-L1 expression level. 
The clinical benefit was, however, more pronounced in patients with high PD-L1 expres-
sion level on tumor cells and/ or tumor-infiltrating immune cells. Grade 3-4 AEs occurred 
in 15% of azetolizumab and 43% of docetaxel treated patients. Subgroup analyses of the 
OAK trial presented at the WCLC 2016 confirmed the clinical benefit of atezolizumab in 
NSCLC, regardless of histology and in subgroups of never smokers and patients with brain 
metastases 40.  
Durvalumab and avelumab are two additional PD-L1 blocking antibodies currently under 
investigation in multiple malignancies.  In a phase 1/2 study, patients with advanced NSCLC 
were treated with durvalumab 41 -the ORR was 14% in the 149 enrolled patients eval-
uable for response. The single arm phase 2 ATLANTIC study investigated the efficacy of 
durvalumab in NSCLC patients who progressed after 2 or more lines of prior systemic 
treatments. The study demonstrated durable clinical responses, and the primary outcome of 
ORR increased with higher PD-L1 expression levels on tumor cells 42. Furthermore, the role 
of durvalumab as adjuvant therapy is currently under study in a phase 3 randomized, place-
bo-controlled study in locally-advanced NSCLC patients following chemoradiation (PACIFIC, 
NCT02125461). In addition, there is an actively accruing clinical trial evaluating the efficacy of 
adjuvant durvalumab after complete resection in NSCLC patients (BR31, NCT02273375). 
Avelumab is a PD-L1 blocking monoclonal antibody which is currently being tested in multiple 
clinical settings and cancer types (JAVELIN programme). At the ASCO 2016 and WCLC 2016 
meetings, preliminary results of clinical studies of avelumab in both NSCLC and mesotheli-
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oma were presented. Interim results from a phase 1b clinical trial of first-line avelumab in 156 
advanced NSCLC patients demonstrated an ORR of 22.4% 43, 44. Concomitantly, avelumab 
is being investigated as first-line treatment in advanced PD-L1 positive NSCLC patients in 
a phase 3 clinical trial (JAVELIN Lung 100). In a phase 1b study in advanced mesothelioma 
patients, second-line treatment with avelumab resulted in an ORR of 9.4% (14.3 % in PD-L1 
positive (PD-L1 expression ≥5% as cut-off) and 8.0% in PD-L1 negative patients) 45. To the 
best of our knowledge, there are no results of clinical trials available on the potential of 
PD-L1 blocking antibodies in SCLC. 
Conclusions regarding PD-1/PD-L1 blockade in thoracic malignancies
It is now well appreciated that overall survival is prolonged with checkpoint inhibitors 
although long-term data are lacking, due to the limited time of follow-up of the clinical trials. 
One of the common findings among the studies is the fact that most of the long term sur-
viving patients are those who had demonstrated a radiographic response to treatment with 
checkpoint inhibitors 46. Response rates (and consequently prolonged OS) of the PD-1 and 
PD-L1 blocking antibodies in advanced NSCLC are remarkably similar, with ORR approx-
imately 20% in nearly all clinical trials, leaving much room for improvement. Randomized 
clinical trials with various monoclonal antibodies directed against PD-1 and/or PD-L1 in lung 
cancer and mesothelioma are ongoing in different stages of the disease and lines of treatment. 
Although the clinical potential of these antibodies is undisputed, many questions remain to 
be answered regarding the selection of patients most likely to benefit from monotherapy 
or combination treatment and which combinations of treatment at which sequence of 
treatment should be given. 
CTLA4 blockade in lung cancer and mesothelioma 
Cytotoxic T-lymphocyte associated protein 4 (CTLA4) is upregulated on CD4 effector T 
cells upon activation and constitutively overexpressed on regulatory T cells (Tregs) 47. CTLA4 
functions upon ligation with CD80 or CD86 on APCs - e.g. dendritic cells - in the onset of 
the immune response during T cell priming and activation and enhances the immunosup-
pressive function of Tregs 48, 49. Unlike the PD-1/PD-L1 checkpoint which functions in the 
tumor microenvironment, CTLA4 has a global impact on the immune system and functions 
primarily in the lymph nodes. 
Compared to the PD-1-PD-L1 axis, clinical studies investigating CTLA4 blockade in lung 
cancer and mesothelioma are relatively scarce.  The CTLA4 blocking IgG1 antibody ipili-
mumab was investigated as first-line therapy in combination with carboplatin/paclitaxel versus 
placebo plus chemotherapy in a phase 2 trial for advanced NSCLC patients 50. There were 
three experimental arms in this study: chemotherapy plus placebo; and chemotherapy plus 
ipilimumab in a phased or concurrent regimen. None of the outcomes were significantly 
improved in patients enrolled in the concurrent chemoimmunotherapy arm, but phased 
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ipilimumab showed significant improvement in the primary endpoint, median PFS. The inci-
dence of grade 3-4 AEs was 15% for the phased arm, 20% for the concurrent arm and 6% 
for the control arm. The phased ipilimumab schema is being actively evaluated further in an 
ongoing phase 3 study comparing chemotherapy vs phased ipilimumab and chemotherapy 
in squamous NSCLC (NCT02279732). In ongoing clinical trials of anti-CTLA-4 monoclonal 
antibodies in NSCLC, attention is mostly focused on the role of ipilimumab in a combinatorial 
approach with nivolumab.
The potential of ipilimumab has also been investigated as first-line treatment in advanced 
SCLC patients in a large phase 3 clinical trial, after an initial positive phase 2 study. This trial 
comparing chemotherapy with etoposide and platinum plus ipilimumab 10 mg/kg or pla-
cebo in a phased induction schedule followed by ipilimumab or placebo maintenance was 
negative for its primary endpoint, OS 51, 52. There are no data available regarding the efficacy 
of ipilimumab in mesothelioma patients.  
The CTLA4 blocking IgG2 antibody tremelimumab has been investigated in NSCLC and 
mesothelioma, but not in SCLC. A phase 2 study randomized advanced NSCLC patients to 
second-line treatment with tremelimumab or best supportive care and was negative for its 
primary endpoint PFS at 3 months 53. 
By far the largest clinical trial investigating immunotherapy in mesothelioma has been the 
DETERMINE trial; a phase 3 placebo-controlled study of tremelimumab in 571 advanced 
mesothelioma patients as second and third-line treatment. The results of this trial were 
presented during the 2016 ASCO meeting, and demonstrated that there was no statistically 
significant difference in median OS, despite promising results in the phase 2 trial 54 55. A phase 
2 study in which tremelimumab is combined with durvalumab in mesothelioma patients in 
second or third-line is currently ongoing in Italy (NCT01843374). 
Thus far, in lung cancer and mesothelioma, CTLA4 blocking antibodies have not produced 
the clinical benefits seen in melanoma. Given the current absence of robust response bio-
markers of CTLA4 blockade, the potential mechanisms behind these disappointing results 
are the subject of ongoing debate while ipilimumab and tremelimumab are moving forward 
in combination with PD-1/PD-L1 blockade in multiple clinical trials. 
Biomarkers of response
Can PD-L1 expression predict efficacy of PD-1 blockade?
Topalian et al. recently provided an overview of the current potential biomarkers for PD-1- 
and CTLA4 blockade and provided guidance on how best to move forward in the quest for 
robust biomarkers 16. The authors proposed that potential biomarkers should be identified 
based on the mechanism of action of the drug target. As the PD-1 checkpoint regulates local 
immune responses within the tumor microenvironment, local PD-L1 expression on both 
tumor and infiltrating immune cells qualifies as an attractive potential biomarker for PD-1/
PD-L1 blocking antibodies. 
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The immune contexture of tumors is known to be profoundly heterogeneous and dynamic. 
The identification of potent biomarkers of immunotherapies is therefore challenging. For 
example, how well PD-1/PD-L1 blocking antibodies will perform in inducing effective anti-tu-
mor immune responses is dictated by the portion of the anti-tumor immune response which 
is suppressed by PD-1/PDL-1/2 interaction 16, 56, 57. Two fundamental mechanisms play a role 
in the expression of PD-L1 in tumors: innate and adaptive immune resistance. Tumor cells are 
capable of constitutively expressing PD-L1 regardless of the presence of an active immune 
response in the tumor (innate immune resistance) 15. In addition, tumor cells, immune cells 
and stromal cells will upregulate PD-L1 in a negative-feedback response to intra-tumoral 
infiltration of activated T cells (adaptive immune resistance) 58, 59. There is certainly validity 
in the principle that PD-L1 expression within the tumor microenvironment (on tumor cells 
and/or infiltrating immune cells) functions as a hallmark of local immune activation and 
potential response to blockade of the PD-1/PD-L1 axis 59-61. As described above, however, 
PD-L1 upregulation may also be independent of an anti-tumor-directed immune response. 
Despite all the inherent biases, the results of the clinical trials do support the concept that 
higher levels of PD-L1 expression on immunostaining enriches for patient populations that 
will respond more robustly to PD-1/PD-L1 inhibition. Table 2 provides an overview of the 
available data regarding response rates according to stratified PD-L1 expression in landmark 
clinical trials. Since the PD-1/PD-L1 blocking antibodies are very similar in structure, the 
differences in the outcomes of the various clinical trials are subject of ongoing debate. It is 
clear that PD-L1 expression is an enriching factor; therefore studies that include more PD-L1 
positive patients or apply a higher cut-off include more responders. Furthermore, there is 
heterogeneity of the different staining antibodies used to determine PD-L1 expression. 
As PD-L1 expression is a continuous and dynamic variable which is heterogeneously 
expressed throughout the tumor, the challenges concerning the implementation of a PD-L1 
expression immunohistochemistry score as a robust biomarker are clear 62, 63. The Interna-
tional Association for the Study of Lung Cancer (IASLC) has therefore launched a project 
to compare available PD-L1 immunohistochemistry assays (Blueprint Project) 62. First results 
were recently published and demonstrate that for 37% of the reviewed cases, a different 
PD-L1 classification would be made depending on which assay/scoring system is used 64. This 
potential misclassification could also explain the finding that in some study cohorts PD-L1 
‘negative’ patients demonstrate good clinical responses. Whether the differences in study 
outcomes are attributable to the characteristics of the different monoclonal antibodies or 
to the study characteristics (e.g. inclusion criteria, PD-L1 immunohistochemistry clone) will 
need to be determined. 
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Table 2 Objective response rates according to stratified PD-L1 expression after PD-1-PD-L1 blockade in 
lung cancer and mesothelioma
Compound Study Antibody PD-L1 score (% positivity)
Prevalence 
(%)
ORR (%)
Nivolumab CheckMate 057 Dako 28-8 < 1 47 9
≥1 53 31
≥5 41 36
≥10 37 37
Nivolumab CheckMate 017 Dako 28-8 < 1 40 17
≥1 47 17
≥5 31 21
≥10 27 19
Pembrolizumab KEYNOTE-010 Dako 22C3 <1 34 excluded
≥1-49 38 18
≥50 28 30
Atezolizumab BIRCH Ventana 
SP142
TC or IC <5 unknown excluded
TC or IC 5-49 54 10
TC or IC ≥50 46 26
POPLAR Ventana 
SP142
TC and IC <1 32 8
TC or IC ≥1 and <5 31 14
TC ≥ 5 and <50 or IC ≥ 5 
and <10
20 8
TC ≥50 or IC ≥ 10 16 38
OAK Ventana 
SP142
TC and IC <1 45 8
TC or IC ≥ 1 55 18
TC ≥ 5 or IC ≥ 5 31 22
TC ≥50 or IC ≥ 10 16 31
Durvalumab ATLANTIC Ventana 
SP263
<25 (cohort 2) 61 8
≥25 (cohort 2) 39 16
≥90 (cohort 3) 100 31
Avelumab JAVELIN DAKO 
73-10
<1 22 0
≥1 78 20
Mesothelioma <5 64 8
≥5 36 14
Abbreviations: ORR overall response rate; TC tumor cells; IC immune cells
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Towards biomarkers for CTLA4 blocking antibodies
Since response rates to CTLA4 blockade in lung cancer and mesothelioma are low and grade 
3-4 AEs are relatively common, there is a pressing need for the identification of predictive 
biomarkers. As CTLA4 exerts its effect during T cell priming and activation in the lymph 
nodes, many studies in search of biomarkers for ipilimumab and tremelimumab have focused 
on the phenotype of peripheral blood leukocytes before and during treatment. An increased 
absolute lymphocyte count and specifically increased number of peripheral CD8 T cells have 
been associated with higher response rates to ipilimumab 65. Several studies, including the 
phase 2 study of tremelimumab in mesothelioma, described increased expression of the 
co-stimulatory molecule, inducible T cell co-stimulator (ICOS) on peripheral CD4 T cells 
following treatment with CTLA4 blockade 55, 56, 66. As this potential biomarker is not a baseline 
characteristic, however, it is not useful as a selection criterion for patients who are likely to 
benefit from CTLA4 blockade. Unfortunately, none of the found associations have currently 
led to the identification of a robust biomarker of response to CTLA4 blockade. 
Perhaps the best biomarker for response to CTLA4 blockade is not in the peripheral blood, 
but rather obtained from minimally invasive assessment (i.e via E(B)US-FNA) of CTLA4 
expression on T cells in the draining lymph nodes of patients with lung cancer and meso-
thelioma 67, 68. 
Combinatorial immunotherapy in lung cancer and mesothelioma
As it is known that CTLA4 modulates T cell activation in the lymph nodes, while PD-1/PD-L1 
controls T cell activation locally at the tumor site, the combined blockade of these check-
points seems an attractive strategy. Following the example set in metastatic melanoma, the 
combination of CTLA4 inhibitors and PD-1/PD-L1 blockade is currently being evaluated in 
multiple cancers. In the phase 1 CheckMate 012 study, 148 advanced NSCLC patients were 
treated with nivolumab plus ipilimumab in 4 dose cohorts and ORRs ranged from 13% to 
39% 69. The follow-up phase 3 CheckMate 227 trial will establish the role of the nivolumab/
ipilimumab combination in advanced NSCLC patients in first line (NCT02477826). In a phase 
1 study, the combination of durvalumab and tremelimumab demonstrated an ORR of 23% in 
the optimal tolerable dosage group 70, leading to the phase 3 MYSTIC trial which is currently 
being analysed for results. In SCLC, the combination of nivolumab and ipilimumab showed 
a slight increase in response rates compared to nivolumab monotherapy in the CheckMate 
032 phase 2 trial 30. The phase 3 CheckMate 451 study currently investigates the efficacy of 
nivolumab versus nivolumab in combination with ipilimumab as switch maintenance therapy 
versus placebo and aims to enroll 810 advanced SCLC patients with at least stable disease 
after chemotherapy (NCT02538666). Following the disappointing results of tremelimumab 
monotherapy in mesothelioma, a phase 2 trial investigating the combination of tremeli-
mumab and the PD-L1 blocking antibody durvalumab has been initiated (NIBIT-MESO-1, 
(NCT02588131)). Furthermore, first line treatment with the combination of nivolumab 
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and ipilimumab is currently being investigated in comparison to standard chemotherapy 
in mesothelioma patients in the phase 3 CheckMate 743 study which aims to enroll 600 
patients (NCT02899299).  
As stated above, the combination of ipilimumab and nivolumab performed better than ipil-
imumab monotherapy in melanoma 71, 72. It should be noted, however, that the addition of 
ipilumumab to nivolumab only resulted in a modest increase of overall survival at the expense 
of a clear increase of toxicity, and only in these tumors which were PD-L1 negative. Because 
single agent nivolumab resulted in long-term survivors, a large percentage of the melanoma 
patients treated with combination therapy therefore could have responded to nivolumab 
alone, depending on the PD-L1 positivity of the tumor. These patients were exposed to 
possibly toxicity due to the lack of proper biomarkers to guide appropriate treatment reg-
imens. The fact that monotherapy may be effective in selected patient populations should 
play a major role in the design of immunotherapy trials in lung cancer and mesothelioma, 
as toxicities in general are higher in these diseases, as well as for the significant financial 
consequences associated with combination treatment. Also in the development of the trials 
the different tumor microenvironment between lung cancer and mesothelioma compared 
to other malignancies should be taken into account.
Conclusion
Over the last years, checkpoint blockade has become a part of the treatment backbone of 
NSCLC and in the near future could possibly prove its efficacy in SCLC and mesothelioma. 
Following the success in melanoma, numerous clinical trials are being conducted investi-
gating a constantly expanding armamentarium of checkpoint inhibitors. The challenge to 
fully develop checkpoint blockade in lung cancer and mesothelioma necessitates both the 
identification and implementation of predictive biomarkers. Furthermore, only when these 
biomarkers are available can rational combinatorial approaches be designed. In difficult to 
treat diseases such as lung cancer and mesothelioma, clinicians and scientists have an even 
stronger obligation to collect and share as much clinical and translational data as possible 
in order to achieve these goals. Given the potential benefit of immunotherapy in these 
devastating diseases, implementation of current and new knowledge in trial designs and 
interpretation of results is essential to move forward. 
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abstract
Purpose: PD-1 checkpoint-blockers have recently been approved as second-line treat-
ment for advanced non-small cell lung cancer (NSCLC). Unfortunately, only a subgroup 
of patients responds and shows long term survival to these therapies. Tumor vaccines 
and cellular immunotherapies could synergize with checkpoint blockade, but which of 
these treatments is most efficacious is unknown. In this meta-analysis we assessed the 
efficacy of tumor vaccination and cellular immunotherapy in NSCLC. 
Methods: We searched for randomized controlled trials investigating cellular immu-
notherapy or vaccines in NSCLC. We used random effects models to analyze overall 
survival (OS) and progression free survival (PFS) expressed as hazard ratios (HR) and 
differences in months. The effect of immunotherapy type, disease stage, tumor histology, 
and concurrent chemotherapy was assessed using subgroup analysis and meta-regres-
sion. All procedures were performed according to the PRISMA guidelines.
Results: We identified 18 RCTs that matched our selection criteria, including 6756 
patients. Immunotherapy extended NSCLC survival and PFS, expressed as HR (OS: 
HR=0.81, 95%CI=0.70-0.94, p=0.01, PFS: HR=0.83, 95%CI=0.72-0.95, p=0.006) and 
month difference (OS: difference=5.43 months, 95%CI=3.20-7.65, p<0.005, PFS: differ-
ence=3.24 months, 95%CI=1.61-4.88, p<0.005). Cellular therapies outperformed tumor 
vaccines (OS as HR: p=0.005, month difference: p<0.001, PFS as HR: p=0.001, month 
difference: p=0.004). There was a benefit of immunotherapy in low stage over high stage 
NSCLC and concurrent administration of chemotherapy only in one of four outcome 
measures evaluated (PFS in months: p=0.01 and PFS as HR: p=0.031, respectively) There 
was no significant effect of tumor histology on survival nor PFS.
Conclusion: Tumor vaccines and cellular immunotherapies enhance overall survival and 
PFS in NSCLC. Cellular immunotherapy was found to be more effective than tumor 
vaccination. These findings have implications for future studies investigating combination 
immunotherapy in NSCLC. 
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introduction
Lung cancer is the leading cause of cancer related mortality worldwide 1. Non-small cell 
lung cancer (NSCLC) comprises 85% of all lung cancers and has a 5-year survival rate of 
4% in case of metastatic disease 2. Current treatment options for advanced NSCLC include 
chemotherapy and radiotherapy, but these treatments only modestly improve survival. Recent 
advances include the targeting of several driver mutations responsible for tumor progression. 
Targeting the mutant EGF receptor and the EML4-ALK fusion protein has been found effec-
tive; however, resistance to these therapies inevitably ensues 3-5. Therefore, novel treatment 
strategies to improve NSCLC survival are warranted.
Immunotherapy aims to establish or enhance an effective immune response toward the 
tumor. This can be accomplished via different strategies including tumor vaccination, adoptive 
transfer of immune cells and modification of the immune system to boost an established 
immune response 6. The latter category of drugs includes the checkpoint inhibitors anti-pro-
grammed death 1 (PD-1) and anti-CTLA-4 that have recently been tested for efficacy in 
NSCLC 7-9. The beneficial role for blocking CTLA-4 in NSCLC remains inconclusive 9, 10, but 
PD-1 blockade has proven to be effective in treating NSCLC 7, 11. Nevertheless, the majority 
of patients does not respond to checkpoint inhibition therapy 7, 12, 13. 
There are several ways in which an immune response toward a tumor can be induced as has 
been described in some reviews on this topic 6, 14, 15. Tumor vaccines elicit an in vivo immune 
response specifically towards a tumor-associated antigen formulated in the vaccine. This form 
of therapy has proven to be safe and effective in eliciting tumor-specific immune responses 
in different cancers, including NSCLC 16-18. It is also possible to circumvent endogenous anti-
gen presentation by directly administering antigen stimulated T cells or dendritic cells (DCs) 
19, 20. Tumor vaccines and cellular therapies are aimed specifically toward tumor antigens 
and, therefore, have a limited toxicity profile as opposed to established chemotherapy and 
checkpoint blockade 21-23. 
Eliciting potent T-cell response via vaccines or cellular therapies and simultaneously releasing 
the brakes on these T cells with checkpoint inhibitors may unleash the full potential of immu-
notherapy and improve the proportion of patients responding to therapy. Synergies between 
checkpoint inhibitor therapy and tumor or cellular vaccines are currently being investigated 
in several clinical trials 24. Which form of immunotherapy; vaccine or cellular therapy, is most 
promising to combine with checkpoint inhibitors such as PD-1 blockers is currently unknown. 
In this meta-analysis we show that vaccination and cellular immunotherapies improved the 
overall survival (OS) and progression-free survival (PFS) in patients with NSCLC. Cellular 
therapies outperformed tumor vaccines for all the outcomes assessed. Other factors such 
as tumor histology or the preconditioning of patients with low-dose cyclophosphamide had 
no effect on survival or PFS. 
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Database search
On June 17, 2015, we searched for relevant studies in the following databases: Embase, 
Medline (Ovid SP), Web of Science, Cochrane Central Register for Controlled Trials, Pubmed 
Publisher and Google Scholar. There were no limitations on the year of publication for all 
the databases interrogated. Search entries were constructed for each individual database 
(Appendix, online only). The search initially involved other thoracic malignancies including 
small-cell lung cancer and mesothelioma. No language restrictions were applied. We also 
searched manually through conference abstracts and checked references from relevant 
publications and review articles. All procedures were performed according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 25.
Eligibility 
Articles were included based on title and abstract if they concerned clinical evaluation of 
a tumor vaccine or cellular immunotherapy in NSCLC. Articles were excluded when they 
involved less than 5 NSCLC patients, or did not report well-defined clinical endpoints 
for survival or time to progression of disease. All articles on checkpoint blockade therapy 
or biological response modifiers (e.g. interferons, interleukins) were excluded. When we 
obtained all records on vaccine and cellular therapies in NSCLC, we selected the randomized 
controlled trials to study the efficacy of treatment. Studies that were not randomized or 
lacked complete outcome data were excluded for this particular research question. If multiple 
articles covered the same study population, the study with the most recent and complete 
survival data was used. Remaining studies that investigated the predictive value of immune 
factors in blood were later used for systematic review. Authors of the individual studies were 
contacted in case of missing data. Two investigators (F.D. and L.L.) independently screened 
abstracts and reviewed full texts for eligibility. Data extraction was performed (F.D. and 
G.V.) according to a predefined data extraction form. Any discrepancies were resolved by 
consensus with a third reviewer (J.A.). 
Data collection and outcomes
Treatment characteristics (type and timing of treatment, dose) patient demographics, tumor 
histology, disease stage (low stage disease ranging from stage I-II/IIIA and high stage disease 
being III(B)-IV), and relevant outcome measures were collected according to a predefined 
data extraction form. The outcome measures OS and PFS were assessed, and when PFS 
was not available, time to progression and relapse free survival were included to increase 
the comparability and power of our analysis. These outcome measures were inconsistently 
reported as either hazard ratios (HRs) or as median months survival or time to disease 
progression or both, and all were included for further analysis. Tumor response rates were 
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not evaluated because they were inconsistently reported and have been found to correlate 
poorly with immunotherapy efficacy 26. The risk of bias was determined using the Cochrane 
Collaboration risk of bias assessment tool 27. 
Statistical Methods
Random effects models were used to compute summary effect sizes for all the outcome 
measures investigated, thereby taking heterogeneity across studies into account 28, 29. When 
available, HRs from different studies were pooled to calculate the OS benefit of vaccine 
and cellular immunotherapy in NSCLC. Additionally, median differences were generated 
and combined when median survival times or median months of PFS were reported. We 
addressed several possible sources of heterogeneity (expressed as I²) including type of 
immunotherapy (tumor vaccine vs. cellular therapy), limited or advanced disease (I-II/IIIA vs. 
III(B)-IV), histology (percentage of adenocarcinoma), preconditioning therapy with low-dose 
cyclophosphamide (in case of vaccines), and concurrent administration of chemotherapy, 
using subgroup analysis and meta-regression (in cases where the percentage of adenocarci-
noma was given). Funnel plots were generated to assess the presence of publication bias. In 
order to define the extent of publication bias, the Duval and Tweedie trim-and-fill test and 
the classic fail-safe N test were used 30. The Begg and Mazumdar rank-correlation test and 
the Egger test were applied in cases of suspected publication bias to quantify the level of 
bias 31, 32. All analyses were performed by a biostatistician (L.A.), using a registered copy of 
Comprehensive Meta-Analysis statistical software (version 2.2.064; Biostat, Englewood, NJ).
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results
Search strategy result and study characteristics of included trials
Our database and manual searches yielded a total of 7832 records of which 5992 records 
remained following removal of duplicate articles (Figure 1). An additional four records were 
manually selected from conference abstracts and reference lists. All records were screened 
on the basis of title and abstract to identify trials investigating the benefit of tumor vacci-
nation or cellular immunotherapy in the context of NSCLC. After screening, a total of 114 
potential records remained that were eligible for full-text assessment. Of these, 18 individual 
randomized controlled trials (RCT) were eligible for subsequent meta-analysis.
Figure 1 Prisma Flow Chart displaying the search and selection process performed.
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The 18 RCTs included in our analysis comprised a total of 6756 patients treated with 
immunotherapy for NSCLC distributed over different outcome measures. A summary of 
the main study characteristics is listed in table 1. Most studies focused on late stage disease 
(15/18 trials stage III(B)-IV). The type of treatment was evenly distributed, with 10 studies 
investigating tumor vaccines and the other 8 treating patients with either DC-therapy, a 
form of T-cell therapy (AKT; autologous activated killer T cells or CIK; cytokine induced killer 
cells) or a combination of the two. The proportion of adenocarcinoma histology varied 
extensively between studies ranging from 28 to 88% of total cancers. Immunotherapy was 
administered as monotherapy with or without low-dose cyclophosphamide preconditioning 
or concurrently with chemotherapy. The control treatment arm was heterogeneously com-
posed of control groups receiving only the placebo or best supportive care (BSC) and others 
receiving chemotherapy (when immunotherapy was combined with chemotherapy in the 
experimental arm). There were no studies that investigated the efficacy of tumor vaccines 
or cellular therapies alone versus chemotherapy treatment. 
Immunotherapy significantly prolongs NSCLC survival and delays tumor progression
Studies reported different outcome measures with some reporting hazard ratios of disease 
progression or survival while others reported only median OS and/or time to disease pro-
gression in months. Therefore, we analyzed HRs and the differences in medians for survival 
and PFS separately. Cancer immunotherapy was found to be effective in extending NSCLC 
overall survival and PFS, both expressed as HR (cumulative OS: HR=0.81, 95%CI=0.70-0.94, 
p=0.01, PFS: HR=0.83, 95%CI=0.72-0.95, p=0.006, Figure 2) and median month difference 
(cumulative OS: difference=5.43 months, 95%CI=3.20-7.65, p<0.005, PFS: difference=3.24 
months, 95%CI=1.61-4.88, p<0.005, Figure 3).
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Figure 2 (A) Overall survival and (B) progression free survival when hazard ratios (HR) were reported.
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Figure 3 (A) Overall survival and (B) progression free survival expressed as mean differences in months when 
median overall survival data were reported.
Cellular immunotherapeutic strategies perform significantly better than tumor vaccination ther-
apies 
There was a moderate level of heterogeneity between sample estimates for both OS 
and PFS expressed as HR (OS: I²=43.9%, PFS: I²=57.7%) and significant heterogeneity for 
outcome measures expressed in months (OS: I²=86.5%, PFS: I²=85.8%). To test whether 
this heterogeneity could be attributed to differences in type of immunotherapy (vaccine or 
cellular therapies), disease stage (low vs. high), concurrent chemotherapy, NSCLC histology 
(% adenocarcinoma) or preconditioning with low dose cyclophosphamide, subgroup analysis 
and meta-regression were performed. 
Significant heterogeneity existed between studies evaluating tumor vaccination and cellular 
immunotherapy treatments, with cellular therapies being more effective than tumor vaccines 
for all outcome parameters evaluated (OS as HR: p=0.005 and median month difference: 
p=0.001, PFS as HR: p=0.001 and as median month difference: p=0.004, Table 2). There 
were no significant differences in survival or disease progression between studies investi-
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gating immunotherapy in high versus low stage NSCLC disease, except for the difference in 
median months of PFS, being more favorable for studies involving low-stage NSCLC than 
those involving high-stage disease (p=0.010). Studies that evaluated immunotherapy with 
concurrent chemotherapy performed better than studies investigating immunotherapy alone, 
only for time to disease progression as HR (p=0.030) There was no correlation between the 
proportion of patients with adenocarcinoma histology and the standardized mean difference 
for survival (p=0.448) or PFS (p=0.426, Appendix figure 1, online only) nor could we detect 
a benefit of pre-conditioning with cyclophosphamide in case of the tumor vaccines (HR OS: 
p=0.577, HR PFS: p=0.928). 
Bias assessment 
The level of bias varied extensively between studies, with several studies being deficient in 
thorough methodological reporting, which, in most cases, was because only an abstract was 
available 33-36.The studies that properly reported randomization procedures, blinding and all 
outcome measures were generally low in bias 21, 37, 38, but selection bias and detection bias 
could be detected in some trials, or were not reported 39-41 (Figure 4). With the exception 
of three studies with an unclear risk of bias 33, 35, 36, all studies lacked reporting bias, attrition 
bias and other sources of bias not specifically addressed by the Cochrane Collaboration 
risk of bias tool.
Funnel plots were constructed to investigate the presence of publication bias. There was 
no or minimal publication bias for overall survival expressed as HR and median months 
difference (Appendix figure 2A and 2C, online only). Adjusted values after the Duval and 
Tweedie trim-and-fill test revealed no significant alteration of the observed point estimate 
(data not shown). There was no publication bias for the outcome PFS expressed as median 
month difference (Appendix figure 2D). There was, however, possible publication bias for PFS 
expressed as HR (Appendix figure 2B), as indicated by a potential loss of significance from the 
Duval and Tweedie trim-and-fill test (data not shown). Additional tests to quantify publication 
bias were inconclusive (the Egger test being significant for publication bias but two tailed 
Begg and Mazumdar’s test not). Also, the classic fail-safe N test indicated that 40 additional 
studies would be required to reach a p-value greater than alpha (p=0.05, data not shown). 
Therefore, the presence of publication bias for PFS expressed as HR remains uncertain. 
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Figure 4 The assessment of bias of included studies using the Cochrane Collaboration Risk of Bias Assessment 
Tool.
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discussion
Targeting the immune system to combat cancer is an effective way to enhance survival 
and prolong time until progression in NSCLC. In contrast to disease-modifying drugs such 
as cytokines (interleukin-2, interferons) and the recently investigated checkpoint inhibitors, 
tumor vaccines and cellular therapies induce formation of specific tumor-directed cytotoxic 
T cells capable of destroying cancer cells. Because of their high specificity, based on the 
selection of only tumor associated antigens, tumor vaccines and cellular immunotherapies are 
associated with limited side effects, but the efficacy of these therapies, with tumor vaccines 
in particular, has been controversial 42, 43. In this meta-analysis, combining the data from all 
published tumor vaccine trials resulted in a significantly improved survival and prolonged time 
to disease progression. These results were even more pronounced for the cellular therapies. 
The distinction between these two immunotherapeutic strategies was the only factor that 
was consistently different for all outcome measures analyzed. Other factors such as disease 
stage and combination chemotherapy also significantly differed regarding clinical efficacy 
albeit not for all outcome measures. Tumor histology was not significantly associated with 
changes in survival or time to disease progression. 
Large phase III studies such as the MAGRIT trial and the belagenpumatucel-L phase III trial 
were initiated following promising phase II results but they were prematurely terminated due 
to lack of clinical efficacy 42. Discordant results of phase II and III studies in NSCLC research 
have been reported by others in the past and are thought to arise from differences in phase 
II and III study population characteristics, size and the (intermediate) outcome measures and 
the target effect size aimed for 44. Most of the phase III studies included in our analysis con-
cerned tumor vaccination trials, and these studies attributed the majority of patients to our 
analysis. Given the disappointing results of these trials it is remarkable that in our meta-analysis 
tumor vaccination therapies significantly enhanced survival and time to disease progression, 
suggesting insufficient power in previous phase III trials. 
Even though there was no or limited publication bias for the majority of parameters inves-
tigated, overrepresentation of phase II studies in the cellular therapies included could have 
attributed to the differences in efficacy compared to tumor vaccination therapy. On the 
other hand, the differences may be ascribed to the activation of the immune system with 
cellular therapies such as DC and T-cell therapies. First, cellular therapies partially or totally 
circumvent potential immune suppression induced by vaccination and, therefore, directly acti-
vate anti-tumor T cells capable of targeting the tumor 19, 45. Second, whereas vaccines target 
one predominant tumor antigen, DC (and, to a lesser extent, T cells) activated in vitro could 
potentially induce a polyclonal antitumor response 46, 47. This might prevent immune escape 
by the tumor and induce immune responses to a multitude of tumor antigens.
Screening patients before vaccination for expression of the targeted tumor antigen and 
designing personalized tumor vaccines could increase response rates to tumor vaccines 48, 49. 
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Several studies have correlated a specific immune response to the vaccine with increased 
survival and tumor responses following therapy 37, 50-57. Identifying these patients before or 
after the first vaccination as personalized therapy could specifically benefit those that are 
most likely to respond and favor the use of combination treatment in nonresponding patients. 
We found a statistically significant effect of chemotherapy combined with immunotherapy for 
the HR of disease progression, but not for other outcome measures. Chemotherapy could 
synergize with immunotherapies by causing immunogenic cell death of cancer cells and by 
disrupting immune evasion pathways, but timing of combination therapies is crucial 58. We 
found no additive effect on tumor vaccine efficacy of low-dose cyclophosphamide in our 
analysis (Table 2), but this could be due to the limited amount of studies available for analysis. 
Also, few studies reported antibody responses towards the vaccine, making it difficult to 
assess the effect of prior immune modulation. Importantly, to further target immune-evasion 
pathways in patients, enhancing antitumor T-cell functionality with checkpoint inhibitors acting 
via PD-L1/PD-1 blockade could further improve therapeutic efficacy 59. The PD-1 blocking 
antibodies nivolumab and pembrolizumab have been recently approved for NSCLC treat-
ment following positive phase III results 7, 60. 
There are several limitations relevant to this meta-analysis. First, there was a limited amount 
of studies available for some outcome measures investigated with subgroup analysis (e.g. 
OS HR for type of therapy and disease stage). Second, variability in control treatments with 
cellular therapies (BSC) and vaccine studies (mostly placebo) could have biased our results 
in favor of cellular immunotherapy. Because of incomplete reporting and heterogeneity 
in methodology we did not further investigate potential immune markers (e.g. antibody 
responses following vaccination) that could be predictive for therapeutic efficacy. More stud-
ies will have to be awaited to properly address this issue. Finally, bias could not be assessed 
in several of the studies included. Therefore, we did not perform sensitivity analysis after 
exclusion of studies with a high or unspecified degree of bias. Several larger phase III studies 
on tumor vaccines and cellular therapies are still awaited and it is inevitable in meta-analysis 
that studies will be missed. However, to our knowledge, this meta-analysis is the first analysis 
to give a comprehensive overview of specific immunotherapies in NSCLC, assessing both 
tumor vaccines and cellular therapies. 
In conclusion, specific immunotherapies significantly prolonged NSCLC survival and PFS. 
Cellular immunotherapies were more effective than tumor vaccines for all outcome measures 
evaluated. Low-stage disease and the concurrent use of chemotherapy improved efficacy 
but only for disease progression in months and as HR, respectively. There was no association 
between treatment efficacy and adenocarcinoma histology or preconditioning low-dose 
cyclophosphamide. These findings are useful for the design of future studies investigating 
immunotherapies in NSCLC and possible synergistic combination strategies that could 
improve patient survival. 
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summary
At the start of the studies described in this thesis we knew that macrophages are the pre-
dominant cell type in the microenvironment of mesothelioma tumors. Evidence regarding 
their potential role in tumor initiation, outgrowth and dissemination was arising from pre-
clinical studies in other tumor types. In the studies described in this thesis we used multiple 
translational approaches to investigate the role of TAMs in the mesothelioma environment 
and their potential as a therapeutic target.  We started in chapter 2 and 3 by evaluating the 
presence, phenotype and correlation with patient survival and local tumor outgrowth (LTO). 
We demonstrated that the ratio of M2 macrophages to total macrophages present in tumor 
biopsies is a potential prognostic marker. Furthermore, determination of this ratio in diagnos-
tic biopsies made it possible to predict the occurance of LTO. In addition to the infiltration 
of TAMs in the tumor microenvironment, we investigated their phenotype and function in 
pleural effusion of mesothelioma patients (chapter 4). Pleural effusion was shown to be able 
to induce a profound immunosuppressive macrophage phenotype capable of inhibiting T 
cell proliferation. In chapter 5, we further investigate the properties of pleural effusion and 
demonstrate that its composition is dynamic, influenced by treatment and doesn’t necessarily 
mirror the immunological properties of the tumor. Together, chapter 4 and 5 provide novel 
insights regarding the presence and phenotype of TAMs in pleural effusion, which should be 
considered when applying (intrapleural) immunotherapy in mesothelioma. In the first part of 
the thesis we validated the hypothesis that TAMs are an important and detrimental part of 
the mesothelioma microenvironment. Targeting TAMs as an immunotherapeutic approach has 
proven to be challenging. Multiple strategies are described in the literature which aim mainly 
at the re-education or depletion of TAMs. In chapter 6 we use a CD40 agonistic antibody 
in a pilot study and demonstrate that it has an additive effect to DC immunotherapy. CD40 
agonists have been described to exert their effect through the stimulation of local TAMs, 
whether this mechanism also underlies our results in a mesothelioma mouse model will be 
the subject of future studies. The reduction of TAMs using a CSF1R-inhibitor as described in 
chapter 7, did not improve survival but the combination with DC-immunotherapy showed 
clear synergistic effects in mesothelioma mouse models. As these preclinical studies pro-
vide leads for future clinical trials, it is pivotal to critically evaluate the design of these trials. 
Checkpoint blockade is quickly conquering the field of cancer immunotherapy thanks to the 
promising results of clinical trials in multiple tumor types. However, in order to benefit most 
from these novel agents in pulmonary oncology, it is pivotal that predictive biomarkers will 
be identified. In chapter 8 and 9, we discussed this need for biomarkers, provided an over-
view of the landmark clinical studies and the hurdles to overcome to implement checkpoint 
blockade in pulmonary oncology. Chapter 10 demonstrated that cellular immunotherapy is 
more effective than tumor vaccination in NSCLC which opens new roads for combinatorial 
immunotherapy in pulmonary oncology. 
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discussion
Macrophages are key players in the mesothelioma environment
TAMs are the predominant immune cells in the mesothelioma environment. Characterization 
of their phenotype and more importantly local function is challenging. In chapter 2 and 3 of 
the thesis we attempted to quantify and qualify the infiltrating TAMs in mesothelioma biopsies. 
The scavenger receptor CD163 is often used to identify alternatively activated or M2 macro-
phages in human studies whereas CD68 is recognized to be a general macrophage marker 
1. Using immunohistochemistry as a relatively simple method we were able to establish the 
clinical value of the TAM infiltrate. We demonstrated in chapter 2 that although the total 
number of TAMs in tumor tissue did not correlate with survival, the CD163/CD68 ratio did in 
the total patient group (surgery or non-surgery). Therefore we identified this CD163/CD68 
ratio as a potential prognostic marker, however it cannot be used as a predictive marker 
for outcome after surgery. Another group showed that in a large group of mesothelioma 
patients the combination of a high CD163+ TAM infiltration and a low CD8 T cell infiltration 
indicated a worse prognosis 2. Furthermore, in chapter 3 we demonstrated that the CD163/
CD68 ratio and amount of CD8 T cells within diagnostic tumor biopsies were predictive of 
local tumor outgrowth after a local intervention. Although only performed in limited patient 
groups, these results do indicate the regulation of a local immunological profile in meso-
thelioma which has clinical consequences. Evidently, when applying immunohistochemistry 
to characterize TAMs, the subtleties of the phenotype cannot be appreciated. Furthermore, 
whether the taken biopsy is representative of the entire tumor remains questionable. How-
ever, the studies presented in this thesis do show a correlation of the CD163/CD68 ratio 
with survival and local tumor outgrowth, thus providing a potential easy to perform clinical 
tool and the validation of TAMs as a therapeutic target in mesothelioma. 
Expansion of the environment: pleural effusion
Malignant pleural effusion occurs as a consequence of pleuritis carcinomatosa in many can-
cers. In mesothelioma, it occurs in 70% of patients and the dyspnea it causes often is the 
first clinical sign 3, 4. Drainage of pleural effusion is performed to relieve symptoms and for 
diagnostic purposes. In chapter 4 and 5 we further investigated the immunological properties 
of pleural effusions derived from mesothelioma patients. Initially we hypothesized that pleural 
effusion might be a direct reflection of the pleural tumor and could therefore function as an 
easy-access liquid biopsy. However in the proof-of-concept study we described in chapter 
5 we demonstrated that the composition of pleural effusion is dynamic and influenced by 
treatment. Furthermore we established that the immune cell composition of pleural effu-
sion does not necessarily mirror the composition of the tumor. These data will have to be 
confirmed in larger patient studies, indicating the importance of patient enrollment in clinical 
studies in a rare disease as mesothelioma. However our data do indicate that pleural effu-
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sion should be considered a separate part of the mesothelioma environment. In chapter 4 
we investigated the immunosuppressive properties of pleural effusions from mesothelioma 
patients prior to any treatment. We show that as in tumor biopsies, macrophages are the 
most abundant immune cells present although clear patient to patient variety is present. The 
capability of pleural effusion to induce macrophages with a M2 phenotype which suppress T 
cell proliferation illustrates the profound immunosuppressive character of this compartment. 
Therefore, the characteristics of pleural effusion should be taken into account when applying 
(intrapleural) immunotherapy in mesothelioma. As we identified PGE2 as a potential key 
regulator of the immunosuppressive environment, an elegant application of personalized 
immunotherapy would be to consider to administer COX-2 inhibitors to patients with high 
levels of PGE2 and M2 macrophages in their pleural effusion 5-7. In contrast, the drainage of 
pleural effusion followed by pleurodesis to eliminate the immunosuppressive compartment 
seems an intuitively logical suggestion. However, as the intrapleural cavity is a potentially 
attractive site to administer (immuno)therapies we suggest to characterize the local profile 
and add a personalized adjuvant (e.g. COX-2 inhibitor, CD40 agonist) to the proposed 
therapy in order to be able to take advantage of the macrophages present in pleural effusion. 
Infiltrating the environment: TAMs as a therapeutic target
The clinical and in vitro studies described in the first part of the thesis identified TAMs as an 
attractive potential therapeutic target in mesothelioma. There are several therapeutic strat-
egies available, including the inhibition of recruitment of macrophages, the depletion of (M2) 
macrophages, the inhibition of (M2) macrophage function and the induction of a phenotypic 
switch from M2 to M1 8, 9. This induced re-polarization is the most attractive strategy since 
it would make use of the unique plasticity of macrophages and therefore allows to skew an 
immunosuppressive environment to a more pro-inflammatory environment. Stimulation of 
CD40 using agonistic antibodies has been described to skew macrophages towards a more 
M1-like phenotype and has shown promising results in other tumor types 10. Therefore in 
chapter 6 we performed a pilot study with a CD40 agonistic antibody in a mesothelioma 
mouse model. In addition to the treatment with the CD40 agonist we also combined the 
antibody with DC immunotherapy. As DC immunotherapy relies on the activation of T cells 
followed by their infiltration and local anti-tumor response, DC immunotherapy could ben-
efit from a M1-prone pro-inflammatory local environment 11, 12. The combination therapy 
indeed showed additive results, with an increased systemic immune activation and survival 
in this treatment group. However, whether this additive effect can be attributed to the local 
re-polarization of TAMs could not be concluded from this pilot study. Given the pleiotropic 
expression of CD40, multiple cell types could contribute to the observed effect 13. However, 
others have shown that in pancreatic cancer, a tumor type with a microenvironment dom-
inated by macrophages as mesothelioma, tumor regression after treatment with a CD40 
agonist required macrophages, not T cells 10. Furthermore, in a mouse model of pancreatic 
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cancer, extra-tumoral macrophages residing in the lymph nodes and secondary lymphoid 
organs have been demonstrated to regulate the intra-tumoral infiltration of T cells following 
CD40 agonistic therapy, a finding which potentially expands the influence of macrophages 
beyond the tumor microenvironment 14. Interestingly, in a recent study this group demon-
strates that CD40 activation induces macrophages which originate from peripheral blood 
monocytes to induce fibrosis via the production of specific MMPs 15.  This effect depended 
on the systemic release of IFN-γ and CCL2 following CD40 activation. Degradation of the 
local fibrosis increased sensitivity to chemotherapy. These findings elegantly demonstrate the 
potential of the targeting of TAMs in tumors with a robust TAM infiltrate. As scavenging of 
local fibrotic material would originally be classified as a typical M2 trait, these findings also 
illustrate the evolving insights regarding macrophage plasticity. The continuum of macrophage 
phenotypes allows for the induction of specific traits, e.g. phagocytosis, antigen presentation 
or fibrosis degradation, depending on the required local effect. 
In addition to the skewing of TAMs we investigated the potential of TAM depletion in chapter 
7. Using the CSF1R-inhibitor in mesothelioma mouse models we were able to reduce TAMs 
without improving survival. However in combination with DC immunotherapy there was a 
synergistic effect improving survival, decreasing TAMs and enhancing CD8 T cell frequency 
and functionality. These findings illustrate that targeting of the tumor microenvironment as 
a single strateqy will unlikely be sufficient to unleash a potent anti-tumor immune response 
in a tumor with a profound immunosuppressive environment as mesothelioma. However, 
these preclinical data do illustrate the great potential of combinatorial approaches. As this 
thesis focuses on immunotherapy, (combinations with) conventional therapies were not 
investigated. Evidently, it is essential to evaluate immunotherapy in the context of treatment 
modalities which have proven their benefit in the past. 
Towards combinatorial immunotherapy
The final part of the thesis focuses on how checkpoint blockade should be implemented 
in pulmonary oncology. Since this class of immunotherapy is evolving quickly and multiple 
agents are now clinically available, a rational design of clinical studies investigating these com-
pounds is key. Although initial results are promising and have lead to the approval of  PD-1 
blockade in NSCLC patients, the vast majority of lung cancer and mesothelioma patients do 
not respond to the currently available checkpoint blocking antibodies 16-19. As discussed in 
chapter 8 and 9, the identification of robust biomarkers is crucial for the successful clinical 
implementation of checkpoint blockade. Given the costs and potentially serious side effects 
research should be focused on identifying those patients who are most likely to benefit from 
checkpoint blockade. The local and systemic immunosuppressive environment in lung cancer 
and mesothelioma hampers the efficacy of checkpoint blockade. We propose a combinatorial 
immunotherapeutic approach based on the targeting of both systemic and local immuno-
suppression in combination with cellular immunotherapy. In our view, this approach should 
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be personalized and adapted to the suppressive mechanisms in action in each particular 
patient and in every compartment (peripheral blood, pleural effusion and tumor). In our 
model we propose the use of cellular immunotherapy as the strategy to induce a specific 
anti-tumor T cell response. This is based on the findings in our meta-analysis in chapter 10 
which demonstrates that cellular immunotherapy is more effective in NSCLC compared to 
tumor vaccination. Given the up-regulation of the PD-1/PD-L1 axis following a potent local 
T cell response, combination of cellular (DC) immunotherapy with PD-1/PD-L1 blockade is 
reasonable. Furthermore, traditional treatment modalities as chemotherapy and in selected 
mesothelioma patients, surgery, could be very useful neoadjuvant sensitizing approaches. 
Various chemotherapies have been demonstrated to induce immunogenic cell death which 
can lead to the release of tumor associated antigens, enhancing the potential of immuno-
therapeutic approaches 20. 
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Concluding remarks and future directions
The main goal of this thesis was to investigate the role of tumor-associated macrophages in 
the mesothelioma environment and their potential as a therapeutic target. We established 
that macrophages are key immunosuppressive players in mesothelioma (both locally and 
in pleural effusion) and their presence and phenotype has major clinical implications. The 
preclinical studies in this thesis demonstrate the great therapeutic potential of targeting 
macrophages in mesothelioma, especially in combination with DC immunotherapy. Although 
questions have been answered, new questions arose which will lead the way of future studies. 
One of the major insights from this thesis is the pressing need for patient-tailored immuno-
therapy in mesothelioma and probably multiple other tumor types. Since mesothelioma is 
a rare disease, patient numbers in our clinical studies were relatively low. On one hand this 
evidently is a drawback, on the other this allowed us to recognize the profound patient-to-
patient variability regarding the characteristics of the tumor environment in mesothelioma. 
Future studies should be directed at the standardized characterization of the immunosup-
pressive mechanisms at play. Ideally, in concordance with the molecular profiling of a tumor 
an additional immunological profiling should take place which includes both the local and 
systemic dominant cell types and phenotype. For mesothelioma, local tumor-associated 
macrophages and systemic myeloid cells should be among the main cells of interest. As 
immunological reactions and tumor characteristics are dynamic by nature, a single diagnostic 
biopsy is not sufficient to investigate potential biomarkers and treatment effects. Although 
stressful for the patients, multiple biopsies during a treatment regimen will allow for the 
identification of working mechanisms and therefore further improvement of immunotherapy. 
Future preclinical studies are necessary to design rational treatment combinations depending 
on the immune profile identified. Clinical studies investigating immunotherapy should focus 
on the identification of potential biomarkers based on hypotheses derived from preclinical 
work. Therefore, a close collaboration between basic scientists and clinical researchers is 
essential to fully develop cancer immunotherapy. 
Chapter 11
226
references
1. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-
CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846-59.
2. Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, et al. The tumoral and stromal immune microenvironment 
in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 
2015;4(6):e1009285.
3. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397-408.
4. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591-603.
5. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188(1):21-8.
6. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, et al. COX-2 inhibition 
improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in 
mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010;10:464.
7. Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-Dependent Tumor 
Growth through Evasion of Immunity. Cell. 2015;162(6):1257-70.
8. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature 
immunology. 2010;11(10):889-96.
9. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49-61.
10. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and 
show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612-6.
11. Cornelissen R, Hegmans JP, Maat AP, Kaijen-Lambers ME, Bezemer K, Hendriks RW, et al. Extended Tumor Control 
After Dendritic Cell Vaccination With Low Dose Cyclophosphamide as Adjuvant Treatment in Patients With 
Malignant Pleural Mesothelioma. Am J Respir Crit Care Med. 2015.
12. Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant 
mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med. 2005;171(10):1168-77.
13. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(5):1035-43.
14. Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, et al. Exclusion of T Cells From Pancreatic Carcinomas 
in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. Gastroenterology. 2015;149(1):201-10.
15. Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL. IFNgamma and CCL2 Cooperate to Redirect 
Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. 
Cancer Discov. 2016;6(4):400-13.
16. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in 
Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015;373(2):123-35.
17. Kindler HS, A.; Calabro, L. . Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma 
(MM): Results from the global, double-blind, placebo-controlled DETERMINE study. J Clin Oncol 34, 2016 (suppl; 
abstr 8502).
18. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-
cell lung cancer. The New England journal of medicine. 2015;372(21):2018-28.
Summary and Discussion
 227
11
19. Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with 
chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 
2013;14(11):1104-11.
20. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: Chemotherapy with 
immunogenic cell death inducers. Oncoimmunology. 2013;2(3):e23510.

Nederlandse samenvatting
230
nederlandse samenvatting
Kanker en het immuunsysteem
Aan het einde van de 19e eeuw poneerde Stephan Paget (Engelse chirurg, 1855-1926) de 
hypothese dat niet alleen de intrinsieke eigenschappen van de tumorcel belangrijk zijn, maar 
dat ook de omgeving waar een tumorcel in terecht komt bepalend is voor de manier waarop 
een tumor zich verspreidt door het lichaam. Paget observeerde namelijk dat bepaalde 
soorten van kanker, zoals borstkanker, voornamelijk uitzaaien naar specifieke organen zoals 
de lever. Het uitzaaiingspatroon wordt niet bepaald door toeval. Sommige organen vormen 
namelijk een betere voedingsbodem voor bepaalde tumorcellen dan andere. Inmiddels weten 
we dat normale lichaamscellen niet alleen invloed hebben op de plek van uitzaaiing van een 
tumor, maar ook bepalend kunnen zijn voor de ontwikkeling van de tumor zelf. 
Gedurende de ontwikkeling van een tumor ontstaat er een ingewikkeld netwerk van niet 
alleen tumorcellen, maar ook van bloedvaten, bindweefsel en cellen van het afweersysteem; 
de immuuncellen. Dit netwerk wordt het micromilieu van de tumor genoemd.
 De primaire taak van het immuunsysteem is de bescherming van ons lichaam tegen infecties 
door onder andere bacteriën en virussen. Om deze bescherming mogelijk te maken is ons 
immuunsysteem uitgerust met verschillende type immuuncellen die in staat zijn om lichaams-
vreemde indringers te herkennen en vervolgens onschadelijk te maken. Macrofagen spelen 
een grote rol bij de eerste verdediging tegen indringers en zijn in staat om lichaamsvreemd 
materiaal op te nemen en te vernietigen. 
Dendritische cellen zijn gespecialiseerd in het herkennen van lichaamsvreemd materiaal en 
presenteren dit vervolgens aan T cellen die een belangrijk deel uitmaken van de specifieke 
afweer. 
Als een tumorcel ontstaat wordt deze normaal gesproken ook herkend door het immuun-
systeem en opgeruimd waardoor de uitgroei van een tumor voorkomen wordt. Echter, soms 
ontsnapt een kwaadaardige cel aan het immuunsysteem waardoor de cel zich kan gaan 
vermenigvuldigen en een tumor de kans krijgt zich te ontwikkelen. Een tumor kan daarnaast 
in staat zijn om immuuncellen te onderdrukken of zo te beïnvloeden dat ze de groei van 
de tumor ondersteunen. 
Het doel van immuuntherapie is om het immuunsysteem zo te stimuleren dat het de tumor 
herkent als lichaamsvreemd en vervolgens aanvalt. 
Macrofagen en kanker
De macrofaag speelt een belangrijke rol in de eerste verdedigingslinie van het immuun-
systeem. Een bijzondere eigenschap van macrofagen is dat deze cellen veel verschillende 
soorten functies kunnen uitoefenen, afhankelijk van de omgeving waarin de macrofaag zich 
bevindt. Als weefsels beschadigd raken door trauma of infectie worden de voorlopers van 
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macrofagen, monocyten, vanuit de bloedbaan naar de plek van schade gerekruteerd. Het 
hangt af van de omgeving waarin de monocyt terecht komt tot wat voor type macrofaag 
hij zich ontwikkelt. 
De macrofaag fenotypes zijn in te delen in een breed spectrum met aan de uiteindes de M1 
en de M2 macrofaag. De M1 macrofaag is gespecialiseerd in het aanvallen en opruimen van 
indringers en lichaamsvreemde cellen zoals bacteriën en tumorcellen.  De M2 macrofaag 
speelt een belangrijke rol bij verschillende aspecten van de wondgenezing zoals het vormen 
van bindweefsel en nieuwe bloedvaten. De M1 macrofaag heeft een belangrijke pro-inflam-
matoire functie, de M2 macrofaag onderdrukt de immuunrespons juist. Een M1 macrofaag 
wordt dan ook anti-tumor genoemd, terwijl een M2 macrofaag als pro-tumor bekend staat. 
Een belangrijke eigenschap van de macrofaag is de plasticiteit van het fenotype; een macro-
faag is in staat om het fenotype te veranderen afhankelijk van de signalen die hij ontvangt uit 
zijn omgeving. Tumoren kunnen voor een groot deel uit macrofagen bestaan en het fenotype 
van deze macrofagen (M1 of M2) heeft klinische betekenis. 
Zo heeft onderzoek in verschillende vormen van kanker aangetoond dat patiënten met 
tumoren waar veel macrofagen met het M1 fenotype in zitten een betere overleving hebben 
dan patiënten met veel M2 macrofagen in de tumor. 
Mesothelioom en Longkanker 
Als iemand asbestvezels inhaleert kunnen deze terecht komen op het borstvlies (pleura) 
of buikvlies (peritoneum). Asbest is niet afbreekbaar lichaamsvreemd materiaal wat lokale 
macrofagen op proberen te ruimen, maar gezien het formaat van de asbestvezels lukt dit niet. 
Vaak vele jaren na blootstelling aan asbest kan er kanker ontstaan van het long- en/of buikvlies; 
het mesothelioom. In Nederland worden jaarlijks ongeveer 500 mensen gediagnosticeerd 
met mesothelioom en de verwachting is dat dit aantal de komende jaren verder zal stijgen. 
Mesothelioom kan (nog) niet genezen worden en de gemiddelde overleving na diagnose is 
ongeveer 12 maanden, ondanks behandeling met chemotherapie.  
Longkanker wordt meestal veroorzaakt door roken en wordt jaarlijks in Nederland bij ruim 
10.000 patiënten vastgesteld. Voor de prognose van de levensverwachting is het stadium 
waarin longkanker wordt vastgesteld van groot belang. De 5-jaars overleving is slechts 17%, 
met name doordat longkanker vaak pas in een vergevorderd stadium gediagnosticeerd wordt 
waardoor de behandelopties beperkt zijn. 
Het is duidelijk dat er voor zowel mesothelioom als longkanker behoefte is aan nieuwe 
manieren om deze ziekten te behandelen. Immuuntherapie is daarvan een veelbelovende 
optie. 
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Doel en resultaten van het onderzoek
Het doel van het onderzoek beschreven in dit proefschrift is om de bijdrage van macrofagen 
aan de progressie van het mesothelioom (deel 1) en hun potentie als therapeutisch aangrij-
pingspunt (deel 2) te onderzoeken. Daarnaast wordt ook de potentie van immuuntherapie 
bij longkanker en mesothelioom in beschouwende zin onderzocht (deel 3). 
Hoofdstuk 1 van dit proefschrift geeft een uitgebreide introductie van de achtergronden 
waar dit onderzoek op gebaseerd is. Het principe en de verschillende vormen van immuunt-
herapie wordt besproken. Verder wordt een algemene introductie gegeven over het ontstaan, 
de klinische kenmerken en de mogelijke behandelingen van mesothelioom en longkanker. 
Daarnaast beschrijft de introductie de huidige kennis over de eigenschappen van macro-
fagen en hun rol bij het ontstaan en de progressie van kanker. In hoofdstuk 2 en 3 wordt 
allereerst de aanwezigheid en het fenotype van macrofagen in mesothelioom onderzocht. 
Het grootste gedeelte van de macrofagen bleek van het M2 (pro-tumor) fenotype te zijn. Er 
wordt aangetoond dat hoe meer van de aanwezige macrofagen in mesothelioom een M2 
fenotype hebben, hoe slechter de prognose van patiënten is. Daarnaast wordt aangetoond 
dat dit M2 fenotype ook de kans op een lokale uitgroei van het mesothelioom vergroot. 
Bij patiënten met een pleuraal mesothelioom is er vaak sprake van vocht tussen het borst- en 
longvlies; dit wordt pleuravocht genoemd. Aangezien pleuravocht zorgt voor kortademigheid 
wordt het regelmatig weggehaald door middel van drainage. Dit biedt de mogelijkheid om 
eigenschappen van dit pleuravocht nader te onderzoeken. In hoofdstuk 4 wordt het fenotype 
en de functie van macrofagen in pleuravocht onderzocht en wordt aangetoond dat macro-
fagen onder invloed van factoren in het pleuravocht van mesothelioompatiënten in staat zijn 
om de anti-tumor immuunrespons te onderdrukken. Hoofdstuk 5 toont verder aan dat de 
eigenschappen van pleuravocht dynamisch zijn en worden beïnvloed door therapie. Daarbij 
bleek pleuravocht geen afspiegeling te zijn van kenmerken van de tumor maar een op zichzelf 
staand immunologisch compartiment. De in hoofdstuk 4 en 5 aangetoonde eigenschappen 
van pleuravocht zijn belangrijke factoren om rekening mee te houden bij de toepassing 
van, in het bijzonder intrapleurale, immuuntherapie bij mesothelioom. Daarnaast resulteert 
het eerste gedeelte van het proefschrift in de hypothese dat macrofagen een interessant 
potentieel therapeutisch aangrijpingspunt zijn bij mesothelioom. In de literatuur worden 
verschillende manieren beschreven om macrofagen aan te vallen. In de eerste plaats kan de 
therapie zich richten op het verwijderen van alle aanwezige macrofagen. Deze opzet heeft 
als nadeel dat ook de aanwezige anti-tumor M1 macrofagen verwijderd worden. Een andere 
optie is dan ook om te trachten de aanwezige pro-tumor M2 macrofagen te veranderen in 
anti-tumor M1 macrofagen. In het tweede deel van het proefschrift, hoofdstuk 6 en 7, zijn 
met behulp van preklinische mesothelioom muismodellen verschillende opties om macrofa-
gen te beïnvloeden onderzocht. Het aangrijpen van macrofagen is steeds gecombineerd met 
een andere vorm van immuuntherapie; het toedienen van dendritische cellen. Door dend-
ritische cellen die specifieke eigenschappen van de tumor herkennen toe te dienen wordt 
Nederlandse samenvatting
 233
de anti-tumor immuunrespons geïnitieerd. Aangezien deze immuunrespons lokaal ook weer 
teniet gedaan kan worden door pro-tumor macrofagen zou de effectiviteit van dendritische 
cel immuuntherapie vergroot kunnen worden door deze te combineren met macrofaag-ge-
richte therapie. In hoofdstuk 6 is gebruik gemaakt van een CD40-agonistisch antilichaam en 
wordt aangetoond dat dit een additief effect heeft op dendritische cel immuuntherapie in een 
mesothelioom muismodel. Van deze CD40-stimulerende antilichamen is beschreven dat het 
werkingsmechanisme berust op het effect op het fenotype van macrofagen. Of dit mecha-
nisme ook ten grondslag ligt aan de gevonden effecten in mesothelioom is het onderwerp 
van toekomstige studies. In hoofdstuk 7 is gebruik gemaakt van een techniek om het aantal 
macrofagen in een mesothelioom te verminderen. Zoals eerder beschreven worden initieel 
de voorlopers van macrofagen, monocyten, vanuit de bloedbaan naar de tumor toegetrok-
ken waarna deze monocyten zich lokaal differentiëren tot macrofagen. De aantrekking en 
overleving van macrofagen kan verstoord worden door gebruik te maken van een CSF1R 
inhibitor. In hoofdstuk 7 wordt gedemonstreerd dat een CSF1R inhibitor alleen geen effect 
heeft, maar in combinatie met dendritische cel immuuntherapie een sterke toename van 
de overleving laat zien in een mesothelioom muismodel. Deze preklinische studies tonen 
de potentie van macrofagen als therapeutisch aangrijpingspunt bij mesothelioom, zeker in 
combinatie met dendritische cel immuuntherapie. 
Het derde deel van het proefschrift is gericht op het beschouwen van nieuwe vormen 
van immuuntherapie bij mesothelioom en longkanker. In hoofdstuk 8 en 9 worden de 
beschikbare klinische studies die de effectiviteit van checkpoint inhibitors onderzoeken in 
mesothelioom en longkanker geëvalueerd. Checkpoint inhibitors zijn antilichamen gericht 
tegen immuuncel gebonden signalen die de immuunrespons remmen. Door deze negatieve 
signalen te blokkeren wordt de rem op het immuunsysteem opgeheven. Hoewel deze 
antilichamen veelbelovend zijn, heeft maar een beperkt gedeelte (ongeveer 20%) van de 
longkanker en mesothelioom patiënten profijt van deze behandeling. Het is daarom essen-
tieel dat er onderzoek verricht wordt naar het identificeren van zogenaamde biomarkers; 
eigenschappen van een patiënt of tumor die de respons op behandeling kunnen voorspellen 
zodat er geen patiënten onnodig behandeld worden. 
In hoofdstuk 10 wordt tenslotte aangetoond dat bij longkankerpatiënten cellulaire immuun-
therapie een effectievere vorm van immuuntherapie is dan therapie op basis van vaccinatie. 
Dit is een belangrijke bevinding met het oog op de combinaties van immuuntherapieën die 
steeds vaker uitgevoerd worden. De eerdergenoemde checkpoint inhibitors zouden der-
halve goed gecombineerd kunnen worden met cellulaire immuuntherapie (zoals dendritische 
cellen) in mesothelioom en longkanker. 
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Conclusie 
Macrofagen spelen een essentiële rol in het micromilieu van het mesothelioom door hun 
vermogen om de immuunrespons te onderdrukken, zowel lokaal als in pleuravocht, en 
hun aanwezigheid en fenotype hebben klinische consequenties. De preklinische studies in 
het mesothelioom muismodel demonstreren de potentie van macrofagen als therapeu-
tisch aangrijpingspunt in mesothelioom, in het bijzonder in combinatie met dendritische 
cel immuuntherapie. Aangezien de studies beschreven in dit proefschrift laten zien dat de 
samenstelling van het micromileu van de tumor sterk kan verschillen van patiënt tot patiënt, 
ondersteunen deze resultaten de ontwikkeling van persoonlijke, op maat gemaakte therapie. 
Preklinische studies zullen nodig blijven om rationele combinaties van immuuntherapieën 
te ontwerpen en te testen. Een nauwe samenwerking tussen basale wetenschappers en 
klinische onderzoekers is dan ook essentieel voor de toekomst van immuuntherapie in de 
(pulmonale) oncologie. 
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Zoals een belangrijke hypothese die ten grondslag ligt aan dit proefschrift voorschrijft, zijn er 
twee dingen belangrijk voor groei; ‘seed and soil’ oftewel ‘nature and nurture’. Hetzelfde geldt 
voor de totstandkoming van een proefschrift en er zijn een aantal mensen die de afgelopen 
jaren op verschillende manieren een bijdrage hebben geleverd aan de omgeving waarbinnen 
ik mijn onderzoek heb mogen doen. 
Allereerst wil ik alle patiënten bedanken die belangeloos hebben meegewerkt aan een deel 
van de studies beschreven in dit proefschrift. Of het nu gaat om deelname aan klinische 
studies of het ter beschikking stellen van materiaal, uw bijdrage is essentieel voor de weten-
schappelijke vooruitgang. 
Prof. dr. J.G.J.V. Aerts, beste Joachim, toen ik in het Amphia als beginnend arts-assistent ging 
werken hoorde ik al snel dat als ik onderzoek bij de Longziekten zou willen doen, ik dan bij 
jou moest zijn. Na een mailtje volgde een gesprek en heel snel volgden een gesprek met 
prof. dr. Hoogsteden en een kennismaking op het lab. Deze doortastendheid heb ik in de 
afgelopen jaren nog veel vaker mogen meemaken. Joachim, met je gedrevenheid en passie 
haal je het beste uit de mensen om je heen en ik wil je ontzettend bedanken voor alle kansen 
en mogelijkheden die je me geboden hebt. Naast je wetenschappelijke prestaties is je werk 
als clinicus voor mij een voorbeeld. 
Prof. dr. R.W. Hendriks, beste Rudi, een belangrijke reden waarom het lab Longziekten zo’n 
prettige en vruchtbare werkplek is ben jij. Je combineert een zeer indrukwekkende parate 
immunologische kennis met een scherp en vriendelijk oog voor alle mensen die rondlopen 
op jouw lab. Hartelijk dank voor alle waardevolle toevoegingen die je gedaan hebt aan mijn 
proefschrift. 
Prof.dr. H.C. Hoogsteden, beste Henk, hartelijk dank voor het warme welkom op jouw 
afdeling. Eenmaal toegetreden tot jouw afdeling kun je op steun rekenen en zo heb ik dat 
ook ervaren, bedankt voor alle geboden mogelijkheden. 
Dr. J.P.J.J. Hegmans, beste Joost,  jouw bijdrage aan de totstandkoming van dit proefschrift is 
heel groot. Bedankt voor je dagelijkse advies, steun, kritische blik en gevoel voor humor. Ik 
denk met ontzettend veel plezier terug aan onze samenwerking en het doet me goed dat 
de weg die je ingeslagen bent zo goed bevalt.  
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Verder wil ik graag prof.dr. S.H. van der Burg, prof.dr. P.D. Katsikis en dr. J.E.M.A. Debets 
hartelijk danken voor het plaatsnemen in de leescommissie en het kritisch beoordelen van 
het proefschrift. Beste Reno, daarnaast ook bedankt voor de waardevolle toevoegingen en 
kritische blik tijdens de TIP meetings de afgelopen jaren, ik heb er veel van geleerd. 
Beste Robin, bijna twee jaar na jouw promotie is het mijn beurt en werken we nog steeds 
samen en blijven er talloze mails over en weer gaan. Ik heb veel plezier beleefd aan onze 
samenwerking en de congressen die we hebben bezocht. Naast dat ik je nog nooit in een 
slecht humeur heb meegemaakt heb ik veel geleerd van je indrukwekkende kennis op het 
gebied van long oncologie. Ik hoop dat we onze samenwerking kunnen voortzetten en dat 
ik ook op klinisch gebied veel van je mag gaan leren. 
De 22e staat niet voor niks bekend als een van de leukste afdelingen in de toren en ik wil 
iedereen van het Lab Longziekten ontzettend bedanken voor de prettige samenwerking en 
alle leuke sociale momenten de afgelopen jaren. In mijn jaren op het lab heeft de groep een 
snelle groei doorgemaakt. Het was bijzonder om steeds weer mee te maken hoe nieuw-
komers met open armen worden ontvangen. Een aantal mensen wil ik in het bijzonder 
bedanken. Marthe, Marlies, Roel en Laurens, bedankt voor het warme welkom. Het gaf moed 
om jullie met zoveel verve jullie proefschriften te zien verdedigen. Heleen, Sabine, Pauline, 
Irma, Bobby, Peter en Tridib veel succes met het afronden van jullie onderzoek, ik kijk uit naar 
de verdedigingen! Koen, de betere helft van team TAM, als ik klaar was om de handdoek in 
de ring te gooien na wederom een serie mislukte proliferatie assays hield jij de moed erin. 
Bedankt voor al je kunde, hulp, gevoel voor humor en geduld. Menno, de Holden Caulfield 
van het lab, bedankt voor je hulp en goede humeur bij de muisstudies. Het muizenwerk was 
niet mijn grootste hobby maar dankzij jou en Floris is het toch nog wat geworden. 
En toen kwam er op het lab een student binnen wandelen die mij meer kon leren dan ik 
hem. Beste Floris, je bent een getalenteerd en gedreven onderzoeker en ook nog eens heel 
prettig om mee samen te werken. Je hebt de muisstudies met beide handen aangegrepen 
en ik twijfel er niet aan dat je je promotie tot een succes gaat maken. Bedankt voor je col-
legialiteit, vriendschap en dat je mijn paranimf wilt zijn. Ik weet zeker dat onze paden elkaar 
in de toekomst zullen blijven kruisen. 
Na ruim 4 jaar basaal wetenschappelijk onderzoek doen weer terug de kliniek in valt niet 
mee. Niet voor mij, maar waarschijnlijk ook niet voor de betrokkenen. Dr. Marco Groo-
tenboers, dr. Joost van Esser en de medisch specialisten en collega arts-assistenten uit het 
Amphia ziekenhuis wil ik graag bedanken voor het warme welkom. Jullie hebben me er snel 
aan herinnerd waarom ik ook alweer dokter wilde worden, we hebben toch het mooiste vak. 
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Dan mijn steun en toeverlaat Caroline Broos. Lieve Ca, we begonnen als goede vriendinnen 
bijna tegelijkertijd aan onze promotie op hetzelfde lab. De afgelopen jaren heb ik ontelbare 
keren gedacht hoe blij ik was met jou naast me. Promoveren gaat gepaard met hoogte- en 
dieptepunten en het was heel erg fijn om die met jou te kunnen delen. Dat we nu dan ook 
op dezelfde dag promoveren is een feest, ik ben heel erg  trots op je! Bedankt voor al je 
steun, vriendschap en inspiratie, ik kijk uit naar een carrière zij aan zij. 
Heel belangrijk in mijn leven zijn mijn leuke lieve vriendinnen, fysiek vaak op afstand maar 
gevoelsmatig altijd dichtbij. Lieve Diaan, je bent zelfgekozen familie, bedankt voor je steun 
en betrokkenheid bij alles wat ik doe. Lieve Charlaine, bedankt voor je vriendschap (al 25 
jaar!) en gevoel voor humor. Lieve Floor, Jip, Rens en Ca, ondanks dat we elkaar door onze 
drukke levens veel te weinig zien blijft het altijd als vanouds. Ik ben ontzettend blij met jullie! 
Lieve (oud-) Linque-ies, van de kroeg in Maastricht naar app-groepen over zwangerschap 
is best een stap maar ik vind het een feest om er getuige van te zijn hoe jullie allemaal het 
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